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SUMMARY  
Hepatitis C virus (HCV) is a blood-borne, enveloped, single-stranded, (+)-oriented RNA virus that mainly 
infects hepatocytes. Most infections progress into chronicity and eventually lead to severe liver disease. 
Although effective treatments have been developed, access to diagnosis and treatment is low, particularly 
in non-developed countries. Thus, eradication of the disease is unlikely without a prophylactic vaccine. 
Research, therefore, has to continue despite the high cure rates of today’s HCV regimens. 
We use mathematical modeling to study HCV replication and its intricate connection with the infected host 
cell. A model that is able to simulate intracellular HCV RNA replication suggested a host factor species (HF), 
representing a protein (complex) or a host process, to be critically involved in HCV replication. Gene 
expression profiling revealed several candidates potentially representing this HF. We validated those 
candidates in two variants of the human hepatoma cell line Huh7 and could confirm that five of them indeed 
played a role for HCV replication, namely CRAMP1, LBHD1, CRYM, THAP7, and NR0B2. The latter three are 
nuclear receptors or transcriptional (co-)repressors, suggesting they could influence HCV replication 
indirectly, e.g. through glucose, lipid, or cholesterol metabolism. Follow-up studies will help to understand 
the implication of those factors in HCV replication and reveal important insights into the metabolic pathways 
regulating HCV replication. 
Model analyses also revealed the most sensitive steps in HCV RNA replication that could potentially be 
targeted by specific intervention. The standard of care for chronic HCV infection has been interferon alpha 
(IFN-α) therapy that elicited a very broad but rather unspecific antiviral response of the host cell and came 
along with severe side effects. IFN-α activates signaling cascades that lead to the expression of hundreds of 
interferon stimulated genes that exert antiviral action. Despite its decades-long use, the exact mechanism 
of the suppression of HCV replication by IFN-α treatment remains elusive. We thus combined experimental 
data with an intracellular model for HCV replication and revealed the steps in the viral replication cycle that 
are most probably affected by IFN-α treatment. The obtained findings were well in line with in vitro data 
and confirmed the validity of our intracellular model to make such analyses. 
Recently, direct-acting antivirals (DAAs) have replaced IFN-α-containing regimens as the standard of care 
for chronic HCV infection. Those DAAs possess much less side effects, can be taken orally, and give 
extraordinarily high cure rates. Mainly three classes exist: inhibitors of the viral protease, the viral 
polymerase, and a viral multifunctional phosphoprotein. The latter class constitutes highly potent inhibitors 
of the HCV NS5A protein, exerting effects in the low picomolar range. However, due to the many roles of 
NS5A in the HCV life cycle, the exact mechanism of action of those DAAs remains unclear. For the other two 
classes, the mode of action is distinct and well defined. We, thus, used one representative member of each 
of these classes to validate the capacity of our model to implement drug effects and predict HCV replication 
correctly. Model predictions upon a priori fixing of the affected parameters in the model qualitatively 
resembled HCV replication dynamics under the respective drug treatment. This allowed us to apply our 
model to HCV replication data under treatment with an NS5A inhibitor in order to gain insights into its mode 
of action. The model revealed that the translation rate of HCV RNA as well as RNA synthesis steps in the 
HCV replication compartment are most probably affected by the drug. These findings were reasonable and 
supported by known roles of NS5A in the HCV life cycle. However, our model was limited to intracellular 
HCV replication and did not account for steps like particle assembly or infection of target cells. Therefore, 
we extended our intracellular model to cover the full viral life cycle. Our new full life cycle model could 
simulate viral (+)- and (-)-strand RNA, viral titers as well as spread of the infection, and was able to correctly 
predict HCV replication under drug treatment. 
Our new model will be helpful in further elucidating the mode of action of NS5A inhibitors and IFN-α and in 
deciphering the role of host factors that determine permissiveness for HCV. 
Hence, this study provides a novel, extended mathematical model of the full HCV life cycle with the proven 
capacity of simulating and analyzing HCV replication even under pharmacological intervention. It can serve 
as an invaluable tool to study further molecular details of HCV replication and to devise and test novel 
therapeutic approaches. 
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ZUSAMMENFASSUNG 
Das Hepatitis C-Virus (HCV) ist ein durch Blut übertragenes, umhülltes, einzelsträngiges, (+)-orientiertes RNA-Virus, das 
hauptsächlich Hepatozyten infiziert. Die meisten Infektionen verlaufen chronisch und führen schließlich zu schweren 
Lebererkrankungen. Obwohl wirksame Therapien entwickelt wurden, sind die Diagnose- und Behandlungsraten niedrig, 
speziell in Entwicklungsländern. Daher ist eine Ausrottung der Krankheit ohne einen prophylaktischen Impfstoff 
unwahrscheinlich. Die Forschung muss daher, trotz der hohen Heilungsraten bei Therapie, fortgesetzt werden.  
Wir verwenden mathematische Modelle um die Replikation von HCV und seine komplexe Verbindung mit der infizierten 
Wirtszelle zu untersuchen. Ein solches Modell, das die intrazelluläre HCV-Replikation beschreibt, legte nahe, dass eine 
Wirtsfaktor-Spezies (WS), welche ein Protein, ein Proteinkomplex oder ein Wirtsprozess sein kann, entscheidend an der 
HCV-Replikation beteiligt ist. Die Erstellung von Genexpressionsprofilen ergab mehrere mögliche Kandidaten, die diese 
WS repräsentieren könnten. Wir validierten diese Kandidaten in zwei verschiedenen Varianten der menschlichen 
Hepatomzelllinie Huh7 und konnten bestätigen, dass fünf von ihnen tatsächlich eine Rolle für die HCV-Replikation 
spielten, nämlich CRAMP1, LBHD1, CRYM, THAP7 und NR0B2. Die letzteren drei sind nukleäre Rezeptoren oder 
transkriptionelle (Co-)Repressoren, was vermuten lässt, dass sie die HCV-Replikation indirekt beeinflussen, zum Beispiel 
durch den Glukose-, Lipid- oder den Cholesterinstoffwechsel. Folgestudien werden helfen, die Auswirkungen dieser 
Faktoren auf die HCV-Replikation zu verstehen und wichtige Einblicke in die Stoffwechselwege zu gewinnen, die die 
HCV-Replikation regulieren. 
Eine Modellanalyse zeigte auch die empfindlichsten Schritte in der intrazellulären HCV-Replikation auf, auf die eine 
spezifische Behandlung möglicherweise abzielen könnte. Die Standardbehandlung der chronischen HCV-Infektion war 
für lange Zeit die Interferon-alpha-(IFN-α)Therapie, die eine sehr breite, aber eher unspezifische antivirale Reaktion der 
Wirtszelle auslöste und mit schweren Nebenwirkungen einherging. IFN-α aktiviert Signalkaskaden, die zur Expression 
von Hunderten von Interferon-stimulierten Genen führen, welche wiederum eine antivirale Wirkung entfalten. Trotz 
des jahrzehntelangen Einsatzes ist der genaue Wirkmechanismus von IFN-α auf die HCV-Replikation nicht genau 
bekannt. Wir kombinierten daher experimentelle Daten mit einem intrazellulären, mathematischen Modell der HCV-
Replikation und zeigten die Schritte im viralen Replikationszyklus auf, die höchstwahrscheinlich durch eine IFN-α-
Behandlung beeinflusst werden. Die erhaltenen Ergebnisse stimmen gut mit experimentellen Daten überein und 
bestätigen somit die Tauglichkeit unseres intrazellulären Modells für eine solche Art von Analysen. 
In den letzten Jahren haben spezifische, auf HCV gerichtete, antivirale Medikamente (DAAs) die IFN-α-basierte 
Standardtherapie für chronische HCV-Infektionen ersetzt. Diese DAAs zeigen weitaus weniger Nebenwirkungen, können 
in Tablettenform eingenommen werden und führen zu außerordentlich hohen Heilungsraten. Es gibt hauptsächlich drei 
Klassen dieser DAAs: Inhibitoren der viralen Protease, der viralen Polymerase und eines viralen multifunktionellen 
Phosphoproteins. Die letztere Klasse sind hochwirksame Inhibitoren des HCV NS5A-Proteins, die im niedrigen 
pikomolaren Bereich wirken. Aufgrund der vielen Rollen von NS5A im HCV-Replikationszyklus ist der genaue 
Wirkmechanismus dieser DAAs jedoch unklar. Für die beiden anderen Klassen ist der Wirkmechanismus allerdings 
eindeutig und gut definiert. Wir haben daher jeweils ein repräsentatives Mitglied dieser beiden Klassen verwendet, um 
die Fähigkeit unseres Modells zur Implementierung von Inhibitoreffekten und zur korrekten Vorhersage der HCV-
Replikation während der Therapie zu validieren. Modellvorhersagen nach der a priori-Festlegung der betroffenen 
Parameter im Modell ähnelten qualitativ der HCV-Replikationsdynamik unter der jeweiligen Therapie. Dies ermöglichte 
uns die Anwendung unseres Modells auf HCV-Replikationsdaten unter der Behandlung mit einem NS5A-Inhibitor, um 
Einblicke in dessen Wirkmechanismus zu gewinnen. Das Modell zeigte, dass sowohl die Translationsrate der HCV RNA 
als auch die HCV RNA-Syntheseschritte im HCV-Replikationskompartiment höchstwahrscheinlich durch das 
Medikament beeinflusst werden. Diese Ergebnisse waren sinnvoll und wurden durch die bekannte Rolle von NS5A im 
HCV-Replikationszyklus unterstützt. Unser Modell beschränkte sich jedoch auf die intrazelluläre HCV-Replikation und 
berücksichtigte keine extrazellulären Schritte wie die HCV-Partikelproduktion oder die Infektion von Zielzellen. Daher 
erweiterten wir unser intrazelluläres Modell, um den gesamten viralen Replikationszyklus abzudecken. Unser neues 
Modell für den gesamten Replikationszyklus konnte virale (+)- und (-)-Strang-RNA, produzierte virale Partikel, sowie die 
Ausbreitung der Infektion simulieren und war zudem in der Lage, die HCV-Replikation unter medikamentöser 
Behandlung korrekt vorherzusagen. 
Unser neues Modell wird bei der weiteren Aufklärung der Wirkungsweise von NS5A-Inhibitoren und IFN-α sowie bei der 
Entschlüsselung der Rolle der WS, die die Permissivität für HCV bestimmt, hilfreich sein. 
Somit stellt diese Arbeit ein neuartiges, erweitertes mathematisches Modell des gesamten HCV-Replikationszyklus mit 
der geprüften Fähigkeit, die HCV-Replikation auch unter pharmakologischer Intervention zu simulieren und zu 
analysieren, bereit. Das Modell kann als sehr wertvolles Werkzeug dienen, um weitere molekulare Details der HCV-
Replikation zu untersuchen und neue therapeutische Ansätze zu entwickeln und zu testen. 
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ABBREVIATIONS 
°C degree celsius   
µM micromolar   
µCi micro curie (radioactivity)   
32P Phosphorus-32 (radioactive isotope)   
bp base pairs   
DAA direct-acting antiviral   
DAPI 4′,6-diamidino-2-phenylindole   
DCV daclatasvir   
DEPC diethyl pyrocarbonate   
DNA deoxyribonucleic acid   
ds double-stranded   
DTT dithiothreitol   
EI EMCV IRES   
ER endoplasmic reticulum   
EV extracellular vesicle   
FCS fetal calf serum   
GITC guanidinium isothiocyanate   
gt genotype   
h hour/hours   
HCV hepatitis C virus   
HIV human immunodeficiency virus   
hpe hours post electroporation   
hpi  hours post infection   
HRP horse radish peroxidase    
IC50 half maximal inhibitory concentration   
IEG interferon-effector gene   
IFN interferon   
IRES internal ribosome entry site   
ISG interferon-stimulated gene   
IU international units   
IVT in vitro-transcribed   
kb kilo base pairs   
LCS low complexity sequence   
Luc firefly luciferase   
MOI multiplicity of infection   
nM nanomolar   
ORF open reading frame   
PEG polyethylene glycol    
PI polio virus IRES   
pM picomolar   
nt nucleotide   
RBV ribavirin   
RC replication complex(es)   
RLR RIG-I-like receptor   
RLU relative light units   
RNA ribonucleic acid   
RNase ribonuclease   
rNTP ribonucleoside tri-phosphate   
RVFV rift valley fever virus   
sg subgenomic   
SOF sofosbuvir   
ss single-stranded   
SVR sustained virologic response   
TEL telaprevir   
TMD transmembrane domain   
UTR untranslated region   
 
  
XIV 
 
 
 
 
 
  
XV 
 
 
 
TABLE OF CONTENTS 
DECLARATION ........................................................................................................................................................... I 
ACKNOWLEDGEMENTS ........................................................................................................................................... VII 
SUMMARY ............................................................................................................................................................... IX 
ZUSAMMENFASSUNG .............................................................................................................................................. XI 
ABBREVIATIONS .................................................................................................................................................... XIII 
1. INTRODUCTION ............................................................................................................................................... 1 
1.1. Global disease burden by chronic viral infections ................................................................................... 1 
1.2. HCV classification & epidemiology .......................................................................................................... 2 
1.3. HCV genome organization, polyprotein processing, and protein function ............................................... 3 
1.4. On the history of hepatitis C virus (HCV) ................................................................................................. 6 
1.5. The HCV life cycle ................................................................................................................................... 8 
1.6. Host factors involved in HCV replication ................................................................................................. 9 
1.7. Treatment of chronic HCV infection ....................................................................................................... 10 
1.8. The innate immune response to HCV infection ...................................................................................... 11 
1.8.1. HCV RNA detection and signal cascade activation......................................................................... 11 
1.8.2. ISGs with anti-HCV activity ........................................................................................................... 13 
1.8.3. Countermeasures by HCV ............................................................................................................. 14 
1.9. Mathematical modeling of HCV infection .............................................................................................. 14 
2. MATERIAL ...................................................................................................................................................... 17 
2.1. Cell lines ........................................................................................................................................... 17 
2.2. Constructs ......................................................................................................................................... 17 
2.3. Chemicals and reagents .................................................................................................................... 17 
2.4. Primary antibodies ............................................................................................................................ 18 
2.5. Secondary antibodies ........................................................................................................................ 18 
2.6. Buffers and solutions ........................................................................................................................ 18 
2.7. Viruses .............................................................................................................................................. 18 
2.8. Consumables .................................................................................................................................... 19 
2.9. Instruments ...................................................................................................................................... 19 
2.10. Software ...................................................................................................................................... 19 
3. METHODS ...................................................................................................................................................... 21 
3.1. Bacterial culture ................................................................................................................................ 21 
3.2. Plasmid purification from bacterial cultures ...................................................................................... 21 
3.3. Gel or PCR mix purification of DNA ................................................................................................... 21 
3.4. Classical cloning ................................................................................................................................ 21 
3.5. DNA amplification ............................................................................................................................. 21 
3.6. Gateway™ cloning............................................................................................................................. 21 
3.7. Cells and cell culture ......................................................................................................................... 21 
3.8. Lunet-CGM cells ................................................................................................................................ 21 
3.9. In vitro-transcription of RNA ............................................................................................................. 22 
3.10. Preparation of standards for absolute quantification ................................................................... 22 
3.11. Electroporation of Huh7 cells ....................................................................................................... 22 
XVI 
 
3.12. Virus stocks preparation .............................................................................................................. 22 
3.13. Titer determination of viral stocks and supernatants ................................................................... 22 
3.14. “Cold” infection of Lunet-CGM cells ............................................................................................. 23 
3.15. Total RNA extraction (phenol) ...................................................................................................... 23 
3.16. RNA extraction (supernatant) ...................................................................................................... 23 
3.17. Strand-specific HCV RT-qPCR........................................................................................................ 23 
3.18. Strand-unspecific HCV RT-qPCR (Taqman) .................................................................................... 23 
3.19. Luciferase assay ........................................................................................................................... 24 
3.20. Immunoblotting ........................................................................................................................... 24 
3.21. Northern blotting......................................................................................................................... 24 
3.22. Fluorescence microscopy of fixed cells ......................................................................................... 24 
3.23. Fluorescence microscopy of live cells & image quantification....................................................... 24 
3.24. siRNA reverse transfection ........................................................................................................... 24 
3.25. Cloning of host factor candidate cDNAs ....................................................................................... 25 
3.26. Establishment of overexpressing cell lines ................................................................................... 25 
3.27. Total RNA extraction (column) and qPCR ..................................................................................... 25 
3.28. Live cell imaging (IncuCyte) .......................................................................................................... 25 
3.29. Cell viability assay ........................................................................................................................ 25 
3.30. Mathematical modeling ............................................................................................................... 25 
4. RESULTS......................................................................................................................................................... 27 
4.1. Deciphering the mode of action of IFN-α and hepatitis C virus (HCV) inhibitors using an intracellular model 
for HCV replication ............................................................................................................................................. 27 
4.1.1. The IFN-α-triggered antiviral response primarily inhibits HCV RNA translation ............................ 27 
4.1.2. HCV inhibitors have distinct modes of action that the intracellular model can recapitulate ......... 30 
4.2. Extension of the intracellular model to the full HCV life cycle ................................................................ 35 
4.2.1. Jc1 replication dynamics resemble those of sgJFH and sgJFH replication is not affected by CD81 
overexpression ............................................................................................................................................... 35 
4.2.2. Quantification of viral determinants during infection .................................................................. 37 
4.2.3. Model simulation of full-length HCV replication ........................................................................... 40 
4.2.4. Model simulation of Jc1 dynamics under DAA treatment ............................................................. 43 
4.3. The intracellular model proposes a host factor that is involved in replication complex formation 
determines permissiveness ................................................................................................................................. 51 
4.3.1. Gene expression profiling suggests potential host factors for HCV ............................................... 51 
4.3.2. Knockdown of proposed host factor candidates restricts HCV replication .................................... 51 
4.3.3. Overexpression of host factor candidates in a low permissive Huh7 variant boosts HCV replication
 53 
4.3.4. Strong NR0B2 overexpression inhibits HCV replication in Huh7-LP and -Lunet cells ...................... 56 
4.3.5. The FXR-NR0B2 axis regulates HCV replication in Huh7-Lunet cells .............................................. 57 
4.3.6. NR0B2 overexpression specifically impairs HCV replication .......................................................... 59 
5. DISCUSSION ................................................................................................................................................... 63 
5.1. Host factors determining permissiveness for HCV ................................................................................. 63 
5.1.1. Gene expression profiling reveals promising HF candidates ......................................................... 63 
5.1.2. Dually decoded genes and LBHD1 (C11orf48) ............................................................................... 64 
5.1.3. CRAMP1 (HN1L, TCE4) .................................................................................................................. 64 
XVII 
 
 
 
5.1.4. CRYM ........................................................................................................................................... 64 
5.1.5. THAP7 .......................................................................................................................................... 65 
5.1.6. NR0B2 (SHP) ................................................................................................................................. 66 
5.2. The intracellular and the new full life cycle model of HCV replication .................................................... 68 
5.2.1. The intracellular model reveals the mode of action of IFN-α......................................................... 68 
5.2.2. Both models are able to predict viral replication dynamics under drug treatment ........................ 69 
5.2.3. Extracellular, non-infectious vesicles ............................................................................................ 74 
6. REFERENCES ................................................................................................................................................... 77 
7. APPENDIX ...................................................................................................................................................... 95 
 
 
 
 
XVIII 
 
  
INTRODUCTION 
1 
 
1. INTRODUCTION 
1.1. Global disease burden by chronic viral infections 
Ever since, viral epidemics and pandemics have cost millions of human lives [1]. The first human 
pathogenic virus isolated in 1901 was yellow fever virus [2], but today we know at least 249 viruses 
that infect humans [3]. Virological research led to the development and widespread use of 
vaccinations and treatments for different viral diseases, culminating in the global eradication of 
smallpox and elimination of polio in most countries [4, 5]. Whereas most of them are very rare or 
cause only acute but still deadly disease, few of them progress into chronic infections and possess 
huge burdens for global health, e.g. human immunodeficiency virus (HIV), human 
papillomaviruses (HPV), or hepatitis viruses B and C (HBV, HCV) [6]. Since many of them cause 
cancers, their attribution to deaths is often underestimated due to limited diagnosis. However, 
the awareness of infectious diseases contributing to cancer and cancer-related deaths is 
increasing. As of 2012, at least 15% of all cancers worldwide, even more in low- to middle-income 
countries, were attributed to infectious agents [7]. In 2017, almost 10 million people worldwide 
died of cancer [8]. HBV and HCV are the causative agents of around 80% of hepatocellular 
carcinomas (HCC), the most common type of liver cancer [9]. Liver cancer rose to being the 
seventh most common and the third most death-causing cancer worldwide in 2014 [10], having 
killed almost 820.000 people in 2017 [8]. The global disease burden of chronic hepatitis and 
associated liver cancer is expected to further increase as annual deaths rose from 0.89 in 1990 to 
1.45 million in 2013 [11], whereas HIV-associated deaths declined from 2 million in 2005 to 1.1 
million in 2015 [6]. In addition, less than 20% of the estimated 71 million people worldwide [12, 
13] living with chronic HCV infection were aware of their infection as of 2017, and only roughly 
15% received treatment in that same year [14]. It is this low rate of awareness of their infection 
of patients, among others, which fuels further spread [15]. Most infections are transmitted by 
sharing needles among people who inject drugs, use of non-sterile medical equipment, 
transfusion of unscreened blood products, and sexual practices among men who have sex with 
men [16-18]. For many years now, direct-acting antivirals (DAAs) have replaced interferon (IFN)-
α-based regimens and revolutionized HCV treatment, especially regarding cure rates and side 
effects [19]. Cure is defined as the absence of detectable HCV RNA in patient serum after a certain 
time of treatment (e.g. 8, 12 or 24 weeks) and called sustained virologic response (SVR). Whereas 
in the IFN era, SVR rates were around 50%, markedly varying depending on the genotype or 
comorbidities, DAA treatment achieves SVR rates of usually above 90%, independent of genotype, 
liver disease, or HIV co-infection [20-22]. Still, due to limitations in diagnosis, access to treatment, 
and the risk of re-infection in high-risk populations, the demand for further research and a 
prophylactic vaccine is highly warranted [23-25]. The World Health Organization (WHO) defined 
the goal of eliminating HCV as a global health threat by 2030, meaning a reduction in incidence by 
90% and by 65% in mortality [26]. 
INTRODUCTION 
2 
 
1.2. HCV classification & epidemiology  
HCV is the typical member of the Hepacivirus genus in the Flaviviridae family [28]. Members of 
the Flaviviridae family are enveloped (+)-stranded RNA viruses with genome length roughly 
between 9–13 kilobases (kb) [29]. Other genera in this family are Flavivirus, Pestivirus, and 
Pegivirus. Members of the Flavivirus genus are usually arthropod-borne, and cause severe disease 
in humans, e.g. yellow fever virus, West Nile virus, dengue virus, or Japanese and tick-borne 
encephalitis virus [29]. Economically important are members of the Pestivirus genus, which can 
cause severe harm to livestock, like bovine viral diarrhoea virus or classical swine fever virus. One 
Pegivirus representative is human pegivirus (HPgV, formerly GBV-C/HGV) that causes persistent 
infections in 1–4% of the world’s population without apparent disease formation, but rather with 
an immune-stimulatory effect [29, 30]. Serological studies suggest that the prevalence is even 
higher as 5–13% of healthy blood donors were shown to be anti-HPgV E2 positive [31]. 
Interestingly, HPgV seems to improve disease outcomes in HIV- and Ebola virus-infected people 
[32, 33]. However, a recent case study described two women that succumbed to leukoencephalitis 
due to an HPgV infection [34]. GB virus B (GBV-B) was for a long time the only other member of 
the Hepacivirus genus [30]. Since deep sequencing methods have become broadly available 
though, many non-human homologs of HCV have been found, e.g. in horses, rodents, and bats 
[30]. This development also led to the identification of many more (sub)types of HCV, which 
comprises now eight different genotypes compiling 90 subtypes [28, 35-37]. The geographical 
distribution as well as incidence of the eight different genotypes varies vastly around the globe 
with genotypes (gt) 1 (up to 50%) and 3 (17.9–30.1%) being the most common [27, 38, 39] (Figure 
1). Gt 1 dominates Europe, America, and most parts of Asia, although gt 3 is common, too. The 
hotspot for gt 4 is Africa, and gt 6 is mainly found in East and Southeast Asia. There have been only 
few patients with gt 7 and 8, originating from the Democratic Republic of Congo and India, 
respectively [40, 41]. Gt 5 spreads almost exclusively in Africa, and gt 2 is most common in West 
Africa, but also widely found in East Asia and Japan. In European countries along the 
 
Figure 1 Worldwide prevalence of HCV and distribution of genotypes as of 2015. Genotype (gt) 1 is the most 
prevalent and dominating gt in most countries, e.g. America, Europe, most parts of Asia, Oceania, and North Africa 
and Middle East. Gt 3 dominates in South Asia and gt 4 is mostly prevalent in Africa. Note that as of 2015 HCV 
classification compiled only six different gt. Figure from [27]. 
INTRODUCTION 
3 
 
Mediterranean Sea, gt 2 is highly prevalent in Italy (27%) [42]. The three most common gts in 
Germany are gt 1 (71.6%), 3 (20.4%), and 2 (5.6%) [27]. 
1.3. HCV genome organization, polyprotein processing, and protein 
function 
Despite the high diversity of HCV genotypes, there are highly conserved structures and features 
that hold true for every genotype and subtype. HCV harbors a (+)-oriented, single-stranded RNA 
genome of about 9.6 kb in length [44]. The 5’- and 3’-ends contain untranslated but highly 
structured regions essential for RNA translation and replication (UTRs) (Figure 2) [43]. The 5’-UTR 
contains several stem loops (SL) of which SLII–IV form an internal ribosome entry site (IRES) 
structure [45-47]. Translation initiates with a very limited set of eukaryotic initiation factors (eIF) 
and by direct recruitment and binding of the small ribosome subunit 40S and eIF3 to the HCV IRES 
structure [46, 48, 49]. Upon recruitment of the ternary complex eIF2-GTP-Met-tRNAiMet and the 
GTPase-activator protein eIF5, the 80S ribosome is assembled and translation starts from the AUG 
at position 342 [50, 51]. HCV has also evolved alternative ways of translation initiation in case eIF2 
is inhibited by phosphorylation of its α subunit as means of an antiviral response of the cell [52]. 
In such a case, translation of HCV RNA can be initiated with eIF5B, eIF2B, or eIF2A as replacements 
for eIF2 [51]. Besides many trans-acting host proteins involved in HCV IRES-mediated translation 
(reviewed in [51]), one micro-RNA (miR) plays an equally unusual as important role, miR-122. The 
HCV 5’-UTR harbors two conserved miR-122 binding sites around SL1, and four more can be found 
in the NS5B coding region as well as in the 3’-UTR [53, 54]. MiR-122 is essential for efficient HCV 
replication, as originally shown by sequestration of miR-122 using complementary 2’-O-
methylated RNA oligonucleotides [55]. The miR-122 effects on HCV RNA are multifaceted and 
include increased translation [56-58], stability [58-61], and replication of the HCV genome [62]. 
The liver-specific expression of miR-122 likely contributes to the hepatotropism of HCV [63]. The 
3’-UTR of the HCV genome contains highly conserved sequences, and especially structures, like a 
 
Figure 2 HCV genome organization and features of the highly structured 5‘- and 3‘-UTRs. The (+)-oriented single-
stranded HCV RNA genome is roughly 9.6 kb in length and flanked by untranslated but highly structured regions (5’- 
and 3’-UTR). The single ORF encodes 10 mature viral proteins, from 5’ to 3’: Core, E1, E2, p7, NS2, NS3, NS4A, NS4B, 
NS5A, and NS5B. The 5’-UTR forms an IRES structure and harbors two miR-122 binding sites and several stem loops. 
The highly structured and partly conserved 3’-end starts already in the NS5B coding region and harbors a cis-acting 
replication element (CRE), a highly conserved polyU/UC tract and the so called X-tail, compiling stem loops 1 to 3 
(SL1–3). Arrows indicate long-range RNA-RNA interactions. Adapted from [43]. 
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pseudoknot (CRE) or stem loops SL1–3, that are essential for replication, probably due to their 
role in (-)-strand synthesis initiation (Figure 2) [43, 64]. Besides the pseudoknot CRE structure that 
is located in the NS5B coding region, important 3’-components are the variable region, a poly 
U/UC stretch, and the X-tail, which is composed of SL1–3 [43]. 
HCV has a single open reading frame (ORF) encoding a large polyprotein that is co- and post-
translationally cleaved by host and viral proteases into ten mature proteins (Figure 3) [65]. Core 
(C) and the two glycoproteins E1 and E2 belong to the structural class of HCV proteins as they form 
the virus particle [44]. The viroporin p7 and the cysteine protease NS2 are dispensable for 
replication but essential for assembly [66]. The remaining non-structural proteins are all required 
for replication: the protease and helicase NS3 with its co-factor 4A, the transmembrane protein 
NS4B, the phosphoprotein NS5A, and the RNA-dependent RNA polymerase (RdRp) NS5B [67]. The 
signal sequence between Core and E1 targets the nascent polyprotein to the endoplasmic 
reticulum (ER), where signal peptidase (SP) cleaves off the immature Core protein from the 
polypeptide chain [68]. The signal sequence is subsequently cleaved off by the membrane-located 
signal peptide peptidase (SPP) from the Core C-terminus to yield the mature Core protein (Figure 
3) [69]. The mature Core protein forms dimers [70], binds and folds the HCV genome [71], and 
localizes to lipid droplets [72]. It is required for particle formation as it builds the nucleocapsid. 
The transmembrane glycoproteins E1 and E2 form heterodimers in the ER membrane and are the 
major components of the HCV envelope [73]. Their ectodomains, reaching inside the ER lumen, 
are highly glycosylated (six and eleven glycosylation sites at E1 and E2, respectively) and contain 
several conserved cysteine residues for potential disulfide bond formation [67]. Indeed, E1 and E2 
form oligomers, connected via disulfide bonds upon particle assembly [74].  
 
Figure 3 HCV genome organization with indicated cleavage sites of host and viral proteases (A) and mature protein 
structure and localization (B). (A) The HCV genome harbors highly structured but untranslated regions in its 5’- and 
3’-ends. The Core protein (C) is cleaved off from E1 by signal peptidase (indicated by scissors) and further processed 
by signal peptide peptidase (indicated by *) to the mature version. Further signal peptidase cleavage occurs between 
E1 and E2, E2 and p7, and p7 and NS2. NS2 cleaves itself off from the polyprotein at its NS3 junction (indicated by 
light purple arrow) and the NS3 protease processes the remaining polypeptide at the indicated sites (dark purple 
arrows). AUG = start codon; Stop = stop codon. (B) All HCV proteins are membrane-associated, either by one or more 
amphipathic helices and/or by one or more transmembrane domains. Details are provided in the main text. Adapted 
from [44]. 
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The viroporin protein p7 forms hexa- and heptameric proton channels to avoid acidification of 
organelles involved in HCV particle maturation and is required for assembly and release of 
infectious virions [75, 76]. However, p7 probably exerts other functions in HCV assembly apart 
from its function as an ion channel [67, 77]. The NS2 cysteine protease liberates itself from the 
emerging polypeptide by cleaving at the NS3 junction [67]. Apart from this cleavage event, no 
other targets of NS2 are known [75]. NS2 plays a major role in particle assembly by interacting 
with various other structural and non-structural HCV proteins [78]; however, NS2 exerts this role 
independent of its proteolytic activity [79, 80]. NS3 has protease as well as NTPase/helicase 
function [81]. Its serine protease function is located in the N-terminal part of NS3 with the catalytic 
triad His-Asp-Ser and is stabilized by a coordinated Zn2+ ion between three cysteines and one 
histidine [81]. The NS3 protease processes the HCV polypeptide at four sites between NS3 and 
NS5B in a specific, non-sequential order [82]. The NS3 helicase function, which resides in the 
C-terminal part, is as well required for efficient replication [83] and assembly of infectious particles 
[84]. It is able to unwind DNA as well as single- and double-stranded RNA (as present in the form 
of secondary structures in the HCV genome) upon hydrolysis of ATP [81, 85]. The NS3 protease 
not only processes the HCV polypeptide but also blunts the antiviral response raised by the host 
cell by cleaving the signaling proteins MAVS [86] and TRIF [87] (details below). NS3’s co-factor 
NS4A helps in proper folding and membrane anchoring of NS3 via its N-terminal transmembrane 
domain [81, 88] but without affecting RNA unwinding rate or processivity of the NS3 helicase [85]. 
The highly hydrophobic transmembrane protein NS4B seems to be the major player in inducing 
the membrane alterations that lead to the formation of the HCV replication compartment (RC), 
often designated the “membranous web” [89, 90]. NS4B consists of two N-terminal amphipathic 
helices, four transmembrane domains, and two C-terminal α-helices with two palmitoylation sites 
[89, 91]. The C-terminal domain is highly conserved and responsible for NS4B oligomerization and 
membranous web formation [92, 93]. The phosphoprotein NS5A has an N-terminal amphipathic 
membrane anchor and three domains (D1–3), separated by the two low complexity sequences 
(LCS) LCS1 and LCS2 [67]. NS5A exists in at least two distinct forms, the hypophosphorylated p56 
and the hyperphosphorylated p58 form [94]. The phosphor-sites are serines mainly located in 
LCS1  and LCS2 [67]. NS5A domains D1 and D2 are indispensable for replication, whereas D3 is 
required for assembly but dispensable for replication [95-98]. D1 is the only domain for which the 
structure could be resolved [99] as D2 and D3 are highly unstructured. Accordingly, D1 forms at 
least dimers in its active form i) in which each monomer coordinates one Zn2+ ion and ii) which 
builds a groove for RNA binding [99]. This theoretical proof for the RNA binding ability of NS5A is 
supported by biochemical evidence of NS5A binding to HCV RNA [100]. The intrinsically unfolded 
nature of D2 and D3 is thought to support the various interactions of NS5A with host and viral 
proteins [67]. Two of these host factors, caseine kinases Iα and II, phosphorylate NS5A and give 
rise to the hypo- and hyperphosphorylated forms [96, 101]. Another one, phosphatidylinositol-4 
kinase III α (PI4KIIIα), is the most robustly reported HCV host factor and recruited as well as 
activated by NS5A. PI4KIIIα is essential for the formation of the membranous web and thus for 
HCV replication [102-104]. The last encoded protein on the HCV genome is the viral RdRp NS5B 
[105]. The polymerase synthesizes the (-)-strand replication intermediate as well as progeny (+)-
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strands for translation or particle assembly in the RC. NS5B is a typical RdRp forming a so-called 
right-hand shape with palm, thumb, and finger domains (Figure 4) [43]. Its active domain is located 
in the N-terminus, separated by a linker domain from the C-terminal membrane anchor [106]. The 
C-terminus is dispensable for its RdRp activity but required for HCV replication [107]. Most 
crystallization studies have used the C-terminally truncated version (∆C21) due to its largely 
increased solubility [43, 108]. The active site of the polymerase is the highly conserved GDD motif 
[109] and has complexed two divalent metal ions for NTP polarization, either Mn2+ or Mg2+ [110, 
111]. 
1.4. On the history of hepatitis C virus (HCV) 
The discovery of hepatitis C, back then non-A non-B hepatitis (NANBH), was already in 1975, when 
HBV and HAV could be excluded as causative agents of the observed transfusion-mediated 
hepatitis [113, 114]. It then took almost 15 years until the tremendous efforts undertaken by many 
groups culminated in the first successfully identified cDNA clones of HCV [115, 116]. This finally 
allowed the screening of blood products for the presence of HCV antibodies and eventually led to 
the disruption of this major route of transmission [117, 118]. Having HCV RNA at hand allowed a 
first characterization of the viral RNA sequence as well as its encoded proteins in expression 
studies [113, 119, 120]. Ten years later, in 1999, many aspects of HCV biology, like genome 
orientation, length, polyprotein processing, and the functions of at least the enzymatic HCV 
proteins had been illuminated [121-123]. However, just then, the first successful, robust and 
continuous replication of HCV in cell culture was reported [124]. Key to this success was the 
development of self-replicating subgenomes, dubbed “replicons”, where the structural gene 
information was replaced by a neomycin phosphotransferase gene (neo) conferring resistance to 
neomycin (G418) (Figure 5) [124]. This allowed the selection of cell clones stably replicating HCV 
RNA and expressing the antibiotic resistance gene to sufficient amounts. Among many tested cell 
lines, only one yielded clones with robust replicon levels after selection, the human hepatoma cell 
line Huh7 [125] (reviewed in [126]). Those stable replicon cells paved the way for studies on 
replication, pathogenesis, and high-throughput antiviral screening [124]. The replicon in this initial 
study was based on a genotype 1b isolate and derived from a consensus sequence that was cloned 
from two genome fragments (Con1). Later, it was found that adaptive mutations that occurred 
 
Figure 4 Ribbon diagram of a genotype 1b (J4) RdRp with a C-terminal truncation (NS5B∆C21) representing the 
so-called right-hand structure with fingers, thumb, and palm. The finger domain is in blue, palm in purple, thumb 
in green, and the C-terminus in yellow. The position of the inhibitory ß-flap and the complexed Mn2+ ions are 
indicated. Adapted from [112].  
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during the selection process were responsible for the efficient replication of that replicon [127, 
128]. Stable replicon cell lines were established and named after their encoded genes, for example 
Huh7-LucUbiNeo (luciferase, ubiquitin, neomycin phosphotransferase) [129, 130]. Similar efforts 
as for the Con1 replicon yielded the subgenomic Japanese fulminant hepatitis (JFH-1) replicon, 
which belongs to genotype 2a, and became the gold standard in HCV research due to its 
unprecedented replication efficiency [131]. Intriguingly, JFH-1 replicated efficiently without 
conferring any adaptive mutations [131]. It became the first full-length HCV genome that could be 
propagated in cell culture and produced progeny virus [132, 133]. Still today, it is the only isolate 
that efficiently replicates in cell culture without requiring adaptive mutations [134]. Based on the 
JFH-1 replicase, infectious chimeric full-length versions of all seven HCV genotypes have been 
developed, allowing the study of their differences in infectivity, neutralization, and particle 
formation [135]. Also the JFH-1 replicon was used to generate a stable replicon cell line, named 
Huh7-LucUbiNeo-JFH [136], that allowed the development of drugs or testing the impact of 
different interferons on HCV replication. Curing such cell lines from their replicon by using IFN in 
combination with nucleotide analogs or drugs directly affecting HCV proteins, yielded cell lines 
with high HCV replication efficiency that could be used for transient replication or infection assays 
[126]. Those cell lines support HCV replication to much higher levels than their mother cell lines, 
although the underlying mechanisms mostly remain elusive [126]. Examples for such cell lines are 
Huh7-Lunet [137] or Huh7.5 cells [138]. We have learned a lot in the last two decades about the 
molecular biology of HCV, its host factors as well as viral determinants, and achieved effective 
treatments [65]. However, there are still many open questions, regarding the role of host factors 
for viral replication, the molecular processes involved in liver disease formation, and the molecular 
action of inhibitors of viral proteins [23]. 
 
 
 
 
Figure 5 Depiction of the strategy that allowed HCV replication in cell culture for the first time. The consensus 
sequence, cloned from a patient isolate, was modified as follows. A neomycin phosphotransferase (neo) gene, 
allowing antibiotic selection with G418, replaced the genetic information for the structural genes. For robust 
expression of the non-structural genes NS3–NS5B (3–5B), an EMCV IRES (EI) was inserted after the neo gene. A T7 
promoter drove the in vitro transcription to gain a high quantity of (+)-strands. These (+)-strands were electroporated 
into cells, and after few weeks of culture under G418 selection, clones, carrying the replicating HCV subgenome, 
came apparent. ScaI, restriction enzyme cleavage site for terminating transcription; NTR = non-translated region; 
EI = EMCV IRES; T7 = T7 polymerase promoter. Adapted from [128]. 
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1.5. The HCV life cycle 
HCV infection is transmitted parenterally where HCV particles reach hepatocytes, the main HCV 
target cells, via the bloodstream [139, 140]. HCV particles are tightly associated with lipids, 
lipoproteins, and cholesteryl esters, forming so-called lipoviroparticles (LVPs), and localize to the 
low- to very low-density lipoprotein (LDL/VLDL) fraction upon purification from patient serum 
[141, 142]. The buoyant densities span from 1.25–1.06 in patient serum and are around 1.1 g/mL 
in cell culture-produced HCV particles (HCVcc) due to heterogeneity of the lipid coat [66]. The 
infection process starts with attachment of the LVPs to the hepatocyte basolateral surface (Figure 
6A). This process is mediated by interaction of heparin sulfate proteoglycans (HSPG), LDL receptor 
(LDLR), and scavenger receptor class B member I (SCARB1 or SR-BI) with mostly the LVP lipoprotein 
components but also the HCV glycoprotein E2 [143, 144]. Conformational changes in E1 and E2 
allow further interactions with cluster of differentiation 81 (CD81) [145] which in turn leads to a 
re-localization of the LVP to tight junctions and the recruitment of claudin-1 (CLDN) [146] and 
occludin (OCLN) [147] [143, 148]. The receptor-LVP complex is internalized in a clathrin-dependent 
manner and the viral envelope fuses with the endosomal membrane in a pH-dependent fashion 
[149-151]. This fusion liberates the viral RNA genome into the cytoplasm where the host 
translation machinery directly starts translation via the IRES structure in the 5’-UTR of the genome. 
After polyprotein processing, replication of the viral genome takes place in specialized, ER-derived 
replication organelles that form the membranous web (Figure 6A) [90, 152, 153]. Those specialized 
compartments highly protect the viral genome and its (-)-strand  
 
Figure 6 Schematic of the HCV life cycle (A), electron micrographs of the membranous web, DMVs, and HCV particle 
(B), and cartoon image of a mature HCV LVP (C). (A) The HCV life starts with the infection of a host cell, 
internalization of the LVP, and release of the viral (+)-RNA (top left corner). Translation yields mature viral proteins 
at the rough ER, which induce the formation of the membranous web where viral RNA replication takes place in 
exvaginations from the ER and DMVs, and assembly of viral particles occurs in close proximity to LDs (middle to lower 
left corner). Assembled particles are secreted via the secretory pathway (right part). (B) Electron micrographs 
showing key features of HCV replication. B1 shows DMVs in close proximity to LDs. B2 shows a single DMV in high 
resolution. B3 shows a single DMV after putative exvagination from and still connected to the ER. B4 shows an 
authentic HCV LVP isolated from patient serum. (C) Cartoon image based on findings from electron micrographs, 
showing the viral genome (RNA) encapsidated by Core (NC), and surrounded by the envelope proteins E1 and E2 
(E1E2). The viral envelope is further enwrapped in a lipid layer, containing apoE (ApoE) and apoB (ApoB) 
apolipoproteins. (A) and B1 are adapted from [43]. B2 and B3 are adapted from [152] and B4 and (C) are adapted 
from [154]. 
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replication intermediate as well as the viral proteins needed for replication as shown by nuclease 
and protease treatment [43]. The membranous web is a polymorphic structure that contains 
single-, double-, and multi-membrane vesicles, originated from various cellular structures, mainly 
the ER, but also endosomes, mitochondria, and lipid droplets (LDs) (Figure 6A, -B) [152]. The 
formation of those vesicles is a concerted action of the viral non-structural proteins since 
expression of neither of the singular ones yields sufficient amounts of especially double-
membrane vesicles (DMV) in which replication is thought to happen (Figure 6B1–3) [152, 155]. In 
contrast to invaginations from the ER membrane as during dengue virus replication [156], DMV 
structures might rather form from exvaginations from the ER during HCV infection (Figure 6B3) 
[152]. Besides the non-structural HCV proteins, also host proteins seem to be involved in DMV 
formation, as suggested for the autophagy protein Atg5 [157] and the vesicle-associated 
membrane protein-associated proteins A (VAP-A) and B (VAP-B) [155], and convincingly shown for 
the integral membrane protein Surfeit-4 [158]. The close proximity to LDs and the nature of the 
LVPs prompted investigators to speculate that LDs are the site of assembly for infectious HCV 
particles for a long time, although convincing studies were missing [66]. A recent study though 
provided evidence for putative assembly sites at LDs tightly wrapped by ER membranes and co-
localized with the envelope protein E2, the nucleocapsid protein Core, and NS5A as a 
representative of the replicase machinery [159]. Key roles in this assembly and recruitment 
processes are not only inherent to Core and NS5A, which are able to localize to LDs via their 
amphipathic helices [160, 161], but especially to NS2, which presumably via p7 and NS3 recruits 
the replicase complex to LDs [78, 162, 163]. Due to the pleomorphic structure and lipid 
composition of HCV particles, visualization of budding particles could still not be achieved in this 
study [164]. However, another recent study was successful in specifically purifying HCV particles 
from patient serum and cell culture supernatants to give us high-resolution insights into the face 
of mature HCV particles (Figure 6B4) [154]. Assembled particles are secreted via the VLDL pathway 
to enter the bloodstream and accordingly contain apolipoproteins E, B, and others [142, 154, 165, 
166].  
1.6. Host factors involved in HCV replication 
Since HCV brings along only the required machinery to replicate its genome and assemble its 
particles, it heavily relies on host components in almost every step of its entire life cycle. Before 
entering the cell, HCV already requires the presence of surface proteoglycans and receptors to be 
able to attach to and enter the cell, namely SCARB1, CD81, CLDN1, OCCL, and others (see also 
above) [167]. Interaction with those surface markers is only partly attributable to the HCV 
envelope but also necessarily to its lipid coat, including apolipoproteins E (apoE), apoB, and many 
others [168]. After entry, HCV RNA is directly translated via its IRES structure. During translation 
initiation, miR-122 plays a central role in stabilizing HCV RNA and favoring a translation-competent 
secondary and tertiary structure [58] (see above). For efficient replication, HCV usurps cellular 
enzymes and lipids to build its membranous web. One of the key enzymes in this process is PI4KIIIα 
that is recruited by NS5A and catalyzes the formation of phosphatidylinositol 4-phosphate (PI4P) 
[104]. PI4P is enriched in HCV replication compartments and recruits further host proteins, like 
oxysterol-binding protein (OSBP), Niemann-Pick-type C1 (NPC1), and others that contribute to the 
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optimal lipid and protein composition of the membranous web [167, 169, 170]. NS5A also 
interacts with a peptidylprolyl isomerase (PPIA, also known as CypA), that is essential for HCV 
replication [171, 172]. The mechanism of action is still elusive, but certainly affects membranous 
web formation [173]. However, if the physical interaction between PPIA and NS5A or the prolyl 
isomerase activity of PPIA is crucial, is hard to determine since both functions reside in the very 
same site of the protein and cannot be separated from each other ([174] and references therein). 
The last step of the HCV life cycle, particle assembly and release, heavily depends on the host 
supply of lipid coat components as well as its secretory pathway. Diacylglycerol O-acyltransferase 
1 (DGAT1) is a critical enzyme involved in LD biogenesis and recruits HCV Core to LDs during the 
assembly process [175]. Upon knockdown of DGAT1 or by using an inhibitor, HCV particle 
assembly and release are severely impaired [175]. The importance of lipids and lipoproteins during 
HCV infection can thus not be underestimated and shows its intricate and sophisticated adaption 
to its human host. 
1.7. Treatment of chronic HCV infection 
Most HCV infections present with very mild to no symptoms and progress into chronicity in 75–
85% of patients [176]. Rare acute hepatitis C shows among other symptoms: jaundice, fatigue, 
vomiting, and abdominal pain [177]. Worldwide, an estimated 71 million people are chronically 
HCV-infected [12] and despite effective treatment options, awareness of infection and access to 
diagnosis are low; hence, numbers of new infections are on the rise [11, 178]. Although NANBH 
was well-described [114], it was even before HCV was identified as its causative agent in 1989 
[115] that the first ten patients were treated in a pilot study using recombinant IFN-α [179]. 
Remarkably, 50% of those patients achieved long-time SVR and were free of detectable viral load 
even 15–25 years later [22, 179]. Unfortunately, this clearance rate could not hold up in large 
trials, and SVR rates turned out be as low as 6–19% [22] (Figure 7). In the following years, SVR 
rates steadily increased by combining IFN-α with the guanosine analog Ribavirin (RBV) that proved 
broad antiviral activity [180], and later by covalently attaching chains of polyethylene glycol (PEG) 
to IFN-α [22] (Figure 7). PEG-IFN-α showed extended serum half-life, which allowed reducing 
 
Figure 7 Cure rates (% SVR) of chronic HCV infection in patients from the 1990s to 2015. Treatment of chronic HCV 
infection started with recombinant IFN-α, was then combined with Ribavirin (RBV) and IFN-α was later replaced by 
polyethylene glycol (PEG)-IFN-α. The first direct-acting antivirals (DAAs) against HCV used in combination with PEG-
IFN-α and RBV were protease inhibitors (PI) targeting HCV NS3/4A. The first nucleotide analog (NA) used in such a 
combination therapy (instead of PIs) was Sofosbuvir. From 2015 on, IFN-free regimens became widely available.  RBV 
= ribavirin. Adapted from [22].  
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administration by injection from daily or three times a week to once per week, probably increasing 
patient compliance [181]. Combination therapies of PEG-IFN-α + RBV led to SVR rates of overall 
50% with vast differences between genotypes [22]. The dawn of direct-acting antivirals (DAAs) 
against HCV improved SVR rates further. The first DAAs used in combination therapies with 
PEG-IFN-α + RBV were inhibitors against the HCV protease/helicase NS3/4A (PI), Boceprevir [182, 
183] and Telaprevir [184, 185] in 2011. These first-wave first-generation PIs increased SVR rates 
to around 70% but were less well-tolerated, genotype-restricted, and had low barriers to the 
emergence of resistance mutations [186] (Figure 7). These downsides of first-generation PIs 
vanished rapidly with the development of second- and third-generation PIs and with the 
combination of DAAs against other viral proteins [187]. Shortly after, in 2013, the first approved 
drug against the HCV RdRp NS5B hit the market and raised clearance rates further to 90% on 
average, the nucleotide analog Sofosbuvir (SOF) [188, 189]. SOF was the first DAA to be 
administered in an IFN-free regimen, either with [190-192] or without RBV [193-196]. In 2014, the 
first all-oral single-tablet regimens were available, providing a huge release of administration and 
side effect burden for the patients [189]. With those, also inhibitors of the HCV phosphoprotein 
NS5A joined the team of clinically administered DAA, amongst the first ones Ledipasvir and 
Daclatasvir [193, 196]. As of today, the majority of patients ca be treated with pan-genotypic, all-
oral single-tablet regimens once daily [20, 197] and achieve SVR rates of 95–100% in the course 
of an eight- or 12-week treatment [198-200]. Besides the overwhelming advantages of no to only 
mild side effects, easy one-pill-per-day-treatments, and short treatment times, hurdles and 
problems in the DAA era still exist. Treatment costs are often high, especially in the developed 
world, drug-to-drug interactions do exist and need to be carefully considered, and resistance-
associated mutations (RAS) arise during therapy [23, 201, 202]. 
1.8. The innate immune response to HCV infection 
The innate immune response poses the first line of defense against invading pathogens. Upon 
sensing of infection, many signaling pathways are triggered and specialized immune cells of the 
innate and adaptive system are recruited [203]. Despite the importance of natural killer (NK) cells, 
dendritic cells (DCs), neutralizing antibodies, the complement system, as well as CD4+ and CD8+ T 
cells in HCV clearance [204, 205], the following section focuses on the cell-intrinsic antiviral 
immune response.  
1.8.1. HCV RNA detection and signal cascade activation 
The first act of an antiviral response of the host cell is detection of the viral invader. Cells evolved 
many ways to sense so-called pathogen-associated molecular patterns (PAMPs) that can be 
nucleic acids or other components of the pathogen body [206]. The main sensors of nucleic acids 
constitute three classes of pattern recognition receptors (PRRs): toll-like receptors (TLRs), retinoic 
acid inducible gene I (RIG-I)-like receptors (RLRs), and cytosolic DNA sensors [207]. Since the 
cytosolic DNA sensors as well as some members of the TLR family mainly recognize bacterial and 
viral DNA [206-208], this chapter will mainly focus on those receptors sensing single- (ss) and 
double-stranded (ds) RNA. Those comprise TLR3, -7, and -8 as well as the RLRs RIG-I, melanoma 
differentiation antigen (MDA5), and DExH-box helicase 58 (DHX58, also called LGP2). The TLRs 
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sense foreign nucleic acids either on cell surfaces or in endosomal compartments, whereas RIG-I, 
MDA5, and LGP2 are cytoplasmic RNA sensors [206]. TLR3, -7, and -8 are widely expressed on 
specialized immune but also on epithelial and other non-immune cells [209]. TLR3, RIG-I, MDA5, 
and LGP2 are strongly activated upon binding of dsRNA, a side product of HCV replication [210-
213]. Consequently, all of them are able to sense HCV infection [214-218], however the main 
sensor for HCV RNA seems to be RIG-I [219] and LGP2 lacks CARD domains that are essential for 
signal transduction, thus its role in antiviral signaling is controversial [213]. Also TLR7 has been 
implicated in HCV RNA sensing in macrophages and plasmacytoid DCs [220, 221], although TLR7 
and -8 mostly recognize ssRNA, for example during HIV-I, influenza A virus or vesicular stomatitis 
virus infections [222, 223]. Although differently located, sensing of such dsRNA by TLR3 or RIG-I 
and MDA5 culminates in the activation of the same signaling cascades. Activation leads to 
phosphorylation of the transcription factors interferon regulatory factor 3 (IRF3) and IRF7 by 
inhibitor of NF-κB kinase (IKK) epsilon (IKKε) and TANK binding kinase 1 (TBK1) [224, 225]. The 
TLR3-TRIF pathway also activates the transcription factor NF-κB via a different route [211, 223]. 
Those executive kinases are recruited by the adaptor proteins Toll-interleukin (IL)-1 receptor 
domain-containing adaptor inducing IFN-β (TRIF) (in case of TLR3) or mitochondrial antiviral 
signaling protein (MAVS) (in case of RIG-I and MDA5) [206]. The phosphorylated IRFs dimerize and 
shuttle to the nucleus where they lead to the expression of type I (IFN-β) and III (IFN-λ) IFNs and 
several ISGs [226-228]. This first wave of IFNs triggers the expression of hundreds of more ISGs via 
JAK-STAT signaling in auto- and paracrine manner [229]. Type I IFNs, which also include IFN-α and 
others, signal through a heterodimer of IFN alpha and beta receptor subunit 1 (IFNAR1) and 
IFNAR2, whereas type III IFNs bind a heterodimer of IFNLR1 and IL10 receptor beta (IL10RB) [230, 
231]. This heterodimerization recruits the Janus kinases JAK1 and TYK2, which phosphorylate the 
intracellular receptor domains, which in turn recruits signal transducer and activator of 
transcription 1 (STAT1) and STAT2 [229]. Phosphorylated STAT1 forms either homodimers or 
heterodimers with STAT2, which further recruit IRF9 to form ISGF3. Those complexes translocate 
to the nucleus and drive transcription of more ISGs [230]. To prevent overshooting of the system, 
negative regulators are also upregulated that prevent further stimulation of the system (see 
below). One highly interesting just recently discovered IFN-λ exerts both, anti- as well as pro-viral 
activities during HCV infection, equally baffling and exciting researchers, IFN-λ4. A single 
nucleotide deletion leads to a frameshift and creates an ORF, which allows the production of 
IFN-λ4 and results in reduced rates of spontaneous clearance and achieved SVR in IFN-based 
treatment outcomes [232]. IFN-λ4 activates JAK-STAT signaling as do the other type I and III IFNs 
and thus inhibits HCV replication in vitro; however, it also leaves the cells refractory to further 
type I or type III IFN stimulation [232]. HCV infection specifically triggers IFN-λ4 expression and 
thereby effectively blocks IFN-α signaling via negative feedback by ISG15, ubiquitin-specific 
peptidase USP18, and suppressor of cytokine signaling 1 (SOCS1) [233, 234]. ISG15 is a 
ubiquitin-like, IFN-stimulated gene (ISG) that is up-regulated not only upon IFN stimulation but 
many other stimuli like dsRNA, viral infection, or lipopolysaccharide (LPS) [235, 236]. It can exert 
its function either unconjugated as a cytokine or by conjugation to other proteins and thus 
modifying their function, a process known as ISGylation, similar to ubiquitination [235]. One 
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example is ISGylation of IRF3, which prevents its polyubiquitination and subsequent degradation, 
thereby preserving the antiviral state of the cell [237]. However, ISGylation can also lead to 
aggregation and lysosomal degradation of proteins, blockage of interaction with other proteins, 
or changes in the autophagic flux in the cell, the latter posing a possible explanation for the often 
chronic course of HCV infection due to increased IFN-λ4 expression [236]. Additionally, it was 
shown that overexpression of ISG15 or knockdown of a protein involved in ISGylation increases 
and inhibits HCV replication, respectively [238]. The mechanism though still needs to be 
determined. USP18, a negative regulator of the IFN pathway cleaves off ISG15 from other proteins 
and thereby markedly contributes to the suppression of JAK/STAT signaling [239, 240]. USP18 also 
blocks the interaction between IFNAR2 and JAK independent of its ISG15 protease activity and 
thus blunts further signal transduction upon IFNAR receptor activation [241]. Collectively, it seems 
that HCV has subverted the antiviral activities of IFN-λ4 and turned them into its own advantage. 
1.8.2. ISGs with anti-HCV activity 
Many of the IFN-triggered ISGs exert antiviral activity against HCV as revealed by large 
overexpression and knockdown studies [242-247]. Most of them have been confirmed in in vitro 
studies, often using the replicon system or transient replication of subgenomic reporter RNAs 
[226]. However, several examples show that an authentic HCV infection is less sensitive to certain 
ISGs and IFN treatment, pointing towards effective interfering strategies by especially structural 
HCV proteins [52, 226, 230]. Still, few examples have robustly proven their anti-HCV action in 
diverse studies. Among them are the RNA sensors that initiate the antiviral response upon 
infection or sensing of dsRNA, like RIG-I, dsRNA-activated protein kinase PKR (also known as 
EIF2AK2), MDA5, or effector and positive feedback loop proteins like many IRFs, IFN-α inducible 
proteins (IFIs), IFN-induced proteins with tetratricopeptide repeats (IFITs), and IFN-induced 
transmembrane proteins (IFITMs) [226, 242]. IFIT proteins for example have been shown to inhibit 
HCV RNA translation by binding and functionally sequestering viral RNA or the translation 
initiation factor eIF3 [247-250]. IFITM proteins rather affect viral entry by interacting with 
important receptors or RNA replication by interfering with membranous web formation or 
homeostasis [247, 251]. The latter mechanism of action might also hold true for viperin (also 
known as RSAD2), which localizes to the ER-LD interface, a hot spot for viral RNA replication and 
assembly [247]. Supporting this notion, IFITM1 as well as viperin bind VAP-A, a major component 
of HCV replication complexes [155, 159, 247]. The role of PKR in controlling HCV replication is 
ambiguous, as reports for pro- and anti-viral effects exist [52, 244, 250]. However, HCV might 
induce and activate PKR at first to stop translation of ISGs (PKR phosphorylates and thereby 
suppresses eIF2 activity, which is required for translation) but later block PKR to assure the supply 
of host products HCV needs for its replication and particle assembly. Further, the 2’-5’-
oligoadenylate synthetase/ribonuclease L (OAS/RNase L) system restricts HCV replication by 
endonucleolytic cleavage of the HCV genome, liberating dsRNA that in turn again can stimulate 
the antiviral response [252]. Despite the robust expression of all those ISGs counteracting HCV 
replication, HCV still persists in a natural infection and high base-level ISGs are even predictive 
markers for non-responsiveness to IFN treatment [253]. Why this is the case, is not entirely clear, 
yet, but countermeasures by HCV proteins probably contribute to this phenomenon. 
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1.8.3. Countermeasures by HCV 
The best established counteraction of an HCV protein is cleavage of the adapter protein MAVS by 
HCV NS3/4A to prevent signaling and activation of IRF3 and similar transcription factors, which 
could be shown in cell culture [86, 254, 255] as well as in vivo [256]. TRIF, the TLR3 signal mediator, 
was reported to be a target of NS3/4A cleavage in vitro and in cell culture systems [87]; however, 
another group found that NS3/4A is not able to cleave TRIF in such settings [257]. The role of PKR 
in HCV immune evasion is controversial due to reasons described above, but NS5A and E2 have 
been reported to suppress PKR activity and thus halt ISG induction [258]. Autophagy, a cellular 
recycling and homeostasis process, is induced upon HCV infection and helps, especially in the early 
phase, to establish HCV replication by suppressing the antiviral response of the host cell [259-
261]. This induction occurs either indirectly via ER or oxidative stress or directly via physical 
interaction of HCV and autophagic proteins [259]. In case those countermeasures are not 
sufficient, HCV has evolved ways to suppress IFN signaling upon activation of the JAK-STAT 
pathway. NS5A [262] and Core [263] have been shown to reduce phosphorylated (p)STAT1 levels 
and expression of several HCV proteins leads to lower total STAT1 as well as pSTAT1 levels, 
although only Core was found to directly bind to STAT1 [264]. Only pSTAT1 forms functional 
transcription factor complexes that shuttle to the nucleus to activate transcription of ISGs. 
Further, the HCV viroporin protein p7 was recently reported to induce SOCS3 expression, a 
negative regulator of the JAK-STAT pathway [265]. In summary, HCV evolved sophisticated and 
multifaceted ways to avoid a strong antiviral response upon infection, allowing it to build its 
replication compartment and establish a persistent infection.  
1.9. Mathematical modeling of HCV infection 
Finding answers to questions regarding the virus-host interplay are difficult considering such 
intricate biological systems. Thus, researchers developed mathematical models describing 
biological systems in the most simplified way to gain such insights. The first patient-relevant 
mathematical models described HIV-1 serum decline upon ritonavir (a protease inhibitor) 
treatment and gave insights into virion half-life, duration of its replication cycle, and provided first 
treatment guidelines [266-268]. Mathematical models of HCV infection derived from those and 
appeared during the IFN-α treatment era [269-271]. Authors explained the dose dependence of 
viral decline during the first 48 hours of IFN-α treatment by a halt in virion production rate and 
estimated the same to be around 1012 virions per day (untreated), whereas virion half-life should 
be around 2.7 hours [269, 270]. Modeling HCV RNA serum kinetics after liver transplantation 
suggested an extrahepatic HCV reservoir that accounts for 3–4% of HCV serum RNA [272, 273] and 
yielded an estimate of infected hepatocytes in the liver of 19% [273]. Such insights were hard to 
achieve at a time where no cell culture models for HCV existed and recommendations for 
improved treatment schedules were highly warranted. The first more detailed model of 
intracellular HCV replication to learn about the molecular virology was developed by Dahari and 
colleagues [274] and is based on the first of its kind detailed models of viral replication for the 
bacteriophage Qβ [275]. Dahari et al. showed the necessity of the replication compartment as a 
restricted space for HCV RNA synthesis to explain intracellular HCV RNA replication dynamics, and 
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especially steady-state levels of HCV RNA [274]. Further, they gave a rationale for the observed 
10:1 ratio of (+)- to (-)-strand RNA in such intracellular settings [274] that could be supported by 
in vitro findings [276]. An extension and refinement of the Dahari model was developed by Binder 
and colleagues to account for the highly initial phase after transfection of a host cell that could 
not be explained by the Dahari model [277]. The Binder and the Dahari model are both based on 
ordinary differential equations (ODEs) that describe every necessary step of intracellular HCV 
replication to accurately simulate replication dynamics (Figure 8). The Binder model underpinned 
the importance of the replication compartment to prevent excessive viral RNA replication and 
translation and allowed to simulate HCV replication in both, lowly and highly permissive cells 
[277]. The latter was remarkable, and was achieved by the introduction of a host factor species, 
which might be a protein, a protein complex, or a host process, involved in the establishment of 
the replication compartment and (-)-strand RNA synthesis [277]. Since the nature of the huge 
differences in permissiveness between different Huh7 derivatives was and still remains elusive, 
those modeling-derived insights were highly valuable and allowed further investigations of the 
key players in this phenomenon [277, 278]. Further, the Binder model was able to simulate the  
 
Figure 8 The Binder model for intracellular HCV replication (A) is based on ODEs (B). (A) The model scheme shows 
one cell with transfected viral RNA (RPunp) that is processed to a translation-competent form (step 1), RPcyt. RPunp 
degrades with rate µPunp and is processed to RPcyt with rate k0. These processes are represented in equation (1) (B). 
RPcyt is then able to be translated by the host translation machinery (2) and the polyprotein P forms. The polyprotein 
is then processed with rate kc into the mature viral proteins Ecyt. Translated RNA, together with Ecyt and a host factor 
(HF) can then initiate (-)-strand synthesis in the replication compartment (RC) (4). The (-)-strand initiation complex 
RIP forms a double-stranded RNA intermediate Rds (5) which can again associate with the viral polymerase (E) (RIds) 
to form progeny (+)-strands (6). Those (+)-strands are then exported to the cytoplasm where they re-enter the cycle 
(7). k are rate constants, and µ are degradation rates. (B) shows one ODE as an example: equation (1) describing the 
amount of unprocessed, transfected RNA over time. Adapted from [277]. 
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 replication of attenuated versions of the subgenomic HCV RNA that it was calibrated on [277]. A 
sensitivity analysis revealed that the most influential parameters through therapeutical 
intervention in the initial phase of replication are the RNA synthesis steps k4m and k4p governed by 
the viral polymerase NS5B in the RC [277]. Interestingly, a fundamental part of today’s HCV 
regimens is the NS5B inhibitor SOF, targeting exactly those steps. In addition, the model correctly 
predicted the rather low sensitivity towards targeting the polyprotein processing step kc, exerted 
by the NS3/4A protease, and the consequent low barrier of developing resistance mutations at 
only minor fitness costs that proved correct in the real world [277]. As such, the model gave 
valuable insights into different aspects of HCV replication that were hard to gain by sole 
experimental approaches. Still a major limitation of the model was the restriction to only 
intracellular HCV replication, which did not represent an authentic infection including cell entry, 
particle production, and spread [277]. In such a model, the impact of pharmacological intervention 
on virus production or spread of the infection could be assessed, gaining useful information about 
the real world efficacy of drugs. Thus, it is highly warranted to expedite mathematical models for 
HCV replication to gain deeper insights into HCV pathogenesis and improve our understanding 
and treatment of the disease. 
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2. MATERIAL 
2.1. Cell lines 
name [reference] used for comment 
Lunet-CGM [this study] Jc1 infection dynamics described in detail in Methods section; based on Huh7-
Lunet [137]/Huh7-Lunet-CD81high cells [279] 
LucUbiNeo-JFH [136] validation of putative HCV host factors Huh7 cells carrying a stably replicating subgenomic 
reporter version of HCV; under G418 selection (1 µg/mL) 
Huh7-LP [277] validation of putative HCV host factors low passage and lowly permissive Huh7 cells 
Huh7-HP [280] validation of putative HCV host factors high passage and highly permissive Huh7 cells 
Huh7.5 [138] Jc1 and JcR2a virus production highly permissive Huh7 cell clone; created by “curing” a 
cell line stably replicating a subgenomic version of HCV 
   
2.2. Constructs 
name purpose reference 
pFK-i389-NS3-3’-JFH (sgJFH) transient HCV replication assay  [281] 
pFK-i341-PI-Luc-EI-sgCon1-ET transient HCV replication assay  [282] 
pFK-Jc1 infection dynamics Lunet-CGM cells [283] 
pFK-JcR2a validation of putative HCV host factors [104] 
pWPI-EF1α::N-HA-THAP7-Puro validation of putative HCV host factors [278] 
pWPI-EF1α::N-HA-CRYM-Puro validation of putative HCV host factors [278] 
pWPI-EF1α::N-HA-LBHD1-Puro validation of putative HCV host factors [278] 
pWPI-EF1α::N-HA-CRAMP1-Puro validation of putative HCV host factors [278] 
pWPI-EF1α::N-HA-NR0B2-Puro validation of putative HCV host factors [278] 
pWPI-EF1α::THAP7-FLAG-Bla validation of putative HCV host factors [278] 
pWPI-EF1α::CRYM-FLAG-Bla validation of putative HCV host factors [278] 
pWPI-EF1α::LBHD1-FLAG-Bla validation of putative HCV host factors [278] 
pWPI-EF1α::CRAMP1-FLAG-Bla validation of putative HCV host factors [278] 
pWPI-EF1α::NR0B2-FLAG-Bla validation of putative HCV host factors [278] 
pWPI-ROSA26::N-HA-NR0B2-Puro validation of putative HCV host factors [278] 
   
2.3. Chemicals and reagents 
If not stated otherwise, chemicals and reagents were supplied by Carl Roth, Sigma-Aldrich, Thermo 
Fisher Scientific, or VWR International in at least molecular biology grade. 
name supplier 
ssRNA ladder Thermo Fisher Scientific 
agarose (for RNA gels) Sigma-Aldrich 
agarose (for DNA gels) Carl Roth 
APS Carl Roth 
β-mercaptoethanol Sigma-Aldrich 
Blasticidin AppliChem 
Clarity (Max) ECL Western Blotting Substrate Bio-Rad 
CloneAmp™ HiFi PCR Premix Takara BioTech 
Coelenterazine PJK Biotech 
DAPI MoBiTec 
DEPC VWR International 
D-Luciferin PJK Biotech 
DMEM, high glucose Thermo Fisher Scientific 
DMSO Carl Roth 
DNA loading dye (6x) Thermo Fisher Scientific 
DTT Sigmal-Aldrich 
EasyTides® CTP, [alpha-32P]-, 250µCi PerkinElmer 
Ethanol absolute VWR International 
Exonuclease I Thermo Fisher Scientific 
FCS Capricorn Scientific 
fluoromount G SouthernBiotech 
Gateway™ BP clonase™ II Life Technologies 
Gateway™ LR Clonase™ II  Life Technologies 
Geneticin (G418) Sulfate  Santa Cruz Biotechnology 
Gentamicin Thermo Fisher Scientific 
Glycerol Sigma-Aldrich 
IFN-α PBL Assay Science 
Isopropanol VWR International 
iTaq™ Universal SYBR® Green Supermix Bio-Rad 
Kanamycin SERVA Electrophoresis GmbH 
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Lipofectamine™ RNAiMax Thermo Fisher Scientific 
Maxima H Minus RT Thermo Fisher Scientific 
MEM Non-Essential Amino Acids Solution (100X) Thermo Fisher Scientific 
Methanol VWR International 
Midori Green Nippon Genetics 
MluI-HF restriction enzyme New England Biolabs 
NTP Set, Tris buffered Thermo Fisher Scientific 
Opti-MEM Thermo Fisher Scientific 
Penicillin-Streptomycin Thermo Fisher Scientific 
Powdered milk Carl Roth 
Precision Plus Protein™ Dual Color Standards Bio-Rad 
Puromycin Sigma-Aldrich 
Q5® High-Fidelity DNA Polyermase New England Biolabs 
qScript XLT 1-step RT-qPCR ToughMix VWR International 
Recombinant RNasin® Ribonuclease Inhibitor Promega 
ROTI®Aqua-Phenol Carl Roth 
RQ1 RNase-Free DNase Promega 
Sodium citrate dihydrate tribasic Th. Geyer 
Spectinomycin Merck KGaA 
T3 RNA Polymerase Thermo Fisher Scientific 
TEMED AppliChem 
Trition-X-100 AppliChem 
Trypsin-EDTA Thermo Fisher Scientific 
TURBO™ DNase Thermo Fisher Scientific 
  
2.4. Primary antibodies 
target source dilution purpose supplier/reference 
ß-actin mouse 1:5000 immunoblotting Sigma-Aldrich (A5441) 
calnexin rabbit 1:2000 immunoblotting Enzo Life Sciences (ADI-SPA-865-F) 
FLAG tag mouse 1:1000 immunoblotting Sigma-Aldrich (F1804) 
HA tag mouse 1:2000 immunoblotting Sigma-Aldrich (H3663) 
NR0B2 mouse 1:1000 immunoblotting Santa Cruz (sc-271511) 
NR0B2 mouse 1:50–1:500 immunofluorescence Santa Cruz (sc-271511) 
NS5A mouse 1:200 TCID50 9E10, Charles Rice, Rockefeller, NY, USA 
THAP7 mouse 1:1000 immunoblotting Abonva (H00080764-B01) 
THAP7 mouse 1:50 immunofluorescence Abonva (H00080764-B01) 
     
2.5. Secondary antibodies 
target source dilution purpose conjugation supplier/reference 
mouse IgG goat 1:10000 immunoblotting HRP Sigma-Aldrich 
rabbit IgG goat 1:20000 immunoblotting HRP Sigma-Aldrich 
mouse IgG goat 1:1000 immunofluorescence Alexa Fluor 647 Thermo Fisher Scientific 
      
2.6. Buffers and solutions 
name content 
Acetatos sodium acetate 0.5 M, acetic acid 0.5 M (mix 28.75 ml of glacial acetic acid in 1 L H2O), keep @ 4°C 
Coelenterazine 1.05 mM in methanol 
D-Luciferin 1 mM D-Luciferin in 25 mM glycylglycine 
GITC buffer 4 M guanidinium thiocyanate, 25 mM sodium citrate, 0.5% sodium lauroyl sarcosinate, freshly added 
0.1 M β-mercaptoethanol) 
glyoxal loading buffer 0.25 mg/mL bromo phenolblue, 0.25 mg/mL xylene cyanol, 10 mM NaPO4 pH 7.0, 50% (v/v) glycerol 
LB agar 30 g peptone, 15 g yeast extract, 15 g NaCl, 15 g agar in 3 L H2O 
  
Luc Assay Buffer 25 mM glycylglycine pH 7.8, 15 mM KPO4 buffer pH 7.8, 15 mM MgSO4, 4 mM EGTA pH 7.8, in H2O 
LB medium 50 g peptone, 25 g yeast extract, 25 g NaCl in 5 L H2O 
Luc Lysis Buffer 25 mM glycylglycine pH 7.8, 15 mM MgSO4, 4 mM EGTA pH 7.8, 1% Triton X-100, 10% glycerol, in H2O 
add freshly 1 mM final DTT 
  
2.7. Viruses 
name reference comment 
DenR2a [284] renilla luciferase reporter version of Dengue virus (DENV) 
Jc1 [283] chimeric virus from a gt2a J6CF (5’-NS2-TMDI) and gt2a JFH-1 (TMDII-3’) isolate 
JcR2a [104] renilla luciferase reporter version based on Jc1 
RVFV [285] ∆NSs renilla luciferase reporter version of RVFV 
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2.8. Consumables 
All general lab consumables were supplied by the DKFZ store and manufactured by BD, Bio-Rad, 
Corning, GE Healthcare, Greiner, Merck Millipore, STARLAB, or Thermo Fisher Scientific. 
2.9. Instruments 
name manufacturer 
C1000 Touch™ Thermal Cycler Bio-Rad 
CFX Connect™ Real-Time PCR Detection System Bio-Rad 
ChemoCam Imager 3.2 INTAS 
Gene Pulser Xcell™ Electroporation Systems Bio-Rad 
Mithras² LB 943 multimode reader Berthold Technologies 
NanoDrop 1000 Spectrophotometer Thermo Fisher Scientific 
Nikon Eclipse Ti-E Nikon 
Qubit 1.0 fluorometer Invitrogen 
Storm 860 Molecular Imager GE Healthcare 
Trans-Blot® Turbo™ Transfer System Bio-Rad 
UV transilluminator Vilber Lourmat 
 
2.10. Software 
name supplier 
Affinity Designer Serif 
Bio-Rad CFX Manager Bio-Rad 
EndNote X9 Clarivate Analytics, Thomson Reuters 
Fiji - ImageJ NIH [286] 
GraphPad Prism 8 GraphPad 
IC Capture The Imaging Source 
Intas Chemostar INTAS 
LabImage 1D INTAS 
Microsoft Office 2016 Microsoft 
SnapGene GSL Biotech LLC 
DeepL DeepL GmbH 
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3. METHODS 
3.1. Bacterial culture 
Escherichia coli DH5α cells were used for almost all bacterial culture. Culture conditions were 37°C 
in LB medium or on LB agar with the respective antibiotics. Empty Gateway™ plasmids were 
amplified in ccdB Survival™ 2 bacteria (Thermo Fisher Scientific). 
3.2. Plasmid purification from bacterial cultures 
Plasmid DNA from bacterial cultures was purified using the NucleoSpin® Plasmid (2 mL culture) or 
the NucleoBond® PC 500 (300 mL culture) kit (Macherey-Nagel) according to the manufacturer 
protocol. 
3.3. Gel or PCR mix purification of DNA 
Plasmid or insert DNA was extracted from PCR reactions or agarose gels using the NucleoSpin® 
Gel and PCR clean-up kit (Macherey-Nagel) according the manufacturer protocol. 
3.4. Classical cloning 
All classical cloning procedures were performed with restriction enzymes and buffer system from 
New England Biolabs. 
3.5. DNA amplification 
Inserts for cloning procedures were amplified from plasmid bank plasmids or cDNA using the Q5® 
High-Fidelity DNA Polymerase (New England Biolabs) according to the manufacturer instructions 
or the CloneAmp™ HiFi PCR Premix (Takara BioTech) according to the manufacturer protocol. 
3.6. Gateway™ cloning 
Gateway™ cloning [287] was used to shuttle cDNAs clones into different expression vectors. 
Original inserts were created by amplifying the desired region from a plasmid bank plasmid or 
cDNA with attB sites-flanked primers: attB-forward 5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCTTC-3’ and attB-reverse 5’-
GGGGACCACTTTGTACAAGAAAGCTGGGTC-3’. Inserts were gel-purified and mixed with a pENTR 
vector in a so-called BP reaction using the BP clonase II according to the manufacturer protocol to 
generate a pDONR vector. The resulting vector was mixed with a pDEST vector in a so-called LR 
reaction and LR clonase II according to the manufacturer protocol to retrieve the expression 
plasmid. 
3.7. Cells and cell culture 
All cell lines used in this study for HCV replication experiments were derivatives of the human 
hepatocellular carcinoma cell line Huh7 [125]. HEK293T [288] cells were used for lentiviral particle 
production and transduction of Huh7 cells to establish stably overexpressing cell lines as described 
in [289]. Cells were cultivated in monolayers that were passaged two to three times a week in 
complete medium (DMEM supplemented with 10% FBS, 100 U/mL penicillin and 100 ng/mL 
streptomycin, and 1x non-essential amino acids). Cells were kept in a humidified incubator at 37°C 
with 5% CO2. 
3.8. Lunet-CGM cells 
In this study, we make use of a highly permissive Huh7 cell clone (Huh7-Lunet [137]) 
overexpressing the HCV entry factor CD81 [279] and two more reporters. First, an mCherry-tagged 
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histone protein H2B to visualize nuclei and allow for automated cell counting, and second, an 
eGFPNLS-MAVS, where the MAVS mitochondrial transmembrane domain and the SV40 nuclear 
localization sequence (NLS) are fused to the eGFP C-terminus [290]. Thus, the cells give a diffuse 
to speckle-like cytoplasmic stain. Upon HCV infection, the viral NS3/4A protease cleaves off the 
MAVS membrane anchor and the eGFPNLS shuttles into the nucleus, giving a sharp nuclear and no 
cytoplasmic signal, anymore. The cells can thus be quantified in an automated manner using image 
quantification software. In the course of this study we call these cells Lunet-CGM (Lunet-CD81high-
eGFPNLS-MAVS-H2B-mCherry). 
3.9. In vitro-transcription of RNA 
Production of in vitro-transcribed (IVT) RNA, purification and was done as described previously 
[169]. In brief, plasmid DNA was linearized and in vitro-transcribed using a homemade T7 
polymerase for (+)-RNA or T3 polymerase for (-)-strand RNA. Plasmid DNA was removed by adding 
RQ1 DNase. RNA was then purified by phenol-chloroform extraction, concentration was measured 
at a NanoDrop device (Thermo Fisher Scientific) and integrity was assessed by native agarose gel 
electrophoresis.  
3.10. Preparation of standards for absolute quantification 
In vitro transcripts were prepared as described above and additionally treated with TURBO™ 
DNase to remove residual plasmid DNA. RNA was again purified using the NucleoSpin® RNA Plus 
(Macherey-Nagel) kit. RNA concentration was assessed on a NanoDrop device as well as on a Qubit 
fluorometer and diluted to the desired concentration.  
3.11. Electroporation of Huh7 cells 
In vitro-transcribed RNA (2–10 µg) was used to electroporate 4x106 (Huh7-Lunet, Lunet-CGM) or 
6x106 (Huh7-LP, -HP, or Huh7.5) cells in Cytomix [291] using the Gene Pulser system (Bio-Rad). 
Settings were 975 µF, 270 V for 0.4 cm cuvettes and 500 µF, 166 V for 0.2 cm cuvettes [292]. 
Electroporated cells were gently resuspended in pre-warmed medium and seeded immediately. 
3.12. Virus stocks preparation 
Huh7.5 cells [138] were electroporated with Jc1 [283] or JcR2a [104] RNA as described above. 24, 
48, and 72 hours later cell culture supernatants were collected, pooled and stored until further 
use at 4°C. Viral particles were precipitated using sterile-filtered 8% PEG-8000 overnight at 4°C 
and spun down at 4000 g for 30 min at 4°C. Pellets were resuspended in complete medium, 
aliquoted and stored at -80°C for further use.  
3.13. Titer determination of viral stocks and supernatants 
Huh7.5 (1∙104) or Lunet-CGM (7.5∙103) cells were seeded in 96-well plates 16 hours prior to 
addition of supernatants or stock dilutions. Supernatants were pre-diluted at least 1:3 and stock 
solutions at least 1:500. All eight wells of one row were used for one dilution. Further dilution 
series were usually 1:3 to minimize standard deviation. Tips of the 8-channel pipette were 
changed after each dilution step. Row 12 of the 96-well plate was mock-infected and well A12 
served as a positive control by adding undiluted virus stock. After 72 hours, cells were fixed with 
ice-cold methanol (-20°C), kept at least 15 min at -20°C, and were then transferred to the BSL-2 
area. Methanol was removed, plates were quickly air-dried, and washed twice with 1x PBS. We 
used the mouse monoclonal NS5A antibody 9E10 (a kind gift from Dr. Charles Rice, NY Rockefeller 
University) in a 1:15.000 dilution in 1x PBS for 1 hour at room temperature or better at 4°C 
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overnight to detect HCV antigen. Primary antibody was detected with a secondary HRP-
conjugated anti-mouse antibody (1:200) for 1 hour at room temperature. Positive cells were then 
visualized using a homemade substrate (5 ml Acetatos, 1.5 ml Carbazol, 20 µl H2O2, per plate, 
sterile-filtered 0.2 µm) was added for roughly 30 min, depending on the intensity of the appearing 
stain. Substrate was removed and plates were washed twice with demineralized water. For 
storage, plates were dried. An Excel spreadsheet for calculating the infectious titer is available at 
[293]. 
3.14. “Cold” infection of Lunet-CGM cells 
2x105 cells per 6-well were seeded in 2 mL 16 hours prior to “cold” infection. During “cold” 
infection, cells were kept at 4°C for 30 min before medium aspiration and inoculation with 
pre-cooled PEG-precipitated HCVcc (Jc1) at an MOI of 1 (stock A) or 2.42 (stock B) at 4°C for one 
hour (1 mL per 6-well). The inoculum was removed and cells were covered with 1 ml per well 
pre-warmed (37°C) medium and incubated for one hour at 37°C (+/- inhibitor). Medium was 
aspirated and cells were treated with an acid wash protocol to remove extracellular vesicles and 
unbound virus particles: cells were washed with an acidic solution (0.14 M NaCl, 50 mM 
Glycine/HCl, pH 3.0, 670 µL per 6-well) for three minutes at 37°C before neutralization with 
neutralization buffer (0.14 M NaCl, 0.5 M HEPES, pH 7.5, 320 µL per 6-well) and one wash with 
pre-warmed medium. After that, fresh medium (+/- inhibitor) was added. All experiments of which 
the results are shown in the Results section were performed with Jc1 stock B. Experiments with 
Jc1 stock A are only shown in the Appendix and data is accordingly annotated.  
3.15. Total RNA extraction (phenol) 
Total cellular RNA during Jc1 infections from infected or control cells was extracted by phenol-
chloroform. Infected cells were washed prior to lysis according to the acid wash protocol described 
above. After three washing steps with cold 1x PBS, cells were lysed in GITC buffer (700 µL per 
6-well) and RNA was extracted as described [294]. 
3.16. RNA extraction (supernatant) 
RNA from supernatants or virus stock dilutions was extracted by lysing 100 µL in 600 µL GITC buffer 
and addition of 1–10 µg of total RNA from uninfected Huh7-Lunet cells. 
3.17. Strand-specific HCV RT-qPCR 
In order to quantify intracellular (+)- and (-)-strand HCV RNA, we performed strand-specific RT-
qPCR as described recently [295]. Briefly, 1–2 µg purified RNA from cell extracts, supernatants or 
virus inoculum or IVT standards spiked with 1 µg total RNA of uninfected Huh7-Lunet cells were 
reverse-transcribed with a thermostable reverse transcriptase at 55°C in a strand-specific manner 
using tagged, strand-specific primers. (+)- and (-)-strand reactions were performed in separate 
reaction tubes. RT reaction was performed on the thermocycler to assure no lower than 55°C 
reaction temperature. After Exonuclease I digest, qPCR was performed using primers against the 
strand-specific tags and the respective strand itself. In vitro-transcribed (+)- and (-)-strand RNAs 
were used to generate standard curves for absolute quantification.  
3.18. Strand-unspecific HCV RT-qPCR (Taqman) 
Strand-unspecific RT-qPCR was performed to determine the IC50s of specific HCV inhibitors as 
described in [296]. 
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3.19. Luciferase assay 
Luciferase activity of subgenomic or full-length reporter constructs after electroporation (sgJFH, 
sgCon1-ET), infection (JcR2a, DenR2a, RVFV), or from stable replicon cell lines (Huh7-LucUbiNeo-
JFH) was assessed as described in [278]. Briefly, homemade Luc Lysis Buffer was used for firefly 
measurements and commercial Passive Lysis Buffer for renilla measurements. Firefly activity was 
measured in Luc Assay Buffer with 10 µM D-Luciferin, 2 mM ATP, 1 mM DTT, whereas renilla 
activity was measured in Luc Assay Buffer with 3.36 µM Coelenterazine. 
3.20. Immunoblotting 
Immunoblotting to assess expression levels of proteins was performed as described in [278]. PAA 
gels were blotted using the Trans-Blot® Turbo™ Transfer System (Bio-Rad) or by wet transfer (in 
case of FLAG tag detection). 
3.21. Northern blotting 
To assess (+)- and (-)-strand levels, cell lysates after electroporation of Huh7-Lunet cells with 
sgCon1-ET were analyzed by Northern blotting as described in essence in [277] and [58] with the 
following minor modifications (a detailed protocol is deposited on the F170-Projekte/F170/F170 
Protocols drive at the DKFZ, Heidelberg). 10 µL of purified RNA (1 µg/µL) or IVT standards (spiked 
with 10 µg of cellular RNA from Huh7-Lunet cells) were mixed with 4.1 µL 100 mM NaPO4 pH 7.0, 
6 µL glyoxal, and 20.5 µL DMSO and incubated at 50°C for 1 hour. Samples were quickly cooled on 
ice or -20°C and 10.9 µL of glyoxal loading buffer was added. Transfer of RNA from the native 1% 
agarose gel (10 mM NaPO4) to the positively charged membrane (highbond N+-membrane, 
Amersham) was performed by upward capillary transfer in 20x SSC overnight at room 
temperature. After disassembling, the membrane was air-dried, UV crosslinked (125 mJ, Bio-Link 
254 (nm), Vilber Lourmat), methylene blue stained, cut, and hybridized (upper part against HCV 
RNA, lower part against ß-actin). Signals were detected in a . 
3.22. Fluorescence microscopy of fixed cells 
Cells seeded on glass cover slips were washed once with 1x PBS, fixed with 4% paraformaldehyde 
in PBS for 15 min at room temperature and washed again thrice with 1x PBS. Cell membranes 
were permeabilized with 0.5% Triton X-100 in PBS for 5 min. Unspecific binding was prevented by 
blocking with 3% BSA for 30 min to one hour. Primary antibody was applied for 1 hour at room 
temperature or overnight at 4°C. Secondary antibodies were applied for 1 hour at room 
temperature. DAPI was added (final dilution 1:5000) during the last five minutes of the secondary 
antibody stain. Cover slips were washed again three times with 1x PBS and once with 
demineralized H2O and mounted with fluoromount G (SouthernBiotech, Birmingham, AL). Images 
were captured with a Nikon Eclipse Ti-E microscope and processed using Fiji. 
3.23. Fluorescence microscopy of live cells & image quantification 
During Jc1 infection dynamics, Lunet-CGM cells were directly imaged in the cell culture plate 
containing complete medium with a 10x phase-contrast objective (Nikon) on a Nikon microscope 
using the IC Capture software. The GFP signal was captured in the 470 nm channel; the mCherry 
signal in the 590 nm channel. Images were processed with Fiji [286] and R [297] with the help of 
Christoph Harmel. At least four images per 6-well were captured for image analysis. 
3.24. siRNA reverse transfection 
Reverse transfection of siRNA for gene knockdown was performed as described in [278]. 
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3.25. Cloning of host factor candidate cDNAs 
cDNA clones were ordered from the ORFeome Collaboration (OC) cDNA Clones [298, 299] or 
cloned by standard molecular biology methods as described in [278]. 
3.26. Establishment of overexpressing cell lines 
To establish stably overexpressing cell lines, Huh7 cells were transduced using lentiviral particles 
produced in HEK293T cells as described in [278] and [289]. 
3.27. Total RNA extraction (column) and qPCR 
Expression levels of mRNAs in overexpressing of control cell lines was assessed after RNA 
purification and reverse transcription of cDNA via qPCR as described in [278]. 
3.28. Live cell imaging (IncuCyte) 
Live cell imaging for quantification of cell proliferation was performed as described in [278]. 
3.29. Cell viability assay 
To assess cell viability upon siRNA transfection, intracellular ATP levels were measured using the 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega) as described in [278]. 
3.30. Mathematical modeling 
To complement our experimental approach, we use mathematical modeling to address questions 
that are difficult to impossible to test in an experimental setting. For this, we closely collaborate 
with the Kaderali lab at the University Hospital Greifswald, Germany. The PhD candidate Darius 
Schweinoch exerted all the mathematical modeling, including model predictions, model fits, and 
the model extension. For details, I am referring to his PhD thesis or our shared first author 
publication that will be submitted soon.  
Drug effects implementation 
We used our intracellular HCV replication model to predict replication dynamics under Telaprevir 
(NS3/4A protease inhibitor) and Sofosbuvir (NS5B polymerase inhibitor) treatment as well as to 
fit our model to data from IFN-α and Daclatasvir (NS5A phosphoprotein inhibitor) treatment. To 
account for inhibitor effects, we included IC50 or EMax terms indicated with red font in the 
corresponding equations.  
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4. RESULTS 
We made use of the robust and well-established transient HCV replication assay in highly 
permissive Huh7-Lunet cells to analyze the effects of therapeutic intervention. Huh7-Lunet cells 
were electroporated with in vitro transcripts of a subgenomic HCV genotype 2a reporter RNA 
(sgJFH) and replication was monitored via luciferase activity as a surrogate for viral protein levels. 
The luciferase reporter gene has replaced the information for the structural genes in this RNA. 
This allows the analysis of effects exclusively on viral RNA translation and replication as no viral 
particles are produced. 
4.1. Deciphering the mode of action of IFN-α and hepatitis C virus (HCV) 
inhibitors using an intracellular model for HCV replication 
This section describes HCV replication and the effects of IFN-α treatment or the use of direct-acting antivirals against 
HCV on its replication. We used mathematical modeling to describe and decipher the highly complex virus-host 
interactions. The modeling part was performed by Darius Schweinoch (Kaderali lab, Greifswald) and 
modifications/extensions of the model as well as interpretation of the results were done in close collaboration between 
the Kaderali lab and us. All plots that show model simulations or model fits were produced and provided by Darius 
Schweinoch on basis of data provided by us. The collaborative project will be published soon with a shared first 
authorship.   
IFN-α treatment has been the standard of care for chronic HCV infection for decades. However, 
the exact mode of action of viral replication inhibition remains elusive. Thus, we asked the 
question which step of intracellular HCV RNA replication is affected by IFN-α treatment and the 
induced antiviral response of the host cell. In a first step, we wanted to analyze the IFN-α-
mediated effects on viral RNA translation. Therefore, we used a replication-defective version of 
the subgenomic reporter RNA, which harbors a 10 amino acid deletion in the catalytic center of 
the viral polymerase (sgJFH∆GDD). 
4.1.1. The IFN-α-triggered antiviral response primarily inhibits HCV RNA translation  
We pre- and co-treated Huh7-Lunet cells with different concentrations of IFN-α, electroporated 
the cells with sgJFHΔGDD RNA and recorded luciferase activity over time. Already 1.5 hours post 
electroporation (hpe), luciferase activity was markedly lower in IFN-α-treated cells than in 
untreated cells (Figure 9A, abs), suggesting a strong translational inhibition of the transfected 
RNA. In addition, when normalizing to the initial value, RNA stability seemed to be decreased as 
well since luciferase signals declined faster in IFN-α-treated cells than in untreated cells (Figure 
9A, rel). However, another explanation might be a faster decay of cellular proteins induced by the 
antiviral response. To underpin the notion of increased RNA decay upon IFN-α treatment, we used 
Northern blotting to assess RNA levels directly. RNA signals seemed quite similar in the different 
conditions. However, upon quantification, IFN-α treatment appeared to increase RNA decay in 
both concentrations used (Figure 9B). Non-linear regression of the signals revealed half-lives of 
1 h 38 min and 1 h 15 min for the untreated and the IFN-α-treated conditions, respectively (Figure 
A1). To assure that not only excess RNA that sticks to the cells was measured, we electroporated 
samples without RNA and added RNA immediately afterwards. The rigorous washing steps  
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Figure 9 The antiviral response triggered by IFN-α inhibits HCV RNA translation and reduces HCV RNA half-life. 
(A) Luciferase activity over time after electroporation of the replication-deficient subgenomic firefly luciferase-
encoding HCV RNA sgJFHΔGDD into untreated or IFN-α pre- and co-treated Huh7-Lunet cells. (B) Quantification of HCV 
RNA levels from strand-specific Northern blot over time after electroporation as in (A). (C) Representative Northern 
blot used for quantification shown in (B). (D) Luciferase activity over time after electroporation of the subgenomic 
firefly luciferase-encoding HCV RNA sgJFH into untreated or IFN-α pre- and co-treated Huh7-Lunet cells. 
(E) Quantification of HCV RNA levels from strand-specific Northern blot (n=2) over time after electroporation as in 
(D). (F) Representative Northern used for quantification shown in (E). ß-actin served as a loading control and for 
normalization. Background RNA was not electroporated but only added to the cells to account for RNA that sticks to 
the cells and could not be washed off. The signal obtained from those lanes was subtracted from all other signals. 
Luciferase activity is given in relative light units (RLU) either in absolute values (abs) or relative to the first time-point 
obtained (rel). Northern blot quantification data is given normalized to ß-actin (abs) or normalized to ß-actin and 
relative to the first time-point obtained (rel). If not stated otherwise, data shows means +/- standard deviation from 
three independent experiments. 
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removed most of the input RNA and gave only a faint signal at 0 hours that vanished within 
1.5 hours (Figure 9C). Thus, the IFN-α-triggered antiviral response raised by the host cell seems to 
largely suppress HCV IRES-mediated translation and only slightly reduce HCV RNA half-life. 
We then used a replication-competent RNA (sgJFH) to examine possible additional effects of IFN-α 
treatment on HCV RNA replication. As IFN-α treatment with 10 or 50 IU/mL severely impaired HCV 
replication in this setting, we included a lower concentration of 2 IU/mL to better visualize the 
dose-dependence and the dynamics of the inhibition (Figure 9D). Similar to sgJFHΔGDD RNA, initial 
translation of sgJFH RNA was reduced already at 1.5 hpe and luciferase activity declined strongly 
in the 10 and 50 IU/mL condition during the initial phase (0–12 hpe) (Figure 9D, abs). Due to this 
translational inhibition, which delays the availability of viral proteins to start replication, onset of 
replication was delayed, especially visible in the 10 and 50 IU/mL IFN-α treatment conditions 
(Figure 9D, rel). Further, the slope of the curve did not seem to be reduced in the 2 and 10 IU/mL 
condition at first, but signals leveled off much faster with increasing IFN-α concentration and did 
not reach the plateau as defined by the untreated condition (Figure 9D). The 50 IU/mL IFN-α 
treatment allowed almost no HCV replication, making it impossible to analyze replication 
dynamics. Quantification of (+)-strand RNA levels directly assessed by Northern blot clearly 
resembled the luciferase signals (Figure 9E, -F). (+)-strand levels initially dropped lower in the 
IFN-α conditions (Figure 9E, abs), the increase in (+)-strand RNA levels reflected a delayed onset 
of replication, and the plateau as defined by the untreated sample was not reached (Figure 9E). 
The (-)-strand is the replication intermediate of HCV, which is only produced from transfected 
(+)-strands, and should not be not present at 0 hpe. Therefore, values measured at 0 hpe were 
technical background (normalized to ß-actin; see Figure 9 legend). Synthesis of (-)-strands first 
appeared at 4 hpe in the untreated condition, giving a very faint band (Figure 9F). In the 10 IU/mL 
IFN-α condition, (-)-strands appeared much later, at 12 hours. There was no visible (-)-strand band 
appearing in the 50 IU/mL IFN-α condition (Figure 9F). Overall, only the untreated condition gave 
strong signals for (+)- and (-)-strands from 24 to 72 hpe (Figure 9F). These pronounced effects on 
HCV replication were unlikely only a consequence of the initial and possibly sustained translational 
inhibition. However, we cannot distinguish between those and direct effects on replication in this 
system. 
To clarify if there is another, distinct effect on viral replication, we made use of a mathematical 
model that is able to simulate intracellular HCV replication [277]. The model consists of ordinary 
differential equations (ODEs) that describe every central step of intracellular HCV replication, from 
translation of the genome to establishment of the replication compartment, and includes 
degradation rates for viral RNA and protein species. We generated a model fit using HCV 
replication without treatment or under 1 or 10 IU/mL IFN-α treatment (Figure 10). Since we knew 
already that IFN-α treatment severely impaired translation of HCV RNA, we pre-selected the 
translation initiation rate k1 and modified it by including an ISG effect using an IC50 term (see 
Methods section). The model was allowed to modify one or more additional parameters in the 
same way to generate the best fit. We achieved the best fit upon adjustment of the viral 
translation rate k1 as well as viral RNA degradation rates µ (in the cytoplasm as well as in the 
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replication compartment (RC) (Figure 10, for details see Methods section). The model fit 
accurately described the biological data and confirmed our in vitro findings of increased viral RNA 
degradation upon IFN-α treatment. However, the adjustment of other parameter combinations 
yielded similarly good fits, suggesting an insufficient amount or variety of data used for model 
fitting. A shorter half-life of the RC might yield a similar outcome; however, this possibility is not 
covered in our model. 
In conclusion, the antiviral response raised by the host cell upon IFN-α treatment strongly inhibits 
HCV RNA translation and slightly reduces HCV RNA half-life. A mathematical model describing 
intracellular HCV replication corroborated these findings by data fitting. Although we cannot rule 
out additional effects, for example on the establishment of RCs, those must be very small 
according to the near optimal fit. Since our system and the model are limited to intracellular HCV 
replication, we cannot address effects on particle assembly, release or infectivity, yet. 
4.1.2. HCV inhibitors have distinct modes of action that the intracellular model can 
recapitulate 
The antiviral response raised by IFN-α treatment is not the only treatment for HCV with an elusive 
mode of action. For a few years now, highly efficacious direct-acting antivirals (DAAs) against 
chronic HCV infection provide cure rates of ≥95 % [300]. Amongst those, the highly potent class of 
inhibitors of the multifunctional HCV phosphoprotein NS5A display half-maximal inhibitory 
concentrations (IC50s) in the picomolar range [301]. NS5A has no enzymatic function but forms 
dimers or even oligomers that bind HCV RNA [302], and is required for replication [152, 303, 304] 
as well as assembly [296]. One of the first clinically approved NS5A inhibitors was Daclatasvir (DCV) 
[305], sold under the market name Daklinza and discovered at Bristol-Myers Squibb [306-308]. 
Despite its efficacy in inhibiting NS5A, how exactly DCV affects HCV replication remains elusive. 
To understand which functions of NS5A DCV impairs, we recorded intracellular HCV replication 
dynamics under DCV treatment using our luciferase reporter construct sgJFH as described above 
and applied our intracellular model to identify the most likely affected parameters or steps in the 
viral life cycle. We used the NS3/4A protease inhibitor Telaprevir (TEL) and the NS5B polymerase 
 
Figure 10 Model fit of the intracellular HCV model (Binder et al., 2013) to HCV replication data under IFN-α 
treatment. Luciferase activity over time after electroporation of the subgenomic firefly luciferase-encoding HCV RNA 
sgJFH into untreated or IFN-α pre- and co-treated (1 or 10 IU/mL IFN-α) Huh7-Lunet cells. For the best fit, parameters 
k1 (translation of the viral RNA in the cytoplasm) and viral RNA degradation rates µ (inside the replication 
compartment as well as in the cytoplasm) were adjusted. For details, see Methods section. Data produced by Aparna 
Pandey. Model implementation, fit and plot by Darius Schweinoch. 
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inhibitor Sofosbuvir (SOF), both possessing distinct and well-defined modes of action, to prove the 
ability of our model to predict viral replication under treatment.  
We electroporated equal amounts of sgJFH RNA into Huh7-Lunet cells treated with the 
aforementioned inhibitors at different concentrations or left them untreated. We took samples at 
indicated time points (see Figure 11 legend) and measured luciferase activity as a surrogate for 
viral protein. TEL treatment resulted in a delayed onset of replication, starting at roughly 12 hpe 
compared to 8 hpe in the untreated setting (Figure 11A). This effect seemed to be dose-dependent 
as increasing the TEL concentration from 100 nM to 200 nM resulted in a substantial decrease in 
luciferase signal at 20 hpe. After replication onset, the luciferase signal increase over time was 
highly similar to the untreated setting leading to almost equal endpoint levels at 70 hpe. In 
contrast, SOF treatment showed no effect on onset of replication even in high concentrations of 
800 nM, but led to a constantly reduced slope of the luciferase signal over the complete time 
course (Figure 11B). This led to a dose-dependent reduction of endpoint levels at 72 hpe. 
Treatment with DCV resulted in a delayed onset of replication, especially with higher 
concentrations (150 pM and 200 pM) as well as a reduced slope of the signal increase between 12 
and 60 hpe (Figure 11C). At 70 hpe, only the lowest dose (75 pM) reached endpoint levels close to 
 
Figure 11 HCV direct-acting antivirals reveal distinct replication kinetics dependent on their mode of action. (A) 
Luciferase activity over time after electroporation of the subgenomic firefly luciferase-encoding HCV RNA sgJFH into 
Huh7-Lunet cells left untreated or treated with 100 or 200 nM Telaprevir (TEL) (A), 100, 400 or 800 nM Sofosbuvir 
(SOF) (B) or 75, 150 or 200 pM Daclatasvir (DCV) (C). Luciferase activity is given in relative light units (RLU), either in 
absolute values (abs) or relative to the first time-point obtained (4h, rel). Time point captured were 4, 8, 12, 18, 24, 
30, 36, 48, 72 hours for (A) and (B), and 4, 6, 8, 9, 10, 11, 12, 15, 18, 24, 36, 48, 58, 72 hours for (C). Data shows 
means +/- standard deviation from at least three independent experiments, except for 100 and 800 nM SOF (n=2). 
Note that the untreated data for (C) is different from that in (A) and (B). Data produced by Aparna Pandey.  
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the untreated condition. Higher doses of 150 pM or 200 pM DCV resulted in markedly reduced 
endpoint levels with more than one log reduction for the highest dose of 200 pM DCV. 
Our intracellular model is able to describe HCV replication in Huh7-Lunet cells, a low permissive 
Huh7 variant (Huh7-LP), and even using manipulated replicons that are impaired in (+)- or 
(-)-strand replication initiation [277]. We challenged our model to predict intracellular HCV 
replication upon targeted intervention using HCV inhibitors with distinct modes of action to see if 
we can use it to identify the unknown mode of action of DCV. We used TEL and SOF as such 
inhibitors and adapted the corresponding steps in our mathematical model to account for the 
drug effect. TEL inhibits the NS3/4A protease, so we included an IC50 term in the polyprotein 
processing step kc∙P, in which k is the rate constant and P is the amount of polyprotein (see also 
Methods section). The model prediction described our biological data upon adjustment of kc only 
quite well, although it overestimated the drug effect in the 100 nM setting (Figure 12A). To 
account for the SOF effect, we modified the RNA synthesis steps k4m and k4p, exerted by the viral 
polymerase NS5B, by including IC50 terms (see also Methods section). The resulting model 
prediction fit the HCV replication data under SOF treatment quite good as well (Figure 12A). 
Importantly, the model is able to recapitulate the two very different modes of action of TEL and 
SOF, which resulted in two very distinct model predictions. Thus, our model proved to be capable 
of predicting HCV replication even under drug treatment. 
We went on and used our model to fit data obtained from HCV replication dynamics under DCV 
treatment. As done before for IFN-α, we allowed the model to modify one or more parameters to 
gain the best fit. The model revealed the best fit upon adjustment of k1 (translation initiation) as 
well as k4p and k4m (RNA synthesis in the RC) (Figure 12C, see also Methods section), and was able 
to describe HCV replication in all the three tested DCV concentrations. Only at 70 hpe, the model 
was not able to capture the pronounced reduction in luciferase activity. As NS5A reportedly binds 
HCV RNA, is part of the replicase complex, and is involved in formation of the RC, our modeling 
outcome seemed reasonable. However, closer monitoring of the replication dynamics and 
 
Figure 12 Model predictions (A, B) and model fit (C) correctly reflect HCV intracellular replications dynamics under 
drug treatment. (A) We used our intracellular model to predict viral replication dynamics after electroporation of 
our subgenomic reporter replicon sgJFH into Huh7-Lunet cells. To account for the drug effect, we inserted IC50 terms 
in the corresponding equations: describing the polyprotein cleavage step in case of Telaprevir (kc∙P) (A) or the RNA 
synthesis steps in the RC involving k4m and k4p in case of Sofosbuvir (B). (C) We used our biological data to fit the 
model and allow adjustment of parameters to achieve the best fit. In the end, adjusting k1 and the RNA synthesis 
steps involving k4m and k4p revealed the best fit. Model predictions, fit, and plots generated and provided by Darius 
Schweinoch. 
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additional concentrations might yield deeper insights. Since NS5A is also crucial for virion 
assembly, our model and experimental setting need to be extended to the full viral life cycle to 
get a comprehensive view of the DCV effects on NS5A function and thus on HCV replication.   
Overall, our model proved to not only be able to simulate HCV replication in unchallenged settings, 
but also successfully fitted HCV replication data under IFN-α treatment, thereby corroborating our 
in vitro findings and proving itself capable of identifying the steps in HCV replication affected by a 
specific treatment. It further correctly predicted HCV replication under NS3/4A or NS5B inhibitor 
treatment and was eventually able to fit HCV replication data under DCV treatment. The DCV 
model fit revealed insights into the possibly affected steps by NS5A inhibition and provides a basis 
for further investigations into this direction. 
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4.2. Extension of the intracellular model to the full HCV life cycle 
This section describes the extension of our intracellular to the full life-cycle model on the biological as well as 
mathematical side, of which the latter represents the PhD project of our close collaborator Darius Schweinoch (Kaderali 
lab, Greifswald). The content regarding the modeling part is thus mostly his intellectual property that he communicated 
and that we commonly discussed in many interactive meetings and presentations. The collaborative project will be 
published soon with a shared first authorship.   
The intracellular model has proven its capability to describe HCV replication in different settings 
and even under drug treatment. However, its limitation to the inside of the cell forbids addressing 
questions about particle assembly, release, infectivity, or spread of the infection. In order to gain 
those insights, we expanded our model in collaboration with Darius Schweinoch (Kaderali lab, 
Greifswald) and extended our experimental setting accordingly to the full viral life cycle. The 
obstacles we had to overcome to achieve our goal were the following. First, we needed to find a 
cell line that was sufficiently similar to Huh7-Lunet cells (which our intracellular model is based 
on) and that supported the full viral life cycle, i.e. is susceptible to cell culture-produced HCV 
(HCVcc) infection. Second, we had to replace our subgenomic reporter replicon sgJFH with a 
full-length version that is able to produce infectious particles and has similar replication dynamics. 
In addition, we replaced our strand-specific Northern blot, which requires 5–10 µg RNA per lane, 
with the much more sensitive strand-specific RT-qPCR that was recently established in the group 
of Volker Lohmann and only requires around 1 µg of RNA [295].  
4.2.1. Jc1 replication dynamics resemble those of sgJFH and sgJFH replication is not 
affected by CD81 overexpression 
Addressing the first obstacle, we compared replication dynamics of the subgenomic firefly 
luciferase-encoding sgJFH replicon with the full-length reporter version JcR2a, encoding a renilla 
luciferase gene. The renilla luciferase gene is inserted into the very N-terminus of the HCV genome 
and is liberated from the HCV polyprotein by a C-terminal foot-and-mouth-disease virus 2a 
peptide [104]. Although the two constructs harbor 5’-UTRs including IRES sequences from two 
different isolates (JFH-1 for sgJFH, J6CF for JcR2a), both belong to genotype 2a and translation 
efficiency should be comparable. Figure 13A shows intracellular replication dynamics of both 
constructs electroporated into Huh7-Lunet, where only replication but no infection and thus no 
spread was possible. We adjusted the amount of RNA electroporated according to genome length 
to assure that the same number of molecules was transfected. The renilla luciferase dynamics 
lacked the sharp drop in signal during the first 12 hours that was apparent for sgJFH and reflects 
degradation of most of the transfected RNA where only few molecules start replicating 
successfully (Figure 13A). This might have been caused by the higher stability of the renilla (t1/2 
4.5 hours) compared to the firefly luciferase (t1/2 3 hours) [309] and posed a problem since we 
used the luciferase signal as a direct proxy for viral protein and model parameters would have 
needed adjustment in this case. Overall replication dynamics appeared delayed for JcR2a and not 
as fast as for sgJFH, which reached almost 100-fold levels 72 hpe (relative to 4h) in contrast to only 
10-fold for JcR2a (Figure 13A). We thus went on and tested a non-reporter full-length version of 
HCV RNA, named Jc1. Jc1 is a chimera cloned from two different genotype 2a isolates, J6CF and 
JFH-1 [283], and was one of the first clones that efficiently replicated and produced sufficient 
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amounts of progeny virus in cell culture. Jc1 is identical to JcR2a but lacks the renilla luciferase 
reporter gene. Thus, we made use of our well-established Northern blot to detect viral (+)-strands. 
Figure 13B shows the quantification of two independent Northern blots after electroporating the 
depicted constructs into Huh7-Lunet as described above. Jc1 resembled sgJFH replication 
dynamics and appeared to replicate even faster and to higher levels than sgJFH (Figure 13B, -C). 
JcR2a failed to replicate as efficiently as sgJFH or Jc1 as the luciferase data already suggested, 
proving that the observed differences between sgJFH and JcR2a luciferase activities were not due 
to different translation efficiencies. Despite the lack of a luciferase gene to monitor replication 
easily, we decided to use Jc1 for downstream experiments due to its robust replication.  
 
Figure 13 Full-length Jc1 replicates with similar kinetics as subgenomic sgJFH and CD81 overexpression does not 
change sgJFH replication kinetics. (A) Luciferase activity over time after electroporation of the subgenomic firefly 
luciferase-encoding HCV RNA sgJFH or the full-length renilla luciferase-encoding HCV RNA JcR2a into Huh7-Lunet 
cells. (B) Quantification of HCV RNA levels from strand-specific Northern blot over time (n=2) after electroporation 
of the subgenomic firefly luciferase-encoding HCV RNA sgJFH, the full-length version Jc1 or the full-length renilla 
luciferase-encoding HCV RNA JcR2a into Huh7-Lunet cells. (C) Representative Northern used for quantification shown 
in (B). (D) Luciferase activity over time after electroporation of the subgenomic firefly luciferase-encoding HCV RNA 
sgJFH into Huh7-Lunet or -Lunet-CD81high cells. (E) Quantification of HCV RNA levels from strand-specific Northern 
blot over time (n=2) after electroporation as in (D). (F) Representative Northern used for quantification shown in (E). 
Luciferase activity is given in relative light units (RLU), either in absolute values (abs) or relative to the first time-point 
obtained (rel). ß-actin was used as a loading control and for normalization in Northern blot experiments. Northern 
blot quantification data was normalized to ß-actin (abs) or normalized to ß-actin and relative to the first time-point 
obtained (rel). If not stated otherwise, data shows means +/- standard deviation from three independent 
experiments. 
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The second hurdle we needed to overcome was to find a susceptible cell line as a replacement for 
Huh7-Lunet cells. Studies on HCV entry successfully identified a number of receptors and co-
receptors involved in HCV infection of host cells (reviewed in [143]). Among the first ones 
identified was the tetraspanin CD81 that binds the HCV glycoprotein E2 [145] and that could block 
infection of cells by HCVcc when added to the medium as a soluble, recombinant peptide [310] or 
when using an α-CD81 antibody [132, 133, 283, 310]. Huh7-Lunet cells do not express sufficient 
amounts of CD81 to support HCVcc infection, however, stable CD81 overexpression allows 
infection levels comparable to Huh7.5, another highly permissive Huh7 clone [279]. We compared 
replication dynamics in Huh7-Lunet versus Huh7-Lunet-CD81high cells using our subgenomic 
reporter replicon sgJFH. Figure 13D shows luciferase activity after electroporation of sgJFH into 
both cell lines. Absolute values revealed a lower baseline of replication in Huh7-Lunet-CD81high 
cells. However, relative to the initial luciferase activity 4 hpe, replication was identical in both cell 
lines, reaching almost 100-fold at 72 hpe (rel. to 4h; Figure 13D, rel). Northern blot quantification 
showed that indeed HCV RNA levels were consistently lower in Huh7-Lunet-CD81high compared to 
Huh7-Lunet cells despite equal starting values (Figure 13E, -F). This might have, however, been 
caused by independent cellular properties, as for example passage number, in which the cell lines 
differed. 
In summary, subgenomic sgJFH and full-length Jc1 replication dynamics were qualitatively highly 
similar in Huh7-Lunet cells and CD81 overexpression did not change sgJFH replication dynamics in 
Huh7-Lunet cells. Thus, we used Huh7-Lunet-CD81high cells and the full-length construct Jc1 for 
further experiments.  
In order to accurately monitor spread of the infection in our cell culture and quantify the number 
of infected cells in an automated fashion, we utilized two cellular reporters that we stably 
transduced in Huh7-Lunet-CD81high cells. First, an eGFP reporter where the SV40 nuclear 
localization sequence (NLS) and the C-terminal (mitochondrial) transmembrane domain of the 
signaling protein MAVS (also known as CARDIF, IPS-1, or VISA; [311]) were fused to the eGFP 
C-terminus [290]. After stable transduction, naïve cells thus show a punctate, mitochondrial 
pattern, whereas upon HCV infection, the viral NS3/4A protease cleaves the MAVS 
transmembrane domain [86, 254, 312] and the eGFPNLS shuttles into the nucleus, giving a sharp 
nuclear signal (see below). Second, in order to quantify total cell numbers, we used an mCherry-
tagged histone protein H2B for a constitutive nuclear signal. In the course of this study, we call 
these triple transduced cells Lunet-CGM (Lunet-CD81high-eGFPNLS-MAVS-H2B-mCherry). 
4.2.2. Quantification of viral determinants during infection 
Having a full-length construct and a susceptible reporter cell line at hand, we went on to quantify 
viral and cellular determinants in a tight time-course to equilibrate and test our extended 
mathematical model (details to the model extension are provided in the next section). 
We infected Lunet-CGM cells with cell culture-produced Jc1 (see 3. Methods, 3.12. Virus stocks 
preparation) at an MOI of 2.42 using a “cold infection” protocol to achieve simultaneous entry and 
onset of replication (see 3. Methods, 3.14. “Cold” infection of Lunet-CGM cells) (Figure 14A). For this, 
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we pre-cooled cells at 4°C for 30 minutes (min), added the pre-cooled virus inoculum and allowed 
attachment of viral particles on cell surfaces for one hour at 4°C. We aspirated the inoculum and 
incubated at 37°C with pre-warmed medium for one hour to allow entry of the attached particles. 
After that, we removed excess particles by an acidic washing step and started the time-course 
with taking the 0 hpi sample. Subsequent samples were then taken as depicted in Figure 14A and 
analyzed for the percentage of infected cells by fluorescence microscopy, viral titer by limiting 
dilution assay, and viral RNA by strand-specific RT-qPCR at each time-point. Before taking RNA 
samples, we washed the cells with the same acidic wash protocol as right after the infection to 
remove extracellular particles or vesicles attached to the cell surface.  
Jc1 replication dynamics after infection of Lunet-CGM cells resembled those of the subgenomic 
replicon sgJFH. After an initial drop in viral RNA levels, replication started and RNA levels increased 
steadily until the assay endpoint at 70 hpi (Figure 14B). In contrast to the intracellular system 
where infection could not spread, RNA levels did not reach a plateau at the assay endpoint in this 
setting. RT-qPCR of an earlier batch of Jc1 virus stock revealed that the (+)-strand content exceeds 
the number of infectious (+)-strand RNA molecules as given by its TCID50 by roughly 3000-fold and 
contains around 5∙108 (-)-strand molecules per mL (Figure A2). Since infectious HCV particles 
contain only one copy of their (+)-strand genome, all the excess (+)- and (-)-strand were probably 
derived from dsRNA secreted in extracellular vesicles [295]. Thus, the majority of HCV RNA 
molecules we detected in the initial phase were probably non-infectious RNAs that were degraded 
and did not start replicating. Newly synthesized (+)-strands could be detected from roughly 4–
8 hpi on and (-)-strands from 12 hpi on (Figure A3). To calibrate our mathematical model, we 
counted only that fraction of (+)-strands as infectious that we measured via infectivity assay 
(TCID50). We modeled all the excess RNAs as non-infectious as they did probably originate from 
inactivated viral particles or extracellular vesicles that possessed similar biophysical properties as 
virions and precipitated along with them during the stock preparation process. We detected 
released infectious particles from 20 hpi on and their number steadily increased until 70 hpi. Since 
the infection could spread in this system and we started with a very low number of infected cells, 
not all of the cells were infected even at 70 hpi (Figure 14C). We could readily detect infected cells, 
marked by their nuclear GFP signal, from 12 hpi on (Figure 14D, middle panel, white arrow). Their 
number increased steadily and reached between 60 and almost 80% at the assay endpoint (Figure 
14C, -D), varying largely between independent experiments.  
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Figure 14 Full-length HCVcc (Jc1) replication kinetics after infection of Lunet-CGM cells. (A) Workflow of Jc1 infection 
experiments. Lunet-CGM cells were seeded 16 hours prior to "cold infection" and samples were taken in a tight time-
course as depicted in the scheme and analyzed for viral RNA, viral titer and the percentage of infected cells via 
fluorescence microscopy. (B) Jc1 replication dynamics after infection of Lunet-CGM cells at an MOI of 2.42. Viral RNA 
levels were assessed via strand-specific RT-qPCR and viral titers were measured using an end-point dilution assay 
(TCID50). (C) The percentage of infected cells per time-point was determined by quantification of fluorescence 
microscopy images (D). (D) Representative images taken at 4, 12 and 70 hpi in the green channel (470 nm). The 
cellular eGFP marker localizes to mitochondria, giving a punctate cytoplasmic pattern, until the cell is infected and 
the eGFP shuttles to the nucleus, giving a sharp nuclear signal. Arrow in the 12h image shows an infected cell. Asterisk 
indicates a newly infected cell with cytoplasmic and nuclear eGFP signal. Uninfected as well as infected cells are 
exemplified and were counted via an H2BmCherry marker. Images were quantified using Fiji. Data in (B) and (C) shows 
means +/- standard deviation from five (viral RNA, % infected cells) and four (viral titer) independent experiments, 
respectively. 226 images in total were quantified for (C). Quantification presented in (C) was performed with the  
help of Christoph Harmel.  
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4.2.3. Model simulation of full-length HCV replication 
This section describes the extension of our intracellular to the full life-cycle model on the mathematical side, which 
represents the PhD project of our close collaborator Darius Schweinoch (Kaderali lab, Greifswald). The content is thus 
mostly his intellectual property that we commonly discussed in many interactive meetings and presentations. The 
collaborative project will be published soon with a shared first authorship.   
After setting up the experimental system to measure viral determinants in the course of a 
full-length HCVcc infection, we extended our mathematical model accordingly to be able to 
describe viral infection, the production and release of infectious particles, and spread in this new 
experimental setting. Figure 15 shows model schemes for both, our intracellular (A) as well as our 
extended full life cycle model (B). The intracellular model was developed in our lab and published 
many years ago [277]. It describes all key steps in the HCV replication cycle after electro-
transfection of Huh7-Lunet cells with the subgenomic reporter replicon sgJFH. Those are: 
processing of the transfected RNA (RPunp to RPcyt, (1)), translation of the processed RNA (2), 
processing of the synthesized polyprotein (3), establishment of the replication compartment and 
initiation of (-)-strand synthesis (4), synthesis of (-)-strands (5) as well as progeny (+)-strands (6), 
and output of the (+)-strand RNA back into the cytoplasm (7) (Figure 15A). We made few 
adaptations and introduced new species to account for the novel experimental system. Since 
target cells (TU) are now infected by authentic viral particles, step (1) was replaced and represents 
infection by viral particles (Va) with rate (β) now (Figure 15B). The number of ribosomes that can 
simultaneously bind one (+)-strand RNA molecule as well as the RNA synthesis rates k4p and k4m 
were adapted to the increased length of the HCV RNA used. The production and release of 
infectious particles was calculated by the total amount of (+)-strand RNA (RP,tot) and structural 
protein ES,tot with the assembly and release rate p (8). The unknown infection rate β and assembly 
rate p were fitted together with several other parameters. All the parameters were identifiable, 
which confirmed that our model includes no redundant parameterization and allows for 
mechanistic interpretation of model simulations. The new age-based model takes into account 
the period a cell is infected and the time-dependent production of viral RNA as well as infectious 
particles. This age-based model is linked to a population model describing the number of infected 
cells to account for viral spread. 
 
RESULTS 
41 
 
 
 
Figure 15 Model schemes of the intracellular (A) and full life cycle model (B) of HCV replication. (A) The intracellular 
model is based on the electroporation of a subgenomic reporter version of the HCV RNA genome (sgJFH) into 
Huh7-Lunet cells. The transfected RNA (RPunp) is processed in a first step (k0) to become translation-competent. The 
model scheme is adapted from and based on the Binder model [277]. (B) The full life cycle model is based on infection 
of Lunet-CGM cells with cell culture-derived full-length Jc1. Cells (TU) are infected by viral particles (Va) with infection 
rate β and turn into infected cells (TI). Total cellular (+)-strand RNA (RP,tot) and structural proteins (ES,tot) are used for 
assembly (assembly rate p) of infectious particles (Va). k are rate constants and µ are degradation rates. 
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Figure 16 shows Jc1 infections dynamics data (as already presented in Figure 14 as means +/- 
standard deviation) plus the new model simulations. We used the recorded data to fit adapted or 
new parameters in our new full life cycle model, which was eventually able to simulate viral RNA 
and infectious particle kinetics as well as infection spread in Lunet-CGM cells after Jc1 infection 
(Figure 16A–D). The variations we observed were of technical nature or caused by cellular 
properties that changed with passage number and affected viral replication. Passage number is 
the one determinant that reportedly most fundamentally affects HCV replication efficiency [280]. 
The percentage of infected cells appeared to vary the most; however, note that all other 
parameters are on logarithmic scale. The model quite accurately fit (+)-strand RNA dynamics 
despite the huge excess of non-infectious (+)-strand RNA in the virus inoculum (Figure 16A and 
Figure A2B). The immense drop in (+)-strand RNA levels between 0 and 8 hpi could also represent, 
at least in part, the minor portion of infectious viral (+)-strands that manage to establish a 
productive infection in the host cell. (-)-strand RNA levels were overrepresented in the first 4 hpi 
as compared to the model fit (Figure 16B). However, this probably owes to the immense excess 
of (-)-strand RNAs in the virus inoculum that was non-infectious and degraded over time as well 
(see above and Figure A3). In the model simulation, we assumed that there is a 12-hour delay in 
the time from a cell being infected to being detected as such. This is based on the nature of our 
eGFP reporter system in which the viral protease NS3/4A needs first to be produced in the infected 
cell so it can cleave the MAVS mitochondrial membrane anchor of eGFP, which then needs to 
translocate to the nucleus in sufficient amounts. The cells that were counted in an automated 
 
Figure 16 HCVcc (Jc1) replication dynamics in Lunet-CGM cells and model fits of the new full life-cycle model. 
Lunet-CGM cells were infected with HCVcc (Jc1) at an MOI of 2.42 and viral and cellular determinants were measured 
in a tight time-course. A strand-specific RT-qPCR was used to determine the absolute numbers of (+)- (A) and 
(-)-strand RNA molecules (B). Viral titers were determined using an endpoint dilution assay (TCID50) (C). Fluorescent 
microscopy images were used to quantify the percentage of infected cells (D). Data points are represented by circles 
and model simulations by lines. Model simulations and plots were generated and provided by Darius Schweinoch. 
Figures show data from six independent biological experiments.  
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manner as infected between 0 and 12 hpi were mostly dead cells that looked highly similar to 
infected cells and were hard to discriminate from the latter by the image quantification software. 
4.2.4. Model simulation of Jc1 dynamics under DAA treatment 
After fitting our new full life-cycle model to the highly time-resolved and quantitative data and 
seeing that it is able to describe viral replication and spread in this setting quite well, we went on 
to validate our model using targeted intervention. For several years now, direct-acting antivirals 
(DAAs) are available on the market and used in the clinics to treat chronic HCV infection with 
remarkable efficacy and only mild side effects. Mainly three classes of DAAs exist: inhibitors of the 
NS3/4A protease (dubbed -previr), the NS5B polymerase (-buvir), and the NS5A phosphoprotein 
(-asvir) (reviewed in [313]). As described above, the mode of action of NS5A inhibitors is still 
elusive due to the many functions of NS5A in the viral life cycle. In contrast, NS3/4A protease and 
NS5B polymerase inhibitors have rather specific modes of action as determined by the functions 
of their targets. Thus, we set out to validate our model by challenging it with HCV replication data 
under treatment with the NS3/4A inhibitor Telaprevir (TEL) and the NS5B inhibitor Sofosbuvir 
(SOF) as we did before with the intracellular model. We determined the IC50s of all three inhibitors 
in the full life-cycle setting and used exactly those to achieve inhibition but no complete 
eradication of viral infection (Figure A4).  
4.2.4.1. The NS3/4A inhibitor Telaprevir (TEL) 
Figure 17 shows Jc1 replication dynamics upon TEL treatment. As expected, TEL treatment led to 
reduced viral replication by inhibiting the polyprotein processing step exerted by NS3/4A. As 
already observed in the intracellular setting, onset of replication was delayed as (+)- and (-)-strand 
levels increased from only 20 hpi on compared to 12 hpi for the untreated condition (Figure 17A). 
In contrast to the intracellular system, RNA levels in the TEL condition did not reach similar levels 
at the assay point as in the untreated condition. RNA levels only reached 20% of untreated at 
70 hpi in this setting (see also Figure A5A). The delayed onset of replication might have impaired 
particle production resulting in less infection spread and thus lower total RNA levels at the assay 
 
Figure 17 Jc1 replication dynamics under Telaprevir (TEL) treatment. (A–C) Jc1 replication dynamics after infection 
of Lunet-CGM cells with an MOI of 2.42 under TEL inhibition (IC50, 182 nM) or untreated. Viral RNA was assessed via 
strand-specific RT-qPCR (A) and viral titers were measured using an end-point dilution assay (TCID50) (B). The 
percentage of infected cells was quantified from fluorescence microscopy images (C). Data in (A) shows means +/- 
standard deviation from five (untreated) and two (TEL), data in (B) from four (untreated) and two (TEL), and data in 
(C) from five (untreated) and two (TEL) independent experiments, respectively. Total images quantified for (C) were 
226 for untreated and 71 for TEL. Image quantification was performed with the help of Christoph Harmel.  
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endpoint. Indeed, viral titers were reduced during the whole time course (Figure 17B). Compared 
to the decline in RNA levels (down to 20%), viral titers seemed reduced even more, reaching only 
10% of untreated at later time-points (Figure A5A), suggesting an additional effect of TEL on 
particle production on top of polyprotein cleavage. Image quantification revealed a strong 
decrease in the percentage of infected cells in the culture dish as well (Figure 17C). This probably 
only partly originated from a real reduced number of infected cells, though, since the NS3/4A 
inhibition by TEL not only impairs polyprotein processing but also cleavage of our eGFP reporter, 
which at least slows down if not partly abrogates translocation of the same into the nucleus and 
thus detection and counting of the cell as infected. Hence, we probably underestimate the number 
of infected cells in this case. Collectively, it seems that TEL not only inhibited polyprotein cleavage 
by targeting NS3/4A, which delayed the onset of replication. The even more pronounced effect 
on viral titer reduction suggests a yet undefined additional impairment of infectious particle 
production or release. 
We wanted to test our new extended and calibrated model if it was able to predict Jc1 replication 
dynamics in the full-length context under drug treatment. We implemented the inhibition term of 
TEL at the polyprotein processing step kc (Figure 18) as we did before in the intracellular setting, 
resulting in a good model prediction (Figure 12A). Unfortunately, the model now underestimated 
the inhibitory effect of TEL treatment on Jc1 replication dynamics (Figure 19, dotted lines). The 
reason for this might be that TEL indeed inhibits additional steps in the viral life cycle besides 
polyprotein processing (kc) that we did not account for in the model, for example particle assembly 
or release. The dramatic decrease in viral titers that we observed in the biological data might 
support this notion. As our subgenomic setup and the intracellular model did not include any of 
these steps, the model prediction for the TEL treatment was quite good (see Figure 12A). However, 
it might as well be that the establishment of a productive replication/infection is much more 
sensitive in the infection setting than it is in the electroporation setting, where hundreds to 
thousands of RNA molecules per cell are present at the assay start. Model predictions including a 
TEL effect on the assembly rate p should reveal if there is an additional effect on top of the 
polyprotein processing rate reduction. Those predictions should resemble the biological data 
 
Figure 18 Model scheme with highlighted mode of action of the NS3/4A inhibitor TEL. TEL inhibits the NS3/4A 
protease, which processes the HCV polyprotein and cleaves it into the mature proteins (kc). Details are provided in 
the Methods section. 
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better than the prediction taking into account only kc as a target step of TEL treatment. Still, to 
find out which step in the viral life cycle is affected on top of kc in an unbiased way, we could use 
the model to fit the data allowing only one additional parameter to change at a time. This would 
give an answer if assembly or any other step in the viral life cycle is possibly affected by inhibiting 
the NS3/4A protease using TEL. 
4.2.4.2. The NS5B inhibitor Sofosbuvir (SOF) 
After decades of standard of care for chronic hepatitis C with PEG-IFN-α and ribavirin, resulting in 
only 50% cured patients along with severe side effects, Sofosbuvir (SOF) was among the first 
direct-acting antivirals (DAAs) to get approval and hit the US market in 2013 [189]. It was the first 
direct-acting antiviral that was administered (together with the NS5A inhibitor ledipasvir) as an 
all-oral, IFN-free, single tablet regimen in 2014 in the US [189]. Its high tolerability, efficacy, and 
low risk for drug-drug interactions made it indispensable for HCV treatment since then [189]. SOF 
is a pro-drug that is metabolized in the liver to its active uridine triphosphate analogue form and 
is incorporated into the nascent RNA strand by NS5B, which leads to chain termination [188, 314]. 
We used SOF to validate our newly extended full life cycle model for HCV replication as described 
before for TEL. Since SOF is a prodrug and needs activation first, we started treatment 16 hours 
prior to infection and continued it throughout the experiment as for TEL. As already observed in 
the intracellular setting, SOF treatment reduced the slope of RNA level increase, whereas onset of 
replication was not delayed (Figure 21A). This eventually resulted in about 50% reduction in (+)- 
and (-)-strand RNA levels at the assay endpoint (70 hpi, see also Figure A5B). The data showed a 
consistent drop in (+)-strand RNA levels at 45 hpi, the cause of which is hard to explain though. 
 
Figure 19 Model simulations of Jc1 replication dynamics in Lunet-CGM cells under Telaprevir (TEL) treatment. The 
model was calibrated on data from the untreated condition and predicted viral replication dynamics by only adapting 
kc, the polyprotein cleavage step exerted by NS3/4A, which was inhibited by TEL. (A) (+)-strand RNA levels, (B) (-)-
strand RNA levels, (C) infectious titers, (D) percentage of infected cells. Model fit for the untreated condition is in 
lines, data points for the treatment (TEL) condition are in circles, and model prediction for the treatment setting is 
in dotted lines. Model simulations and plots were generated and provided by Darius Schweinoch. Figures show data 
from two independent biological experiments. 
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Infectious titers were reduced throughout the experiment but only to a slight extent (Figure 21B). 
Quantification of fluorescence images revealed a minor reduction in the number of infected cells 
(Figure 21C). 
We then wanted to test if our new model was able to predict Jc1 replication dynamics upon SOF 
treatment. We incorporated the SOF effect in our model using IC50 inhibition terms at the rate 
constants k4p and k4m as done before with the intracellular model (Figure 20, see also Methods 
section). The model predicted Jc1 replication dynamics under SOF treatment quite well, although 
the difference to the untreated condition was very small (Figure 22). The data points for (+)-strand 
RNA levels at 45 and 55 hpi were not covered by the model prediction (Figure 22A), although they 
might be outliers as well. The model prediction also missed the (-)-strand RNA data points at 
32 and 45 hpi (Figure 22B). The infectious titer prediction fit quite well although there was a high 
variation in the biological data for few time points (Figure 22C). Due to the high variance of the 
percentage of infected cells data in the untreated condition (n=5, see Figure 21C), the model 
prediction was quite off for the SOF condition, especially at late time points (Figure 22D). In the 
SOF replicates, the percentage of infected cells was comparably high and the model allows only a 
 
Figure 20 Model scheme with highlighted mode of action of the NS5B inhibitor SOF. SOF inhibits the NS5B 
polymerase, which synthesizes (+)- and (-)-strands in the replication compartment (k4p and k4m). Details are provided 
in the Methods section. 
 
Figure 21 Jc1 replication dynamics under Sofosbuvir (SOF) treatment. (A–C) Jc1 replication dynamics after infection 
of Lunet-CGM cells at an MOI of 2.42 under SOF inhibition (IC50, 37 nM) or untreated. Viral RNA was assessed via 
strand-specific RT-qPCR (A) and viral titers were measured using an end-point dilution assay (TCID50) (B). The 
percentage of infected cells was quantified from fluorescence microscopy images (C). Data in (A) shows means +/- 
standard deviation from five (untreated) and two (SOF), data in (B) from four (untreated) and two (SOF), and data in 
(C) from five (untreated) and two (SOF) independent experiments, respectively. Total images quantified for (C) were 
226 for untreated and 83 for SOF. Image quantification was performed with the help of Christoph Harmel. 
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reduction upon treatment (Figure 22D). Overall, the model prediction of Jc1 replication dynamics 
under SOF treatment resembled the biological data adequately, although the effect of SOF 
inhibition was rather small. 
In conclusion, our newly extended full life cycle model is able to predict Jc1 replication dynamics 
even under treatment with inhibitors with a known mode of action. In order to improve the TEL 
prediction, we might need to include an additional effect on a step in the viral life cycle besides 
polyprotein cleavage. Using different drug concentrations should confirm our findings and help in 
refining the model. Still, based on the finding that our model is in principal able to recapitulate 
drug effects in the full-length system, we went on to analyze the effect of DCV treatment on Jc1 
replication in the biological data as well as in the model prediction. 
4.2.4.3. The NS5A inhibitor Daclatasvir (DCV) 
Our model fit of intracellular HCV replication dynamics under DCV treatment revealed k1 as well 
as k4m and k4p as the steps most probably affected by DCV treatment (Figure 12). Except for late 
time points, the model was able to fit the actual data quite well. We used the very same set of 
parameters in order to predict now full-length Jc1 replication dynamics and to see if it was 
necessary to include additional effects on assembly or other steps in the viral life cycle to produce 
an accurate prediction.  
As already observed in the intracellular system, Jc1 replication dynamics under DCV showed 
features of TEL and SOF inhibition at one time. Clearly visible for (+)-strand dynamics, onset of 
replication was delayed by 4 hours under DCV treatment (12 vs. 8 hpi, Figure 23A). The following 
 
 
Figure 22 Model simulations of Jc1 replication dynamics in Lunet-CGM cells under Sofosbuvir (SOF) treatment. The 
model was calibrated on data from the untreated condition and predicts viral replication dynamics by only adapting 
k4p and k4m, the RNA synthesis steps exerted by NS5B, which is inhibited by SOF. (A) (+)-strand RNA levels, (B) (-)-
strand RNA levels, (C) infectious titers, (D) percentage of infected cells. Model fit for the untreated condition is in 
lines, data points for the treatment (SOF) condition are in circles, and model prediction for the treatment setting is 
in dotted lines. Model simulations and plots were generated and provided by Darius Schweinoch. Figures show data 
from two independent biological experiments. 
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increase in RNA levels was not as steep as for the untreated condition and RNA levels reached 
only about 15% of untreated levels at 70 hpi (see also Figure A5C). Infectious titers were markedly 
reduced (Figure 23B), however, not exceeding the reduction in RNA levels as during TEL treatment 
(see also Figure A5C). Despite the big standard deviation due to the high variance in the two 
replicates, the percentage of infected cells under DCV treatment appeared to be lower compared 
to untreated as well (Figure 23C). 
We used our extended full life cycle model to predict Jc1 replication dynamics under DCV 
treatment, assuming that the same set of parameters (k1, k4p, and k4m) as found by model fit in the 
intracellular system is affected here (depiction of affected parameters in Figure 24). RNA level 
predictions fit quite well and reflected what we observed in the biological data: a delayed onset 
of replication that is more pronounced for the (+)-strand than for the (-)-strand, and a less steep 
increase in RNA levels leading to lower plateaus and endpoint levels at 70 hpi (Figure 25A, -B). 
Unfortunately, RNA levels seemed to be off for few time points. This was true for especially one 
 
Figure 23 Jc1 replication dynamics under Daclatasvir (DCV) treatment. (A–C) Jc1 replication dynamics after infection 
of Lunet-CGM cells at an MOI of 2.42 under DCV inhibition (IC50, 82 pM) or untreated. Viral RNA was assessed via 
strand-specific RT-qPCR (A) and viral titers were measured using an end-point dilution assay (TCID50) (B). The 
percentage of infected cells was quantified from fluorescence microscopy images (C). Data in (A) shows means +/- 
standard deviation from five (untreated) and two (DCV), data in (B) from four (untreated) and two (DCV), and data 
in (C) from five (untreated) and two (DCV) independent experiments, respectively. Total images quantified for (C) 
were 226 for untreated and 71 for DCV. Image quantification was performed with the help of Christoph Harmel. 
 
Figure 24 Model scheme with steps affected by DCV treatment as revealed by model fitting in the intracellular 
setting. DCV inhibits the NS5A phosphoprotein, which binds HCV RNA and is involved in building the replication 
compartment and assembly of virions. Upon fitting our intracellular model to HCV replication data, it revealed 
adjustment of k1, k4m, and k4p to give the best fit. Details are provided in the Methods section. See also Figure 12C. 
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replicate and its 20 and 45 hpi time points, where reproducibly (+)-strand RNA levels were too 
high and (-)-strand levels too low, respectively. The model slightly overestimated endpoint RNA 
levels for both strands. This might be a hint that modeling inhibition of only the described 
parameters is not sufficient to predict the impact exerted by DCV treatment. However, virus titer 
predictions are near perfect, except at 45 hours where the biological data shows a slight drop in 
infectious titers (Figure 25C). The number of infected cells was hard to predict as we observed a 
strong variation between our two biological replicates (Figure 23C). The model simulation 
resembled more closely the replicate with a much lower percentage of infected cells than the 
other replicate and was not able to reflect the sharp increase in the percentage of infected cells 
between 45 and 55 hours (Figure 25D). This might in part be due to reasons discussed for the 
percentage of infected cells in the SOF treatment (see above). Eventually, model predictions upon 
adjustment of only k1, k4m, and k4p, fit the biological data quite well and qualitatively resembled 
Jc1 replication dynamics under DCV treatment. It was not necessary to include additional effects 
on particle production, although this might further improve the predictions. A next step would be 
to completely block HCV replication in the steady state with a sufficient dose of DCV and to 
monitor and model infectious titers as well as intra- and extracellular RNA. This would certainly 
reveal if DCV immediately halts particle release or renders particles less or non-infectious. 
Overall, we successfully extended our intracellular HCV replication model to cover the full viral life 
during Jc1 infection of Lunet-CGM cells. We provide an experimental platform to accurately 
measure viral (+)- and (-)-strands, infectious titers as well as the percentage of infected cells in the 
culture dish. The data basis as well as the model extension are sufficient to identify and fit newly 
 
Figure 25 Model simulations for Jc1 replication dynamics in Lunet-CGM cells under Daclatasvir (DCV) treatment. 
The model was calibrated on data from the untreated condition and predicts viral replication dynamics by adapting 
k1, k4p and k4m. Those parameters revealed to be affected using our intracellular model fit. (A) (+)-strand RNA levels, 
(B) (-)-strand RNA levels, (C) infectious titers, (D) percentage of infected cells. Model fit for the untreated condition 
is in lines, data points for the treatment (DCV) condition are in circles, and model prediction for the treatment setting 
is in dotted lines. Model simulations and plots were generated and provided by Darius Schweinoch. Figures show 
data from two independent biological experiments. 
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introduced parameters. The new model is able to simulate (+)- and (-)-strand RNA levels, viral 
titers, and spread in the cell culture during the course of infection. In addition, it is capable of 
predicting the impact of drugs with a known mode of action on HCV replication. The model 
prediction of Jc1 replication dynamics under DCV treatment resembled the data quite well by only 
adjusting parameters that were identifying using the intracellular model. We did not have the 
chance to improve this prediction or generate a model fit to Jc1 replication dynamics data under 
DCV treatment. This, clearly, would give deeper insights into the mode of action of DCV. 
Nevertheless, as such, our new full life cycle model poses the first detailed model of its kind and 
can now be used the study the effect of drugs, including IFN-α and DCV, on HCV replication in an 
infection setting. Furthermore, the model can reveal insights into the molecular origin of 
permissiveness for HCV, the differences in virulence among HCV genotypes, and the impact or the 
nature of host factors governing HCV replication.  
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4.3. The intracellular model proposes a host factor that is involved in 
replication complex formation determines permissiveness  
The findings presented in this part are already published [278] and figures depicted here are taken from the publication 
with minor modifications as indicated in the figure legends. 
The intracellular model could simulate HCV replication in an Huh7 variant with high HCV 
replication efficiency, termed permissiveness, (Huh7-Lunet) as well as in a low permissive Huh7 
variant (Huh7-LP), with roughly 10-fold lower HCV replication efficiency [277]. By doing so, it 
revealed that formation of the replication compartment (RC) is the most probable step for the 
involvement of a host factor (HF) that determines cellular permissiveness [277]. As the model 
further suggested, this HF appears to be limiting for replication in Huh7-LP cells, but not so in 
Huh7-Lunet cells [277]. This HF could be a single protein, a protein complex, or a host process.  
4.3.1. Gene expression profiling suggests potential host factors for HCV 
To identify potential candidates qualifying as such a HF, gene expression data from microarrays of 
eight different Huh7 variants were correlated with their respective HCV permissiveness [277]. 
Those eight different Huh7 variants differed up to 1000-fold in their permissiveness for HCV 
(Figure 26A). Functional annotation of the hits revealed an enrichment for genes involved in “cell 
growth and proliferation” [277]. To exclude that permissiveness for HCV is solely based on 
different growth kinetics of the analyzed Huh7 variants, we quantified proliferation of three of 
them using the IncuCyte™ live cell imaging platform, and found no major differences (Figure 26B). 
We teamed up with Evgeny Gladilin (IPK, Gatersleben) who re-analyzed the microarray data and 
came up with 34 novel candidate genes that we decided to follow up regarding their biological 
relevance for HCV replication (Figure 26C). Those candidate genes showed rather low differential 
expressions but constantly high correlation coefficients with HCV permissiveness across the eight 
tested Huh7 variants (Figure 26C). Raw expression values from microarray data confirmed the 
results from the statistical analysis and showed increasing levels of candidate mRNAs with 
increasing permissiveness for HCV among the tested Huh7 variants (Figure 26D). 
4.3.2. Knockdown of proposed host factor candidates restricts HCV replication 
We used highly permissive Huh7-Lunet cells with presumably high expression of all our candidate 
genes to test for their role in HCV replication. We reverse-transfected three different siRNAs per 
gene and infected the cells with our full-length reporter virus JcR2a 24 hours later to see if their 
knockdown affects HCV replication. 72 hours post infection (hpi), we measured luciferase activity 
and tested for cytotoxicity in in parallel mock-infected plates. Twelve candidate genes targeted by 
14 siRNAs (two siRNA for two of the genes) showed a robust reduction of JcR2a replication (Figure 
27A) from roughly 60–90% without affecting cell viability (except ZNF512B, cut-off 75% viability, 
Figure A6A). The full list of candidates with their effects on HCV replication and cell viability are 
provided in the Appendix (Figure A7, Table A1). We used siRNAs targeting the well-described host 
factor phosphatidylinositol-4 kinase III alpha (PI4KIIIα) as a positive control and an siGFP as a 
negative control. To confirm these results in a different and more robust system, we used a cell 
line that stably replicates a subgenomic reporter version of HCV RNA in its cytoplasm, called 
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Huh7-LucUbiNeo-JFH [136]. This clonal cell line is kept under constant selection pressure by G418 
(neomycin) to which resistance is conferred by the replicon. The selection process and further 
passaging conferred robust replication of the HCV replicon and possible adaptations on the host 
side. This system allowed us to simply reverse-transfect siRNAs as before without the need of 
transfection of or infection with viral genomes. Luciferase measurements 96 hours post siRNA 
transfection confirmed five of the 14 tested siRNAs to reduce HCV replication even in this system 
(Figure 27B). As expected, the effects of gene knockdown on HCV replication were not as 
pronounced as during JcR2a infection (Figure 27A). This might either be caused by roles of the 
knocked down genes in steps not represented in the subgenomic replicon setting, like assembly 
or release of viral particles, or originate from the robustness of the replicon system as described 
above. In addition, transfection efficiencies could be lower in the replicon cell line, but we have 
not tested for this. However, the knockdown effects of PI4KIIIα seemed more robust than those 
of our candidate genes and impaired HCV replication severely. None of the confirmed siRNAs 
showed strong cytotoxic effects in this system (Figure A6B). 
 
 
Figure 26 Correlation of gene expression profiling with HCV permissiveness in eight different Huh7 variants reveals 
novel HF candidate genes. (A) Relative HCV replication efficiency in eight different Huh7 variants based on the 
replication of the subgenomic firefly luciferase reporter replicon Con1-ET (genotype 1b) at 48 hpe vs. 4 hpe. Data 
was normalized to the two low permissive variants Huh7 p15 and -p28. (B) 7500 (Huh7-LP) or 5000 (Huh7-HP, 
Huh7-Lunet) cells were seeded in 96-well plates and imaged every two hours in an IncuCyte machine. Images were 
quantified with the IncuCyte™ ZOOM software and its confluence mask. Data shows means +/- standard deviation 
from technical quadruplicates and one independent experiment. (C) 34 selected candidates after statistical filtering 
for the correlation of their expression with HCV permissiveness in the eight Huh7 variants. Followed-up candidates 
are in color. (D) Raw expression values from microarray data for five candidates that showed promising results and 
were followed up further. Statistical analysis for filtering candidate genes (C) was performed by Evgeny Gladilin. Data 
shown in (A) was produced by Marco Binder [277]. Figure adapted from [278]. 
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Conclusively, the statistical analysis and filtering of genes that correlated in their expression levels 
with HCV permissiveness in eight different Huh7 variants, revealed several promising candidates 
that upon knockdown impaired HCV replication efficiency. This impairment was found upon 
infection with the reporter virus JcR2a as well as in a stable replicon cell lines with robust 
replication of a subgenomic HCV reporter RNA. The five most promising candidates were LBH 
domain containing 1 (LBHD1, also known as C11orf48), cramped chromatin regulator homolog 1 
(CRAMP1), crystalline µ (CRYM), THAP domain containing 7 (THAP7), and nuclear receptor 
subfamily 0 group B member 2 (NR0B2, also known as SHP). The former two are barely 
characterized and the latter three are a nuclear receptors or transcriptional (co-)repressors, 
respectively. However, before characterizing those genes functionally, we sought to further 
analyze the role of their expression levels for HCV replication. 
4.3.3. Overexpression of host factor candidates in a low permissive Huh7 variant 
boosts HCV replication 
Since the model proposed that the HF is of limiting abundance in low permissive Huh7-LP cells 
[277], we speculated that upon overexpression of our candidate genes HCV replication might 
increase. Therefore, we cloned their cDNAs into N-terminally HA- or C-terminally FLAG-tagged 
expression vectors and stably transduced Huh7-LP cells. All the candidate genes were robustly 
 
Figure 27 HCV replication upon siRNA-mediated knockdown of candidate genes using the full-length reporter virus 
JcR2a (A) or the stable replicon cell line Huh7-LucUbiNeo-JFH (B). (A) Huh7-Lunet cells were reverse-transfected 
with indicated siRNAs 24 hours prior to JcR2a infection (MOI ~0.1). 72 hours post infection, cells were lysed and 
luciferase activity was measured. Data is shown relative to an siGFP control. (B) Huh7-LucUbiNeo-JFH cells were 
reverse-transfected and luciferase activity of the subgenomic replicon was measured 96 hours later. Data is shown 
relative to an siGFP control. Candidates that were followed-up further are in color. Data shows means +/- standard 
deviation from three (A) and two (B) independent experiments, respectively. *** p ≤ 0.001, **** p ≤ 0.0001. Adapted 
from [278]. 
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expressed and could be detected on mRNA level via qPCR as well as on protein level as assessed 
by immunoblotting against the corresponding tags or their own epitopes (except for NR0B2-FLAG 
using an α-FLAG antibody, Figure A8, Figure A9, Figure A10). We measured mRNA expression levels 
of CRAMP1, CRYM, and LBHD1 only in the FLAG-tagged versions. However, measurements of 
THAP7 and NR0B2 overexpressing cells showed that HA-tagged versions are at least similarly if not 
more robustly overexpressed than the corresponding FLAG-tagged ones (Figure A9, Figure A10). 
We used our subgenomic reporter replicon sgCon1-ET and our full-length reporter virus JcR2a to 
assess the effect of overexpression on HCV replication. 
CRAMP1 overexpression showed no significant effect on sgCon1-ET replication neither with the 
N-terminal HA- nor the C-terminal FLAG-tag (Figure 28A). However, we observed a slight but 
statistically significant boost of HCV replication in the infection setting (Figure 28B). CRYM 
overexpression led to a 2-fold increase in sgCon1-ET replication at 72 hpe, which was limited to 
the HA-tagged version though (Figure 28C). Again, overexpression of CRYM showed a stronger 
effect on JcR2a replication than on sgCon1-ET replication that reached almost 5-fold levels 
compared to the empty control at 72 hpi (Figure 28D). LBHD1 overexpression effects were 
ambiguous: HA-LBHD1 increased sgCon1-ET replication at 48 and 72 hpe to more than 2-fold; 
however, LBHD1-FLAG reduced HCV by almost 2-fold at those time points (Figure 28E). JcR2a 
infection confirmed the positive effect of HA-LBHD1 overexpression in an infection setting and 
 
Figure 28 HCV replication after electroporation of sgCon1-ET (A, C, E) or infection with JcR2a (B, D, F) in HF 
candidate overexpressing cells. (A, C, E) Huh7-LP cells overexpressing either N-terminally HA- (left panels) or 
C-terminally FLAG-tagged (right panels) versions of CRAMP1 (A), CRYM (C), LBHD1 (E), or the corresponding controls 
(HA-empty, empty-FLAG) were electroporated with the subgenomic reporter replicon sgCon1-ET (gt1b) and 
luciferase activity was measured at 4, 24, 48, and 72 hpe. (B, D, F) Huh7-Lunet cells overexpressing N-terminally HA-
tagged CRAMP1 (A), CRYM (D), or LBHD1 (F), or their respective controls (HA-empty) were infected with JcR2a (MOI 
~0.1) and luciferase activity was measured at 48 and 72 hpi. Data shows means +/- standard deviation from three 
independent experiments (except (B) and (F), n=2) each and is relative to 4 hpe (A, C, E) or relative to the empty 
control (B, D, F). * p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.001, **** p ≤ 0.0001. Adapted from [278]. 
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showed an almost 8-fold increase in HCV replication at 72 hpi (Figure 28F). The contrary results 
with the FLAG-tagged LBHD1 might stem from a functional impairment of the protein by a 
C-terminal tag or by sterical hindrance of its interaction with other proteins. Changing the tags 
would reveal if the position or the tag itself causes the observed difference, but we did not follow 
up on this. The consistently more pronounced effect on JcR2a compared to sgCon1-ET replication 
might simply be explained by the role of the HF suggested by our model, the formation of 
replication compartments. Those are already established in the replicon cell line but need to be 
formed de novo in JcR2a infection. Further, the difference might stem from the genotype 
difference (gt1b vs. gt2a) and the consequent disparate reliance on host factor proteins or 
processes. Another reason might be that the candidate genes have an additional role in particle 
assembly or release and might therefore exert a stronger function in the full-length context. It 
should be noted that overexpression of the host factor candidates literally rescued HCV replication 
in Huh7-LP cells, since without overexpression, JcR2a replication is close to background levels and 
barely detectable. 
Among the tested candidates, THAP7 overexpression posed the strongest and most consistent 
effect on HCV replication. Besides proper expression, we could also detect THAP7 by 
immunofluorescence and confirm its correct subcellular localization in the nucleus as THAP7 is 
reported to be a transcriptional repressor [315, 316]. In the subgenomic sgCon1-ET setting, we 
observed a more than 5-fold and in the JcR2a infection a more than one log10 increase in HCV 
replication upon HA-THAP7 overexpression (Figure 29A, -B). The C-terminally FLAG-tagged version 
showed the same effect in sgCon1-ET replication, although not as pronounced as the HA-tagged 
version (Figure A9A). As the model suggested the HF to be limiting in Huh7-LP cells but not so in 
highly permissive Huh7-Lunet cells, we wanted to challenge this hypothesis and overexpressed 
HA-THAP7 in this highly permissive cell line. HA-THAP7 overexpression had no effect on HCV 
replication in Huh7-Lunet cells, despite robust expression and correct localization (Figure A9F–H), 
consistent with the model prediction (Figure 29C).  
 
Figure 29 THAP7 overexpression boosts HCV replication in Huh7-LP cells. (A) Huh7-LP cells overexpressing 
N-terminally HA-tagged THAP7 or the corresponding control (HA-empty) were electroporated with the subgenomic 
reporter replicon sgCon1-ET (gt1b) and luciferase activity was measured at 4, 24, 48, and 72 hpe. (B) Huh7-Lunet 
cells overexpressing N-terminally HA-tagged THAP7 or the corresponding control (HA-empty) were infected with 
JcR2a (MOI ~0.1) and luciferase activity was measured at 48 and 72 hpi. (C) Huh7-Lunet cells overexpressing N-
terminally HA-tagged THAP7 or the corresponding control (HA-eGFP) were electroporated with the subgenomic 
reporter replicon sgCon1-ET (gt1b) and luciferase activity was measured at 4, 24, 48, and 72 hpe. Data shows means 
+/- standard deviation from at least three independent experiments each and is relative to 4 hpe (A, C) or relative to 
the empty control (B). *** p ≤ 0.001, **** p ≤ 0.0001. Adapted from [278]. 
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4.3.4. Strong NR0B2 overexpression inhibits HCV replication in Huh7-LP and -Lunet cells 
Surprisingly, NR0B2 overexpression led to a moderate to strong inhibition of HCV replication 
instead of the expected increase. Replication of sgCon1-ET was impaired in Huh7-LP cells 
overexpressing HA-NR0B2 (Figure 30A) as well as NR0B2-FLAG by more than 50% (Figure A10A). 
This held true for JcR2a replication as well, of which replication levels dropped by 30–40% (Figure 
30B). Inhibition of HCV replication was even stronger in the highly permissive Huh7-Lunet cells. 
Upon overexpression of HA-NR0B2 in Huh7-Lunet cells, sgCon1-ET replication declined almost 
1000-fold at 72 hpe (Figure 30C), rendering HCV replication basically dead. We confirmed proper 
as well as similar overexpression in Huh7-LP and -Lunet cells via qPCR, immunoblotting, and 
immunofluorescence (Figure A10C–H). NR0B2 localization in the nucleus is in line with its reported 
role as a nuclear receptor and transcriptional co-repressor [317]. However, we also found a diffuse 
cytoplasmic signal and rarely distinct speckles in NR0B2 overexpressing cells (Figure A10E). 
Although this might be an artefact upon the massive overexpression, it aligns with the finding of 
a direct interaction between NR0B2 and NS5A reported by another group [318]. The suppression 
of HCV replication upon overexpression was not limited to genotype 1b (Con1-ET) but also held 
true for genotype 2a (JFH) (Figure 31A), although to a lesser extent. As these findings were in sharp 
contrast to what we expected and to what we found for the other host factor candidates, we were 
wondering if the massive overexpression of NR0B2 caused the observed effects. The basal fold 
expression of NR0B2 in Huh7-Lunet compared to Huh7-LP cells, possibly causing the higher 
permissiveness, was only 2.5-fold (Figure 31B). Overexpression in contrast, caused fold 
expressions of several orders of magnitude (Figure A10). We thus diluted the lentiviral particles 
we used for stable transduction of target cells to reach lower expression levels of NR0B2. 
Additionally, we used the weak ROSA26 promoter to induce overexpression of NR0B2 only very 
mildly (Figure 31B). Reduced NR0B2 levels indeed rescued HCV replication, suggesting a dose-
dependent effect (Figure 31C). By using the ROSA26 promoter for NR0B2 overexpression, leading 
to only 8-fold NR0B2 mRNA levels compared to the control, we could even increase HCV 
replication slightly (Figure 31C). 
 
Figure 30 NR0B2 overexpression inhibits HCV replication in different settings. (A) Huh7-LP cells overexpressing 
N-terminally HA-tagged NR0B2 or the corresponding control (HA-empty) were electroporated with the subgenomic 
reporter replicon sgCon1-ET (gt1b) and luciferase activity was measured at 4, 24, 48, and 72 hpe. (B) Huh7-Lunet 
cells overexpressing N-terminally HA-tagged NR0B2 or the corresponding control (HA-empty) were infected with 
JcR2a (MOI ~0.1) and luciferase activity was measured at 48 and 72 hpi. (C) Huh7-Lunet cells overexpressing N-
terminally HA-tagged NR0B2 or the corresponding control (HA-eGFP) were electroporated with the subgenomic 
reporter replicon sgCon1-ET (gt1b) and luciferase activity was measured at 4, 24, 48, and 72 hpe. Data shows means 
+/- standard deviation from three independent experiments each and is relative to 4 hpe (A, C) or relative to the 
empty control (B). ** p ≤ 0.005, **** p ≤ 0.0001. Adapted from [278]. 
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These results let us hypothesize that there was a sensitive optimum curve of NR0B2 levels 
dictating HCV replication (Figure 31D). The higher NR0B2 expression levels in Huh7-Lunet 
compared to Huh7-LP cells seemed to be beneficial for HCV replication as was a slight 
overexpression in Huh7-Lunet cells using the ROSA26 promoter. In line with this, we also found 
that Jc1 infection of Huh7-Lunet cells led to a more than 2-fold upregulation of NR0B2 expression 
(Figure A11). However, upon exceeding the peak, NR0B2 levels seemed to be detrimental to HCV 
replication, as shown by our overexpression experiments. On the other side, reducing NR0B2 
levels in Huh7-Lunet or -LP cells by siRNA knockdown suppressed HCV replication as well (see 
above). These intriguing findings prompted us to investigate further how NR0B2 manages to 
regulate HCV replication in such an intricate fashion. 
4.3.5. The FXR-NR0B2 axis regulates HCV replication in Huh7-Lunet cells 
Nuclear receptors are ligand-activated transcription factors that play important roles in 
development, homeostasis, and metabolic processes. To investigate if the effects of NR0B2 levels 
on HCV replication are part of its nuclear receptor activity regulating bile acid synthesis, we 
focused on the NR0B2 activator farnesoid X receptor (FXR). FXR (also NR1H4) constitutes the 
major bile acid sensor in the liver and intestines and is activated predominantly by 
chenodeoxycholic acid (CDCA) [319-322]. Bile acids are not only required for solubilization of 
nutrients in the intestinal tract, but also play central roles as signaling molecules in gene regulation 
[323]. Upon ligand-mediated activation, FXR activates the expression of NR0B2 (formerly SHP), 
which in turn suppresses the expression of CYP7A1, the rate-limiting enzyme in bile acid formation 
from cholesterol [324-326] (Figure 32A). We thus used available FXR modulators to analyze their 
 
Figure 31 Effects of NR0B2 overexpression on HCV replication are genotype-independent but highly 
dose-dependent. (A) Huh7-LP cells overexpressing N-terminally HA-tagged NR0B2 or the corresponding control 
(HA-empty) were electroporated with the subgenomic reporter replicons sgJFH (JFH) or sgCon1-ET (Con1-ET) and 
luciferase activity was measured at 4, 24, 48, and 72 hpe. (B) Huh7-Lunet cells were stably transduced using 
increasing dilutions of lentiviral particles carrying overexpression constructs under the EF1α or ROSA26 promoter.  
Expression levels were determined by qPCR. (C) Huh7-Lunet cells expressing different amounts of HA-NR0B2 under 
the EF1α or ROSA26 promoter were electroporated with the subgenomic reporter replicon sgCon1-ET and luciferase 
activity was measured at 4, 24, 48, and 72 hours post electroporation. (D) Proposed model for the dose-dependent 
impact of NR0B2 levels on HCV replication. Adapted from [278]. 
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effects on HCV replication. The non-steroidal and highly selective FXR agonist GW4064 [327, 328] 
increased replication of sgCon1-ET in Huh7-Lunet cells around 2-fold (Figure 32B). This might 
correspond to the slight activation effect of NR0B2 that we observed upon overexpression using 
the ROSA26 promoter. On the contrary, the natural FXR antagonist (Z)-Guggulsterone [329, 330] 
inhibited HCV replication markedly, mirroring the effect of NR0B2 knockdown (Figure 32B). Still, 
we did not measure expression levels of the targeted nuclear receptors and affected downstream 
targets to corroborate our findings and exclude off-target or unspecific effects. Interestingly 
though, we found that FXR levels negatively correlated with NR0B2 levels in our NR0B2 
overexpressing cell lines (Figure 32C). This might either pose an indirect feedback loop due to the 
stalled production of bile acids that would activate FXR or a novel direct feedback loop via NR0B2 
itself that has not been reported, yet. According to the reported role of NR0B2 in bile acid 
synthesis, we assessed total bile acid contents and found indeed a 50% reduction in HA-NR0B2 
overexpressing Huh7-Lunet compared to control cells (Figure A12). It should be noted though that 
the bile acid content in HA-NR0B2 cells was very low and around the detection limit of the assay 
kit. As stalling bile acid production not only lowers bile acid levels but also interferes with the 
catabolism of its precursor cholesterol, we used the fluorescent polyene Filipin-III [331], which 
binds cholesterol and thus allows a direct visualization of its cellular distribution. In contrast to a 
strong punctate pattern and ER-like localization in Huh7-LP HA-empty cells, HA-NR0B2 
overexpression disrupted this pattern and showed a rather diffuse cytoplasmic distribution with 
distinct membrane boundaries, suggesting a transport or localization defect (Figure 32D). Since 
cholesterol is a major component of HCV RCs [155, 169], the disrupted supply with and 
recruitment of it might be another reason for the severe impairment of HCV replication upon 
strong NR0B2 overexpression. More specific visualization and co-localization studies are needed 
to reveal if and how cholesterol distribution or its recruitment to replication organelles is altered 
in NR0B2 overexpressing cells. In addition, ultrastructural and biochemical analyses should 
examine the fate of HCV RCs upon NR0B2 overexpression or knockdown. Identifying the host 
factors involved in these processes could give important insights into the pathways usurped by 
HCV to build its membranous web.  
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4.3.6. NR0B2 overexpression specifically impairs HCV replication 
Since the strong inhibition of HCV replication by high overexpression of NR0B2 poses a possible 
option for treatment and many other human pathogenic viruses rely on membrane-derived 
replication organelles as HCV does, we investigated if this effect is limited to HCV only or holds 
true for other disease-causing viruses as well. We chose the rather closely related Dengue (DENV, 
Flavivirus) and the less related Rift Valley Fever virus (RVFV, Phlebovirus) to test this. We used 
reporter viruses and infected HA-NR0B2 overexpressing Huh7-Lunet cells. Strong HA-NR0B2 
overexpression severely impaired HCV replication but not so much DENV or RVFV replication 
(Figure 33). Interestingly, we observed the same dose-dependence for DENV as for HCV, although 
much less pronounced (Figure 33). This insensitivity of DENV is surprising, as both, DENV and HCV, 
highly depend on cholesterol and other cellular lipids for their replication [332, 333]. Thus, either 
there are fine-tuned differences in the dependence on cholesterol and possibly involved host 
factors between HCV and DENV, or this argues for a rather specific, cholesterol-independent role 
of NR0B2 in HCV replication. RVFV replication, which does not rely on cholesterol or lipids to the 
extent Flaviviridae do, did not show much alteration and no such optimum curve regarding NR0B2 
levels [334].  
 
Figure 32 The FXR-NR0B2 axis modulates HCV replication and cholesterol distribution in Huh7-Lunet cells. 
(A) Schematic of the FXR-NR0B2 axis in the liver. FXR is activated by bile acids and the non-steroidal agonist GW4064, 
and is suppressed by its antagonist (Z)-Guggulsterone. FXR activates NR0B2 expression, which in turn represses the 
rate-limiting step in the formation of bile acids from cholesterol. It is unclear if there is a direct inhibition of FXR by 
NR0B2. (B) Huh7-Lunet cells were electroporated with sgCon1-ET and either treated with 10 µM GW4064, 10 µM 
(Z)-Guggulsterone, or vehicle only. Luciferase activity as a surrogate for HCV replication was measured at 4, 24, 48, 
and 72 hpe. (C) NR0B2 and FXR mRNA levels were assessed via qPCR in NR0B2 overexpressing cell lines. (D) 
Immunofluorescent images of Huh7-LP cells overexpressing HA-NR0B2 or a control using Filipin-III in a 40x 
magnification. Data in (B) shows means +/- standard deviation from three independent biological experiments. 
** p ≤ 0.005, *** p ≤ 0.001.  Adapted from [278]. 
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Figure 33 NR0B2 overexpression specifically impairs HCV replication. Huh7-Lunet cells overexpressing different 
amounts of HA-NR0B2 or HA-eGFP as a control were infected with luciferase reporter versions of the indicated 
viruses: JcR2a (HCV, MOI ~0.1) for 72 hours, DenR2a (DENV, MOI 1) for 48 hours, and a ∆NSs rift valley renilla reporter 
virus (RVFV, MOI 0.01) for 48 hours. Cells were lysed at the indicated time points and luciferase activities were 
measured. Data shows means +/- standard deviations from two to three (HCV), two (DENV), and one to two (RVFV) 
independent biological experiments, respectively. Adapted from [278]. 
In conclusion, our search for novel HCV host factors determining cellular permissiveness in 
different Huh7 variants by correlating gene expression with HCV replication efficiency, yielded 
several promising candidates. We could confirm their role in HCV replication by knockdown and 
overexpression studies, in the latter of which we could confirm what the model proposed: the 
limiting abundance of the HF for HCV replication in Huh7-LP but not in Huh7-Lunet cells. Upon 
overexpression of the putative HFs, HCV replication, especially in the full-length setting with JcR2a, 
increased. This increase was most dramatic for THAP7, of which overexpression caused a more 
than 10-fold increase in JcR2a replication in Huh7-LP cells but had no effect in Huh7-Lunet cells.  
Functional analyses of the candidate genes should reveal insights into the cause of these increases 
in HCV replication. Since several of them appear to be transcriptional regulators, further 
transcriptional analyses should give insights into the regulated genes. The one very intriguing HF 
candidate for HCV replication that we identified is the nuclear receptor and transcriptional co-
repressor NR0B2. The dose-dependent regulation of HCV replication suggests an intricate 
interplay with the HCV life cycle. Further, the involvement of cholesterol and its disturbed 
localization upon NR0B2 overexpression hints towards defects in RC formation or particle 
assembly of HCV. Since many other human pathogenic viruses, e.g. DENV, ZIKV, SARS-CoV, and 
many more, use similar replication organelles to amplify their genomes, elucidation of the host 
factor involved in their formation and homeostasis is highly warranted. Thus, findings from HCV 
could be extended and possibly help to understand basic principles of RC formation during (+)-
RNA virus infection. 
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In conclusion, we showed that the intracellular model for HCV replication is able to recapitulate 
HCV replication even under drug treatment. The model was able to identify steps in the viral 
replication cycle affected by the antiviral response raised by the host cell upon IFN-α treatment, 
which were corroborated by in vitro findings. Furthermore, the model correctly predicted 
intracellular HCV replication dynamics under TEL and SOF treatment and revealed possible steps 
affected by DCV treatment, an inhibitor of the elusive multifunctional HCV NS5A protein. We 
extended the intracellular model for HCV replication to the full HCV life cycle and validated the 
new model using Jc1 infection dynamics in a Huh7-Lunet-based cell line. The new full life cycle 
model is able to i) simulate HCV infection and spread in this setting and ii) incorporate drug effects 
and correctly predict viral replication dynamics under drug treatment in a full-length setting. It 
can now be used to deepen our understanding of the mode of action of the highly potent class of 
NS5A inhibitors, exemplified by DCV, by further experiments and model analyses. However, 
questions regarding genotypic differences in replication dynamics, the mode of action of other 
drugs or the best drug combinations, as well as the role of host factors involved in HCV replication, 
can be addressed as well. We could confirm several novel host factors for HCV replication that 
might contribute to cellular permissiveness for HCV. This finding is based on a model prediction 
and confirms the validity of such an approach. Interestingly, the impact of those host factors on 
HCV replication was consistently more pronounced in the full-length setting, suggesting 
involvement of those factors in infectious particle production steps. We can now use our new full 
life cycle model now to determine the steps in which those host factors are possibly involved and 
gain answers into their mode of action during replication compartment establishment and maybe 
others.  
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5. DISCUSSION 
Our lab has previously published a mathematical model for intracellular HCV replication after 
electro-transfection of Huh7 cells with a subgenomic HCV reporter RNA [277]. The model was able 
to simulate HCV replication in two Huh7 variants that markedly differed in their HCV replication 
efficiency, i.e. permissiveness: viral RNA reached at least one log10 higher steady state levels in the 
high versus the low permissive Huh7 variant [277]. Remarkably, the model revealed that the level 
of a host factor species (HF) that is involved in establishing the HCV replication compartment (RC) 
and initiating (-)-strand RNA synthesis was responsible for the observed differences in 
permissiveness. In this study, we sought to identify this HF species in order to elucidate the cause 
for the differences in permissiveness between various Huh7 variants.  
5.1. Host factors determining permissiveness for HCV 
The search for determinants of HCV permissiveness started soon after the first successful 
replication of HCV in cell culture [124]. Subsequent studies revealed that not only determinants 
on the viral side, but also host determinants played a crucial role in the replication efficiency of 
HCV [138, 280]. Indeed, different passages of the host cell line Huh7 showed up to 200-fold 
differences in HCV permissiveness [280]. One highly permissive cell clone was generated by 
treating a stable replicon cell line (Huh7-LucUbiNeo-ET, [129]) with a selective HCV inhibitor until 
the replicon was no longer detectable [137]. This “cured” cell line, designated Huh7-Lunet, was 
highly permissive and possessed remarkable replication efficiency for HCV [137, 335]. The reasons 
for its high permissiveness, however, remain elusive. A similarly generated and permissive cell 
line, Huh7.5, was found to have a defective RIG-I, thus, the absent immune response seemed to 
be responsible for its high permissiveness [336]. However, a later study showed no reduction of 
permissiveness upon reconstitution of functional RIG-I and no general correlation between the 
innate antiviral response and permissiveness for HCV [337]. 
5.1.1. Gene expression profiling reveals promising HF candidates 
Based on the suggestion of our intracellular model, we used microarrays to determine the gene 
expression profiles of eight different Huh7 variants and correlated expression levels of all genes 
with permissiveness for HCV across all those variants. Statistical analyses and filtering revealed 34 
hits that we sought to investigate for their role in HCV replication. As the intracellular model for 
HCV replication [277] and early elegant in vitro approaches [280] suggested, the host gene product 
or process was of limiting abundance in low permissive cells but not so in high permissive cells. 
Thus, we analyzed the effects of knockdown of those 34 candidate genes on HCV replication in an 
infection setting in high permissive cells and in a stable replicon cell line. We selected the five most 
promising candidate genes and sought to confirm the model prediction by overexpressing them 
in the low permissive Huh7-LP variant. Indeed, all the five HF candidates increased JcR2a 
replication in Huh7-LP cells. This confirms the model prediction that HF is of limiting abundance in 
low permissive cells and reveals novel candidates that might explain the huge differences in HCV 
permissiveness among different Huh7 variants.  
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Although we saw a maximal increase of HCV permissiveness of around 10-fold (THAP7, Figure 29), 
a combination of two or more of the candidate genes might yield additive or synergistic effects to 
reach the two to three orders of magnitude difference between the lowest and highest Huh7 
variants [277]. The fact that at least four of them (CRAMP1, CRYM, NR0B2, and THAP7) are 
reportedly involved in gene expression and regulation, underlines this notion. However, an initial 
attempt combining THAP7 and NR0B2 (under control of the ROSA26 promoter) overexpression 
did not result in an additive effect (data not shown). Still, we have not investigated all the 
remaining combinations. 
5.1.2. Dually decoded genes and LBHD1 (C11orf48) 
Interestingly, THAP7 and LBHD1 (C11orf48), the latter of which showed the second strongest (up 
to 8-fold) increase in HCV replication upon overexpression (Figure 28), have both been reported 
to be dually decoded [338]. THAP7 seems to encode an alternative peptide from an upstream ORF 
(uORF), whereas LBHD1 forms an alternative transcript that leads to a frameshift [338]. The THAP7 
uORF might as well have only regulatory function in translation of the regular ORF [338]; however, 
the alternative LBHD1 peptide was detected in a mass spectrometry study [339]. In addition, 
LBHD1 was reported to be a tumor antigen in a bladder cancer cell line [340]. Given the pro-
proliferative properties of oncogenes, this might give a rationale for the increased HCV replication 
efficiency in LBHD1 overexpressing cells as HCV replication is known to depend on proliferation in 
Huh7 cell [281]. However, using live cell imaging to quantify cell proliferation, we did not observe 
increased cell growth of LBHD1 overexpressing cells (data not shown). The positive effect of LBHD1 
overexpression on HCV replication was abrogated and overexpression even inhibited HCV 
replication upon C-terminal tagging of the protein (Figure 28). Interestingly, the alternative 
peptide originating from the alternatively spliced LBHD1 transcript, seems to be translated from 
the rather 3’-region of the mRNA [338, 339]. The C-terminal tag might thus have interfered with 
the function of the regular or even the alternative peptide. Future experiments should assess 
THAP7 and LBHD1 expression levels upon HCV infection and address the question which forms of 
the peptides are possibly upregulated and exert the positive effect on HCV replication. 
5.1.3. CRAMP1 (HN1L, TCE4) 
The uncharacterized CRAMP1 (also called CRAMP1L, HN1L, or TCE4) exerted the smallest effect 
on HCV replication and did so only during JcR2a infection but not after electroporation of sgCon1-
ET (Figure 28). CRAMP1 seems to have played a role in chicken domestication as revealed by SNP 
analysis [341] and its homolog was reported as a regulator of epigenetic marks in Drosophila 
melanogaster [342]. Thus, it would be interesting to investigate possible transcriptional changes 
upon CRAMP1 overexpression as well as its own expression upon HCV infection. 
5.1.4. CRYM 
Crystalline µ (CRYM) increased HCV replication only when overexpressed with an N-terminal but 
not with a C-terminal tag (Figure 28). Its positive effect was more pronounced during JcR2a 
infection than after electroporation with sgCon1-ET. The C-terminal tag might have interfered 
with its function. CRYM is the main cytosolic thyroid hormone binding protein [343] and has a well 
described ketimine reductase function in the brain [344]. It has been associated with insulin 
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sensitivity in adipose tissue [345] and mutations in CRYM in fibrocytes of the cochlea cause 
deafness [346]. Thyroid hormones are important players in lipogenesis, cholesterol synthesis, and 
insulin regulation [347, 348]. The fact that HCV disturbs the glucose metabolism [349] and 
frequently leads to insulin resistance and type 2 diabetes mellitus in patients [350] might 
represent a link to CRYM. Very recently, a study linked the loss of CRYM expression in mice to the 
development of obesity and fatty liver upon a high-fat diet [351]. Thus, it would be highly 
interesting to analyze CRYM expression levels upon HCV infection or in chronically infected 
patients. However, HCV infection might as well alter the activity or substrate availability for CRYM 
and thereby exert an effect without changing CRYM expression levels. In addition, the lipid 
content of infected cells and produced viral particles as well as their infectivity should be 
investigated. The functional impact of CRYM overexpression might also stem from transcriptional 
changes related to its nuclear receptor activity and could be revealed by transcriptional analyses 
[352]. 
5.1.5. THAP7 
THAP7 is well characterized and offers a sound basis for explanation of its regulatory effect on 
HCV replication. THAP7 is a member of the Thanatos-associated protein family that comprises at 
least 12 members [315, 316]. Only few of them are characterized to date, though [316]. THAP12, 
for example, which is also known as THAP0 or DAP4, reportedly binds to and inhibits PKR activity 
[353] as well as stabilizes RIG-I by preventing its polyubiquitination [354]. Thus, THAP12 seems to 
preserve an antiviral state in the cell and consequently inhibit viral replication. No such antiviral 
function has been described for THAP7. THAP7 is a transcriptional repressor and binds to histone 
tails [315]. It acts by recruiting template-activating factor-Iβ (TAF-1β), nuclear receptor 
corepressor (NCOR1, also known as N-CoR), or histone deacetylase 3 (HDAC3) to histones, and 
thereby induce transcriptional inhibition of the target sequence by hypoacetylation [316]. The 
regulated target genes of THAP7 are not known. Interestingly, the N-terminal domain of TAF-1β 
inhibits protein phosphatase 2a (PTPA, also known as PP2A) [355], which in turn is upregulated 
during HCV infection, possibly by NS5A [356]. Exploitation of PTPA activity poses several possible 
advantages for HCV. For example, the protein arginine methyltransferase 1 (PRMT1), which 
methylates and thus inhibits NS3 helicase function, is repressed by PTPA [357]. Further, PTPA 
reduces STAT1 phosphorylation and thereby inhibits IFNα-mediated JAK/STAT signaling. One 
could speculate that THAP7 sequestrates TAF-1β from the cytosol and thus increases PTPA 
activity, which would be advantageous for HCV. However, MacFarlan et al. reported no effect on 
PTPA activity upon THAP7 overexpression [316]. A recent study showed that HDAC3 inhibitors 
suppressed HCV replication by increasing levels of hepcidin antimicrobial peptide (HAMP, also 
known as LEAP-1) and reducing levels of apolipoprotein apoA1 [358], which is reported to be 
required for HCV particle production [359]. Thus, future experiments should investigate if HAMP 
and APOA1 are target genes of THAP7 and how THAP7 overexpression affects their expression 
levels. Notably, to the best of our knowledge, the degree of the THAP7-mediated increase in HCV 
replication is unprecedented as a host factor and provides a solid basis for further investigations. 
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5.1.6. NR0B2 (SHP) 
The atypical, orphan nuclear hormone receptor NR0B2 (also called SHP or SHP1) exhibited dose-
dependent effects on HCV replication. Strong overexpression led to inhibition of HCV replication 
in low as well as high permissive cells. In the latter, HCV replication was reduced by almost three 
log10 (Figure 30). We could show that this inhibitory effect is genotype independent and can be 
titrated (Figure 31). Minor overexpression of only 8-fold of NR0B2 in Huh7-Lunet cells even 
increased HCV replication slightly (Figure 31). The ligands of NR0B2 remain elusive and it lacks a 
DNA-binding domain, making it a co-repressor [317]. However, there is a plethora of target genes 
and nuclear receptors co-repressed by NR0B2, complicating it in cholesterol, bile acid, glucose 
metabolism and many more [360]. Its activator is the main bile acid (BA) sensor FXR, which itself 
is activated by BAs [324, 361]. We observed an increase and decrease in HCV replication by 
modulating FXR activity with an agonist and antagonist, respectively (Figure 31B). These effects 
might mimic the slight overexpression and the knockdown of NR0B2 that similarly affected HCV 
replication. Hence, the NR0B2-mediated regulation of HCV replication is probably attributable to 
its authentic function as a nuclear receptor. Upon BA- or agonist-mediated activation by FXR, 
NR0B2 suppresses the expression of cytochrome P450 family member CYP7A1 by binding to the 
trans-activator NR5A2 (also known as LRH-1) [360]. CYP7A1 performs the first and rate-limiting 
step in the catabolism of cholesterol [360]. Thus, strong overexpression of NR0B2 presumably 
leads to a block of BA synthesis and cholesterol accumulation. Indeed, we found reduced total BA 
content in NR0B2 overexpressing cells (Figure A12) as well as disturbed subcellular cholesterol 
distribution (Figure 32D). Still, BA contents were near the lower limit of detection of the assay kit 
and the cholesterol distribution, especially its transport to the HCV replication compartment and 
possible co-localization with HCV proteins, needs further assessment. Previous reports already 
showed that BAs could stimulate replication of subgenomic HCV genotype (gt) 1b, but not gt2a, 
replicons [362, 363], although no mechanism was proposed. A subsequent study revealed that the 
refractoriness to BA stimulation of the gt2a replicon was probably due to its already extraordinary 
replication efficiency [364]. The authors showed that an attenuated version of the gt2a replicon 
indeed was sensitive to BA stimulation. In addition, they reported that also full-length gt1b as well 
as gt2a replication profited from BA supplementation. Interestingly, besides an effect on 
replication, the authors observed a slight increase in infectivity of gt2a particles. Lipids, 
apolipoproteins, cholesterol, and cholesteryl esters make up a substantial portion of HCV particles 
[142], thus it would be highly interesting to measure the lipid composition and infectivity of 
released viral particles from NR0B2 overexpressing cells. One follow-up study of the above 
mentioned found the EGFR/ERK pathway to be responsible for the bile acid-mediated increase in 
HCV replication [365]. With NR0B2 and its nuclear receptor as well as transcriptional co-repressor 
activities, we present a number of possible pathways involved in the regulation of HCV replication 
by NR0B2 levels. 
NR0B2 has been implicated in HCV infection and its regulation before, however the findings are 
controversial. Two reports showed reduced NR0B2 levels upon HCV infection in vitro as well as in 
liver specimen of chronically HCV-infected patients [366, 367], and a concomitant progression of 
liver disease. Surprisingly, both studies reported no effect on HCV replication upon NR0B2 
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knockdown or overexpression. Along the same lines, but without the involvement of HCV, NR0B2 
was reported to have a protective effect on the progression from non-alcoholic fatty liver (NAFL) 
to non-alcoholic steatohepatitis (NASH) [368]. In contrast to these findings, an Italian group 
reported increased NR0B2 levels upon HCV infection in vitro as well as in liver specimen, a 
relocalization of NR0B2 into the cytoplasm, and a direct interaction of NR0B2 with NS5A via co-IP 
[318]. Further, they showed a strong reduction of HCV replication upon siRNA-mediated NR0B2 
knockdown. These findings are in line with our observations of increased NR0B2 levels upon HCV 
infection (Figure A11), a reduction in HCV replication upon knockdown of NR0B2 (Figure 27), and 
a localization of overexpressed NR0B2 into speckles in the cytosol (Figure A10E), which might 
allow a direct interaction with HCV proteins. The differences to the findings above might be the 
use of a J6/JFH chimera in our hands and in [318], versus JFH in [366, 367], pointing to a role of 
the structural proteins in the NR0B2-mediated effects.  
Interestingly, NR0B2 controls the expression of miRNAs and lncRNAs [369] that could possibly 
affect HCV RNA directly or indirectly via host dependency factors. However, we could not detect 
consistent changes at least in miR-122 levels, dependent on NR0B2 expression (data not shown). 
Lastly, we showed that the dose-dependent strong impact of NR0B2 expression levels was specific 
to HCV replication, as DENV was much less and RVFV not at all affected in a dose-dependent 
manner (Figure 33). The insensitivity of DENV was surprising since both, HCV and DENV, heavily 
rely on cholesterol and lipids [333]. However, DENV replication did show a dose-dependent effect 
of NR0B2 overexpression, but much less pronounced than HCV. This might allude different host 
pathways and dependency factors involved in the cholesterol and lipid supply of HCV and DENV 
replication and assembly, or point towards other regulatory pathways triggered by NR0B2 that 
affect HCV more specifically. 
NR0B2 seems to dictate HCV replication in a fashion reminiscent of that of PI4KIIIα [370], with 
severe effects. The multifaceted roles of NR0B2 make it difficult but at the same intriguing to 
elucidate the underlying mechanisms of HCV replication regulation. Follow-up studies should 
identify the functions of NR0B2 crucial for HCV replication. This will not only give insights into the 
molecular virology but also into liver disease progression upon chronic HCV infection.  
Overall, we identified five candidates that open up new venues to explain the huge differences in 
host cell permissiveness for HCV. We did so by combining findings from a mathematical model 
with in vitro validation experiments. This underpins the capability of mathematical models to help 
in better understanding and elucidating molecular aspects of viral replication. It will be intriguing 
to analyze the effects of those candidates with a model that supports the full viral life cycle. 
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5.2. The intracellular and the new full life cycle model of HCV replication 
The Binder model proved fit in simulating replication of HCV subgenomes in low as well as high 
permissive Huh7 cells [277]. It could fit replication of attenuated subgenomic HCV RNA versions 
and predicted a HF species involved in RC formation and (-)-strand synthesis initiation to dictate 
HCV replication efficiency in two different Huh7 variants. We could confirm this model prediction 
and found HF candidates that increased HCV replication upon overexpression in low permissive 
Huh7-LP cells and decreased HCV replication upon siRNA-mediated knockdown in high permissive 
Huh7-Lunet cells. The intracellular mode further revealed the most sensitive steps in the 
intracellular HCV life cycle upon targeted intervention [277]. To prove if the model was also able 
to identify those steps in intracellular HCV replication that are targeted by a specific treatment, 
we recorded HCV replication dynamics under IFN-α treatment.  
5.2.1. The intracellular model reveals the mode of action of IFN-α 
IFN-α has been the standard of care as a recombinant protein, PEGylated, and in combination with 
ribavirin for decades [22]. Sustained virologic response (SVR) rates upon IFN-α treatment largely 
depend on HCV genotype and progression of liver disease, but did not exceed 40–50% on average, 
and IFN-α treatment came along with severe side effects [22]. Today, DAAs have mostly replaced 
IFN-α as the standard of care for HCV infection. However, the exact mode of action of IFN-α 
treatment remains largely unsolved. Understanding the effects of IFN-α treatment on HCV 
replication not only reveals insights into the viral life cycle but also in the antiviral response of the 
host cell. IFN-α triggers a signaling cascade via the JAK-STAT pathway and leads to the expression 
of hundreds of ISGs [371]. Several of those ISGs have proved to possess anti-HCV activity but only 
for few of them, the molecular mode of action has been described (reviewed in [371, 372]), e.g. 
the OAS/RNaseL system which leads to endonucleolytic cleavage of HCV RNA [252, 373] or ISG20, 
which has exonuclease activity [372]. However, no comprehensive picture of or the contribution 
of different ISGs on intracellular HCV replication inhibition exists. We used our intracellular HCV 
replication model to decipher the mode of action of an IFN-α-triggered antiviral response on HCV 
replication and to determine the steps most probably affected by the antiviral response of the 
host cell. 
In order to do so, we monitored translation and replication of subgenomic HCV reporter replicons 
under treatment of different doses of recombinant IFN-α. We observed that translation of HCV 
RNA was severely impaired upon IFN-α treatment in Huh7-Lunet cells (Figure 9). This is in line with 
earlier findings, which also showed that HCV IRES-mediated translation is even stronger affected 
by IFN treatment than (cellular) cap-dependent translation [250, 374, 375]. However, a major 
limitation to these studies was that they only used bicistronic luciferase reporter plasmids instead 
of replicons. Thus, possible counteractions or stabilizing effects of viral proteins or secondary RNA 
structures on HCV IRES-mediated translation could not apply. Possible suggested mechanisms for 
the observed translational shutdown were inhibition of eIF2 activity by phosphorylation of its α 
subunit through PKR, sequestration of eIF3 by IFIT1, or reduced supply of ribosomes by 
upregulation of the OAS/RNase L system, which has been shown to cleave 28S ribosomal RNA 
([250] and references therein). However, in a later siRNA-screen study, PKR did not appear as a hit 
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and was subsequently confirmed to play no major role in the IFN-α-mediated suppression of HCV 
replication [244]. The same study also revealed that singular knockdown or overexpression of ISGs 
exerted only moderate effects on HCV replication. However, upon combination, the authors 
observed additive and even synergistic effects on HCV replication upon knockdown of the 
investigated ISGs [244]. Similar findings were obtained upon combinatorial overexpression of ISGs 
[242]. This argues for a concerted action of ISGs against HCV and gives a rationale for the plethora 
of ISGs upregulated by IFN treatment. Besides classical ISGs, miRNAs as well as interferon effector 
genes (IEGs) that are not transcriptionally upregulated upon IFN treatment have been reported to 
possess anti-HCV activity [376, 377]. Large screening studies using either siRNA knockdown or 
overexpression of putative ISGs confirmed the early findings of translation inhibition of HCV RNA 
and revealed many genes involved in mRNA processing and translation initiation or showed 
translational inhibition of HCV RNA directly, respectively [242, 243]. Thus, inhibition of HCV IRES-
mediated translation is clearly a major effect of the antiviral response raised by the host cell upon 
IFN-α treatment. The host factors responsible for this strong inhibition and their relative 
contribution, however, remain to be determined.  
We also found that HCV RNA stability was decreased upon IFN-α treatment (Figure 9), arguing for 
a faster degradation, possibly by RNase L, ISG20, or other nucleases. HCV RNA is usually protected 
from 5’-3’-exonucleases by miR-122 binding to its 5’-UTR and by its 5’-triphosphate [60, 378, 379]. 
However, a possible reduction of miR-122 levels upon IFN treatment [376] could ease the access 
of pyrophosphatases to the 5’-end of HCV RNA, trimming it and consequently allowing Xrn1/2-
mediated degradation [59, 378, 380]. Although HCV replication and later steps in its life cycle have 
been described to be targeted by ISGs [247, 371], our intracellular model could very accurately fit 
intracellular HCV replication data under IFN treatment by only incorporating effects on translation 
and RNA degradation (Figure 10). That means that potential additional effects would be only 
minor and could not improve the model fit much further. However, our system was solely based 
on intracellular HCV replication after electroporation of in vitro transcripts. It would be intriguing 
to test the impact of IFN-α treatment on HCV replication in the full-length setting with a full life 
cycle model to fit the data. Possibly then, effects on replication compartment formation, assembly 
or release of viral particles need to be taken into account to generate a good fit. 
5.2.2. Both models are able to predict viral replication dynamics under drug treatment 
The Binder model revealed promising therapeutical intervention steps in the intracellular HCV 
replication cycle [277]. To investigate if the model was also able to predict viral replication under 
therapeutic intervention, we recorded replication dynamics of a subgenomic reporter RNA under 
treatment with direct-acting antivirals (DAAs). DAAs are the new standard of care for chronic HCV 
infection [20]. They exhibit cure rates of 95–100%, have mild to no side effects, and are 
recommended for most comorbidities or stages of liver disease. The three main classes of DAAs 
against HCV are NS3/4A inhibitors (-previr), NS5B inhibitors (-buvir), and NS5A inhibitors (-asvir). 
Administered regimens are usually combinations of at least two of them [20]. The former two 
have distinct and well-defined modes of action, whereas the mode of action of NS5A inhibitors is 
more elusive. We used Telaprevir (TEL) and Sofosbuvir (SOF) to prove the capability of our 
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intracellular model to predict HCV replication under DAA treatment. TEL and SOF have distinct 
and well-defined modes of action, which allowed us to pre-select the steps in the HCV replication 
cycle targeted by the respective drug. However, to reflect the situation in an infected patient more 
closely, the model needed extension the full viral life cycle. Such a model would include viral 
particle production and infection of target cells, representing spread of the infection.  
Therefore, we have extended the Binder model for intracellular HCV replication, which is based 
on the transfection of reporter replicons, to the full HCV life cycle (Figure 15), represented by 
infection of Lunet-CGM cells with cell culture-produced full-length Jc1 particles. We have added 
novel parameters to the intracellular model that represent crucial steps in an authentic infection, 
as for example rates for infection and assembly of viral particles. In addition, the model now takes 
into account the age of an infected cell, meaning the time it is already infected and thus produces 
more (+)-strand RNA and viral progeny. Moreover, the model is linked to a population model that 
accounts for the number of infected cells. The resulting multilevel model is able to predict intra- 
and extracellular viral determinants as well as spread of the infection. We confirmed the validity 
of our model extension with data obtained from the infection of Lunet-CGM cells with cell culture-
produced Jc1. We assessed viral (+)- and (-)-strand RNA, viral titers, and the percentage of infected 
cells in the culture dish. All the newly introduced parameters were identifiable and could be fitted 
based on the recorded data. The model simulation closely resembled the biological data for all the 
assessed parameters. Thus, our model proved valid and could be used to predict viral replication 
under drug treatment in a more authentic infection setting. 
We started with the intracellular model and predicted intracellular HCV RNA replication by only 
adapting the steps directly affected by the respective drug (polyprotein processing rate kc by TEL 
and RNA synthesis rates k4m and k4p by SOF). The model generated predictions that correctly 
reflected viral replication dynamics under different concentrations of the respective drug (Figure 
12). Although the predictions did not precisely match all the data points and could possibly be 
improved, they, importantly, qualitatively resembled the two very distinct replication dynamics of 
HCV under treatment with these two different classes of inhibitors. Briefly, TEL led to a later onset 
of replication but a similar slope and HCV replication reached the same levels as in the untreated 
condition at the assay endpoint at 72 hpe. SOF in contrast, slowed down HCV replication dynamics 
markedly, which resulted in lower steady state levels of HCV RNA replication. These results 
confirmed that the intracellular HCV replication model was in principle capable of implementing 
drug effects and predicting HCV replication under treatment. Thus, we were tempted to analyze 
the drug effects of Daclatasvir on HCV replication by generating a model fit that could suggest the 
most probably affected steps in the intracellular life cycle of HCV by the treatment. 
5.2.2.1. Mode of action of the NS5A inhibitor Daclatasvir (DCV) 
Daclatasvir (DCV) was approved for HCV treatment by the FDA in 2015 [305] and exhibits inhibitory 
potency in the replicon system in the low picomolar range [307]. Due to the many functions of 
NS5A in the HCV life cycle, the mechanism of action of DCV remains elusive, especially because 
NS5A has no enzymatic function [381]. NS5A consists of an N-terminal amphipathic helix that 
allows membrane anchoring, a structured domain 1 (D1) that coordinates a Zn2+ ion, and two 
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highly unstructured domains, D2 and D3 [382]. Whereas D1 and D2 are required for replication, 
D3 is not; however, D3 is essential for viral assembly [381]. Importantly, the first crystal structure 
of NS5A D1 showed a dimer with a potential groove for RNA binding [99]. Interestingly, other D1 
crystallization studies revealed alternative dimer forms [383, 384], suggesting NS5A could form 
large oligomers [383]. Later studies showed that NS5A indeed is an RNA-binding protein [100, 385, 
386] and dimerization, and possibly oligomerization, is required for efficient HCV replication [387]. 
DCV resistance mutations suggested early on that the compound directly binds to D1 and later in 
vitro experiments confirmed this notion [388, 389]. However, instead of disrupting, DCV was 
shown to stabilize the dimer upon binding and thereby exclude RNA binding of NS5A [388].  
We used our intracellular model to fit HCV replication data under DCV treatment. The model 
achieved the best fit upon including inhibitory drug effects on the translation rate k1 and the RNA 
synthesis rates k4m and k4p (Figure 12). Although NS5B, which is not targeted by DCV [307], is the 
viral polymerase that synthesizes (+)- and (-)-strands, NS5A has been shown to bind HCV RNA [100, 
386] and is probably part of the replicase complex [64]. This gives a rationale for our finding of 
RNA synthesis steps being a target of DCV inhibition. In addition, the D1 mutation Y93H confers 
partial resistance to DCV but reduces RNA levels during replication by 10-fold [390]. There is no 
evidence of a direct involvement of NS5A in HCV RNA translation. However, NS5A reportedly binds 
PKR and leads to its activation, which in turn leads to eIF2α phosphorylation and translational 
shutdown in the cell. A cyclophilin A (CypA) inhibitor was shown to revert this phenotype, probably 
by blocking the interaction of CypA and NS5A, which enables the NS5A-PKR interaction [391]. The 
same might hold true for DCV, but this needs experimental evidence. Instead, delivery of HCV RNA 
to the cytoplasm might be affected by the DCV-mediated NS5A inhibition, which would eventually 
result in lower translation rates. Kinetic analyses of another group have also shown a direct effect 
of DCV on RNA synthesis [392]. This effect was immediate, but could interestingly block RNA 
synthesis only to maximal 50% within the first 12 hours. This argues for different pools of NS5A 
inside the cell, some accessible to DCV and others not [392], and supports a model in which DCV 
blocks formation of new replication compartments, but has no effect on pre-existing ones [303, 
393].  
Our intracellular model and the corresponding experimental system were limited to intracellular 
replication of an HCV subgenome and did not account for effects on the production of infectious 
particles or their release. NS5A, though, reportedly plays an essential role in assembly and particle 
production and localizes together with Core to LDs [95, 96, 394]. Consequently, the kinetic study 
on DCV inhibition mentioned above indeed showed a rapid (≤ 3 hours) abrogation of release of 
infectious viral particles as well as formation of intracellular infectious particles upon DCV 
treatment [392]. A mathematical modeling study using patient data showed that in order to fit 
serum viral load, DCV must exert a direct inhibition of both, replication and assembly [395]. The 
LD-binding motif of NS5A is located in D1 [381], which might be masked or disrupted upon DCV 
binding, leading to an abrogation of LD localization of NS5A, explaining the assembly defect [394].   
We therefore used our new full life cycle model to predict full-length HCV replication under DCV 
treatment. We adjusted the parameters that the intracellular model revealed upon fitting HCV 
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replication data under DCV treatment: inhibition of the translation rate k1 and RNA synthesis rates 
k4m and k4p. The resulting prediction closely resembled Jc1 replication dynamics, although (+)- and 
(-)-strand RNA data posed a high variation in the two biological replicates (Figure 25). Interestingly, 
viral titer data and model prediction fit very well, without changing assembly rate p in the model. 
Overall, the model prediction of Jc1 dynamics under DCV accurately fit the data, even when only 
including effects on k1, k4m, and k4p. However, we did only test one, relatively low (82 pM) 
concentration of DCV and the variance in our biological data was quite high. Still, the 
implementation of an assembly effect of DCV seemed not necessary in our experimental system. 
However, we did not perform a systematic fit of the model to the DCV data, yet. Maybe this would 
result in a different set of adjusted parameters that include the assembly rate. In addition, it would 
be highly interesting to analyze the effect of DCV when steady state levels have been reached, e.g. 
at 72 hpi or later, and monitor the decay in infectious titers and RNA levels upon high doses of 
DCV, to see if the model can fit the data with or without adjusting assembly rate p. This approach 
would more closely reflect an authentic therapeutic intervention. 
5.2.2.2. Mode of action of the NS3/4A protease inhibitor Telaprevir (TEL) 
NS3 is a multifunctional protein due to its protease and helicase domain [81]. The protease 
function is essential for processing of the viral polyprotein and for blunting the antiviral response 
of the host cell by cleaving important adaptor proteins. TEL is a peptidomimetic α-ketoamid that 
blocks the active site of the NS3 protease by covalent binding [396]. 
We used TEL to validate that our intracellular model is capable of predicting HCV replication even 
under drug treatment. We recorded intracellular subgenomic HCV RNA replication under 
treatment with two different TEL concentrations (100 and 200 nM), and generated a model 
prediction after including an IC50 term in the polyprotein processing rate kc. The model prediction 
accurately resembled the qualitative changes in HCV replication dynamics upon TEL treatment. 
Those were a later onset of replication but no reduction in the slope of amplification (Figure 12). 
However, our system did not account for later steps in the HCV life cycle, like assembly and release 
of viral particles, in which NS3/4A reportedly plays essential roles as well [84, 397-400]. We 
extended our intracellular model to the full viral life cycle and used the new model to predict Jc1 
replication dynamics under TEL treatment, again only considering a drug effect on kc (Figure 19). 
The model prediction in this setting strongly underestimated the TEL effect on Jc1 replication, 
including RNA levels as well as infectious titers. This might allude to effects of TEL on steps besides 
polyprotein processing, that we did not account for in the model prediction. However, it might as 
well be that HCV replication during an infection is much more sensitive and relies stronger on viral 
protein production, e.g. for establishing the RC or producing virions for spread, than HCV 
replication of viral subgenomes after electroporation into cells. In case not only the polyprotein 
processing function is affected, TEL might stabilize NS3 in a distinct confirmation – as shown for 
the DCV-NS5A interaction [388]  – that renders it refractory to interact with other (viral or host) 
proteins, or disturbs its recruitment or localization, and thereby exert its inhibitory effect.  
NS3, like NS5A, is probably involved in RNA synthesis and part of the replicase complex [43, 64]. 
The helicase domain might function in resolving RNA secondary structures or unwinding dsRNA 
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intermediates to allow access or higher processivity of NS5B ([43] and references therein). 
McGivern et al. claim a direct effect of TEL on HCV RNA synthesis as they observed a rapid (≤ 12 
hours) decrease in newly synthesized RNA upon treatment at a point where NS5B levels are not 
yet decreased [401]. However, there is evidence that NS5B acts only in cis, meaning it synthesizes 
(-)-strands only directly after translation from its very own (+)-strand it has been translated from 
[402]. This would immediately stop RNA synthesis upon halted production of NS5B. In addition, 
blockage of the formation of new replication complexes as a consequence of inhibited polyprotein 
processing might explain such a phenotype as well. It has been described that the protease 
domain is needed for helicase function [403], giving a rationale for the immediate effect McGivern 
et al. saw on RNA synthesis [401]; however, this is probably attributable to an allosteric effect and 
evidence for the need of the NS3 protease enzyme activity for helicase function is lacking. 
Moreover, TEL was reported to not impair the helicase function of NS3 [404]. This complicates the 
explanation of possible further effects of protease inhibition on virion assembly, because it 
suggests a direct involvement of the protease function in these processes. 
NS3/4A plays an essential role in HCV assembly (reviewed in [75]). Inhibitor treatment as well as 
NS3 resistance mutations to TEL show specific defects in assembly independent of impaired RNA 
replication [405]. Guedj et al. show with their mathematical modeling of patient serum viral load 
that TEL also impairs viral assembly/secretion [395]. This is supported by the kinetic in vitro studies 
of McGivern et al. that show a dramatic loss in viral titers, exceeding the reduction in RNA levels 
upon TEL or boceprevir (a similar NS3/4A inhibitor) treatment [392, 401]. This is also reflected in 
our data, especially at 32 and 45 hpi (Figure A5A). These effects may not necessarily stem from a 
loss of function of the NS3 protease itself though, but rather from the NS3 helicase or the co-
factor NS4A upon loss of stimulation by the NS3 protease (their functions in assembly are 
reviewed in [81]). There is solid evidence for the NS3 helicase domain to function in virion 
assembly [84] and that the NS3 protease domain (but not its enzymatic activity) is needed for the 
helicase to function properly [403]. The N-terminal amphipathic helix α0 of NS3 as well as the linker 
domain between the NS3 protease and helicase are required for assembly as well [397, 406]. Still, 
neither of those domains or their functions should be affected directly by TEL. The NS3/4A 
assembly defect upon TEL treatment could also be exerted via its reported interaction and co-
recruitment with NS5A to lipid droplets [394]. 
Overall, there is solid evidence for a role in virion assembly for all NS3/4A domains, but not yet for 
NS3 protease activity. Still, others and we found that infectious titers are decreased to a level that 
exceeds the reduction in RNA levels. These findings strongly support a role for the NS3 protease 
function in virion assembly or release. However, it is hard to address this question experimentally 
since NS3 protease function is required for replication and cannot be separated from its function 
in assembly easily. Further analyses with our new full life cycle model and additional kinetics data 
should allow to gain new insights into this second role of the NS3 protease and help us understand 
the TEL effect on viral particle production. 
We used the NS5B polymerase inhibitor Sofosbuvir (SOF) as a DAA with distinct and known 
mechanism of action to validate our intracellular model. The intracellular model prediction upon 
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adjustment of the RNA synthesis rates k4m and k4p revealed a good fit and resembled replication 
dynamics under the inhibitor (Figure 12). The full life cycle model prediction fit the data quite well, 
although the drug effect was very small (Figure 22). Importantly, and in contrast to TEL and DCV, 
SOF did not specifically affect infectious particle production and titers dropped just according to 
reductions in RNA levels (Figure A5). Since SOF is a pro-drug, we had to implement an activation 
model to make the model prediction resemble the data closely.  
We extended the intracellular HCV replication model to the full life cycle. This included the 
addition of parameters for yet uncovered steps by the model, e.g. the infection rate β. Those, yet 
unknown, parameters needed to be estimated and fitted based on the available set of data. We 
detected a huge excess of HCV (+)- and (-)-strands in the viral stock that we used for the infection 
dynamics. In order to be able to fit the above mentioned parameter, we had to make the 
assumption that all of those were non-infectious. The following section gives insights into the 
possible origin of these excess (+)- and (-)-strand RNAs. 
5.2.3. Extracellular, non-infectious vesicles 
The cell culture-derived Jc1 particle stocks used in this study were produced by PEG-precipitation 
of culture supernatants after electroporation of cells with in vitro-transcribed Jc1 RNA [283]. 
Strand-specific RT-qPCR of one stock revealed a huge excess of viral (+)- as well as (-)-strands 
compared to infectious particles as determined by limiting dilution assay (Figure A2B). 
Remarkably, because HCV is a (+)-strand RNA virus, (-)-strands should not be present in the viral 
stock at all. We did not attempt to clarify the origin of these excess (+)- and (-)-strands, but they 
probably derived from secreted extracellular vesicles (EVs). Initially, EVs were thought to simply 
dispose of unneeded cellular content [407]. However, it became clear that EVs fulfill various 
functions in intercellular signaling and communication [407]. Very early it became apparent that 
Huh7 cells secrete membranous particles that contain HCV (sub)genomes, independent of particle 
production [408]. However, the transferred nucleic acids largely failed to establish a productive 
replication [408]. Later, it was shown that such HCV (sub)genomes transferred by EVs are able to 
elicit an immune response in professional immune cells [221, 409], and can even establish a 
productive infection in target cells [410, 411]. Although Bukong et al. [410] provided evidence for 
the establishment of a productive infection by HCV RNA-containing EVs, the amount of those in 
cell culture supernatants was at least three log10 lower compared to infectious viral particles [410]. 
This was corroborated by another study that reported only 0.1% of EVs contained HCV RNA and 
in which the authors failed to establish a productive replication in target cells with unpurified EVs 
containing subgenomic replicons [411]. Further, it was reported that the transmission of such HCV 
RNA-containing EVs requires cell-to-cell contacts [221, 411]. Thus, “infection” with EVs might be 
possible, but only after purification or upon cell-to-cell contact, and might be negligible in an 
authentic infection. In addition, purification of such EVs and thereby excluding a cross-
contamination with authentic HCV particles is difficult due to their highly similar size and buoyant 
density [407]. Immuno-purification of exosomes (a subfraction of EVs) via the exosome marker 
CD63 might represent an alternative approach and has been done before [410]; however, another 
exosome marker, CD81 [412], is a HCV co-receptor and thus cross-purification of attached viral 
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particles cannot be excluded. Still, HCV RNA-containing EVs have been isolated from patient serum 
and shown to contain not only (+)- but also (-)-strand RNA [295, 410]. Grünvogel and colleagues 
found that (-)-strands are even enriched in EVs compared to the intracellular milieu, concluding 
that EVs mostly contain dsRNA and secretion of dsRNA-containing EVs poses a way of evading the 
immune response of the host cell by avoiding detection by TLR3 [295]. The ratio of (+)- to (-)-
strands in one of our Jc1 stock preparations was roughly 10:1 in contrast to 4:1 as Grünvogel et al. 
reported [295]. This might be caused by cellular or culture differences, although both studies used 
Huh7-Lunet-CD81high cells, or by the different purification methods: PEG-precipitation in our study 
versus ultra-centrifugation and Exo-spin columns in [295]. The higher amount of (+)-strands in our 
virus stock could also suggest that the purification method or the one freeze-thaw cycle during 
stock preparation rendered viral particles non-infectious. In our mathematical model, we assumed 
that all those excess (+)- and (-)-strand RNAs in the virus stock were non-infectious. The good fit 
of the model simulation to the actual data supports the notion that most if not all of the detected 
excess (+)- and (-)-strands were non-infectious. 
In conclusion, we extended our intracellular model to the full viral life cycle and showed that is 
capable of simulating HCV replication dynamics in the full-length context. In addition, the model 
has proven fit to incorporate drug effects and predict HCV replication dynamics under treatment 
with different DAAs against HCV. It is the first such detailed model of its kind that is based on solid 
experimental data. Our model will be useful in understanding the mode of action of DAAs against 
HCV in detail, and can be used to address various other questions in HCV biology. These might 
regard the differences in replication efficiencies of HCV genotypes or isolates on the viral side or 
qualitative and quantitative host factor involvement on the other side.  
To conclude, we used an intracellular HCV replication model to identify novel HCV host factors 
that possibly contribute to the huge differences in permissiveness between Huh7 variants and 
thus constitute important pillars of HCV replication. By doing so, we confirmed the model 
prediction that a host factors species involved in determining permissiveness is limiting in low 
permissive cells. We further used the model to shed light on the mechanism of action of IFN-α 
treatment on HCV replication and provided a basis for a comprehensive understanding of the 
mode of action of the NS5A inhibitor DCV. We extended the intracellular model and developed a 
multilevel model that covers the full HCV life cycle, including infection of target cells, viral particle 
production, and spread of the infection. The new model can simulate (+)- and (-)-strand RNA 
levels, infectious titers in the supernatant, and spread of the infection in the culture. This new full 
life cycle model allows a comprehensive assessment of drug effects, including IFN-α, DCV, or TEL, 
on the full life cycle of HCV, including particle production and spread. It might serve in solving the 
role and explaining the impact of our newly identified host factor candidates for HCV replication 
in an authentic infection setting. Thus, this study provides a better understanding of HCV 
permissiveness and lays the foundation for gaining further insights into HCV replication as well as 
liver disease progression.  
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7. APPENDIX 
Click ↑ to get back to the according text passage. 
 
Figure A1  ↑ The antiviral response triggered by IFN-α reduces HCV RNA half-life. Non-linear regression of HCV RNA 
levels over time after electroporation of the replication-deficient subgenomic firefly luciferase-encoding HCV RNA 
sgJFHΔGDD into untreated or IFN-α pre- and co-treated Huh7-Lunet cells quantified from strand-specific Northern blot, 
relative to 0 hours (n=3). 
 
 
Figure A2  ↑ ↑  Comparison of HCVcc (Jc1) replication dynamics of two different stock preparations (stock A 01/16, 
stock B 06/19) in Lunet-CGM cells (A) and quantification of HCV RNAs in stock A (B). (A) (+)- and (-)-strand RNA 
quantification after infection of Lunet-CGM cells at an MOI of 1 (stock A) or 2.42 (stock B) using a strand-specific RT-
qPCR (stock A n=3, stock B n=5). (B) (+)- and (-)-strand RNA quantification by strand-specific RT-qPCR from virus stock 
A (n=2). Virus stock titer suggested 2∙105 infectious (+)-strands per mL as determined by end-point dilution assay 
(TCID50).  
 
 
Figure A3  ↑ ↑  Jc1 infection dynamics in Lunet-CGM cells with or without complete inhibition of replication (A) 
and the same infection dynamics cleared from non-replicating RNA (newly synthesized) (B). (A) (+)- and (-)-strand 
RNA quantification after infection of Lunet-CGM cells with Jc1 stock A at an MOI of 1 using a strand-specific RT-qPCR 
(n=2 for untreated, n=1 for non-replicating). Complete inhibition was assured by treatment with 1 µM Telaprevir and 
Sofosbuvir each. (B) Same data as in (A) but non-replicating RNA molecules were subtracted from untreated ones. 
The remaining RNA molecules are presented as “newly synthesized”. 
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Figure A4  ↑ Titration of three different inhibitors (DAAs) against HCV and calculation of their respective IC50s. 
Lunet-CGM cells were infected with HCVcc (Jc1) with an MOI of 2.42 and either left untreated or treated with varying 
concentrations of Telaprevir (A), Sofosbuvir (B), or Daclatasvir (C) for 72 hours (n=1 each). HCV RNA levels were 
assessed by strand-unspecific qRT-PCR (Taqman). Curve fits are non-linear regressions (four parameters, variable 
slope; 4PL) generated with GraphPad Prism 8 software. For Sofosbuvir, the top value was constrained to a non-
treated control (6.15∙107 HCV RNA molecules per µg RNA). 
 
 
Figure A5  ↑  ↑  ↑  Ratios of viral determinants during Jc1 infection of Lunet-CGM cells under treatment. (+)- and 
(-)-strand RNA quantification using a strand-specific RT-qPCR and viral titer determination (endpoint dilution assay, 
TCID50) after infection of Lunet-CGM cells with Jc1 stock B (MOI 2.42) and treatment with IC50s of TEL (A), SOF (B), or 
DCV (C) (n=4-5 for untreated, n=2 for treatments). Data is shown in means +/- SD from the indicated number of 
independent experiments. 
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Figure A6 ↑ ↑ Cell viability after siRNA reverse-transfection in Huh7-Lunet (A) and Huh7-LucUbiNeo cells (B). 
(A) Huh7-Lunet cells were reverse-transfected in white 96-well plates with indicated siRNAs 24 hours prior to mock 
infection. 72 hours later, cell viability was measured using the CellTiterGlo® substrate. (B) Huh7-LucUbiNeo cells were 
reverse-transfected with indicated siRNAs and cell viability was measured 96 hours later using the CellTiterGlo® 
substrate. Data shows means +/- standard deviation from two independent biological experiments. Adapted from 
[278]. 
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Figure A7 ↑ Impact of siRNA knockdown of HF candidate genes on JcR2a replication (A) and cell viability (B). (A) Huh7-Lunet cells were reverse-transfected with three different siRNAs per 
candidate gene 24 hours prior to JcR2a infection (MOI ~0.1). Luciferase activity was measured 72 hours later and is given relative to the eGFP control. (B) Huh7-Lunet cells were reverse-
transfected with three different siRNAs per candidate gene 24 hours prior to mock infection. Luciferase activity was measured 72 hours later and is given relative to the eGFP control. Data 
shows means +/- standard deviation from three (A) and two (B) independent biological experiments, respectively. Adapted from [278]. 
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Table A1 ↑ Results of JcR2a replication (n=3) and cell viability assay (n=2) after siRNA-mediated knockdown of HF 
candidate genes. In grey color highlighted and bold are candidate genes that we studied further. Adapted from [278]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  HCV replication cell viability   HCV replication cell viability 
# siRNA mean SD mean SD # SD mean SD mean SD 
1 MEIS2_6 0,04 0,01 0,50 0,09 73 NAT8L_1 0,90 0,40 0,62 0,13 
2 PI4KIIIα 0,05 0,01 0,90 0,21 74 THBS4_7 0,95 0,21 1,04 0,04 
3 HAS2_4 0,08 0,03 0,33 0,15 75 MYOM1_9 0,97 0,31 0,77 0,09 
4 NR0B2_4 0,09 0,03 0,78 0,09 76 SULT1E1_8 1,01 0,26 1,13 0,09 
5 CRAMP1_7 0,12 0,04 0,81 0,07 77 UCP2_11 1,00 0,19 0,78 0,13 
6 TMED3_6 0,13 0,07 0,46 0,15 78 LBHD1_6 1,02 0,31 0,79 0,05 
7 LOC400655_6 0,15 0,04 0,74 0,09 79 MYOM1_7 1,04 0,17 0,93 0,06 
8 IL17D_5 0,15 0,09 0,60 0,05 80 NAV3_10 1,05 0,25 0,81 0,04 
9 CRYM_11 0,16 0,06 0,71 0,07 81 HAS2_6 1,06 0,28 0,90 0,05 
10 ZNF512B_3 0,17 0,04 0,69 0,12 82 SORCS2_1 1,08 0,29 1,05 0,04 
11 MICAL3_11 0,17 0,05 0,71 0,09 83 PPP1R15A_7 1,07 0,12 0,79 0,07 
12 LBHD1_4 0,18 0,06 0,94 0,06 84 ZNF512B_4 1,14 0,20 0,98 0,09 
13 NR0B2_7 0,19 0,03 0,79 0,04 85 TMED3_5 1,17 0,21 1,03 0,06 
14 THAP7_5 0,19 0,04 0,95 0,07 86 THAP7_1 1,18 0,42 1,15 0,10 
15 A1BG_2 0,21 0,08 0,80 0,12 87 PPP1R15A_6 1,18 0,33 0,83 0,07 
16 ZNF512B_6 0,22 0,08 0,72 0,07 88 C8orf4_6 1,25 0,36 1,11 0,05 
17 CRYM_9 0,25 0,08 1,09 0,08 89 C8orf4_8 1,24 0,39 1,18 0,10 
18 THAP7_6 0,25 0,14 0,67 0,08 90 SNUPN_2 1,29 0,43 0,93 0,13 
19 SFI1_8 0,27 0,07 0,66 0,06 91 IL17D_2 1,32 0,36 0,94 0,04 
20 A1BG_9 0,29 0,12 0,64 0,08 92 ALPK2_6 1,44 0,64 1,20 0,17 
21 PLEKHO1_5 0,28 0,12 0,92 0,06 93 CRAMP1_8 1,41 0,42 0,82 0,03 
22 UCP2_10 0,31 0,08 0,71 0,07 94 TUBB2B_3 1,43 0,51 1,26 0,08 
23 NAV3_9 0,32 0,11 0,77 0,07 95 SFI1_9 1,48 0,58 0,73 0,05 
24 NR0B2_6 0,32 0,10 0,82 0,09 96 PDE8A_9 1,55 0,37 1,01 0,04 
25 IL17D_6 0,34 0,07 0,88 0,03 97 NAV3_11 1,55 0,45 1,07 0,07 
26 CKLF_13 0,34 0,09 0,96 0,02 98 FOXF2_2 1,55 0,28 0,97 0,10 
27 CKLF_5 0,35 0,10 1,24 0,18 99 SNUPN_8 1,69 0,51 1,03 0,14 
28 SFI1_10 0,35 0,06 1,11 0,04 100 CRYM_10 1,66 0,58 1,07 0,04 
29 TUBB2B_2 0,35 0,06 0,79 0,04 101 SORCS2_5 1,78 0,72 0,82 0,04 
30 PC_11 0,35 0,06 1,08 0,04 102 SNUPN_1 2,14 0,44 1,02 0,23 
31 LBHD1_5 0,35 0,07 1,02 0,03 103 CYP2B6_9 2,18 0,96 1,14 0,13 
32 MAP2_6 0,35 0,14 0,84 0,08 
33 MEIS2_7 0,36 0,06 0,90 0,02 
34 MAP2_3 0,38 0,17 0,68 0,08 
35 BCR_7 0,38 0,11 0,86 0,05 
36 A1BG_4 0,40 0,24 0,51 0,05 
37 THBS4_5 0,42 0,10 1,04 0,07 
38 CRAMP1_9 0,42 0,06 1,01 0,02 
39 ALPK2_7 0,42 0,09 0,94 0,03 
40 PDE8A_10 0,44 0,07 1,06 0,05 
41 PC_10 0,45 0,10 0,83 0,04 
42 NAT8L_2 0,47 0,16 0,74 0,05 
43 UCP2_7 0,47 0,06 0,79 0,09 
44 CYP2B6_6 0,47 0,14 0,55 0,06 
45 LOC400655_7 0,47 0,11 0,96 0,05 
46 SORCS2_3 0,50 0,19 1,03 0,13 
47 MAP2_5 0,57 0,14 1,07 0,10 
48 BCR_8 0,57 0,08 0,82 0,05 
49 PDE8A_5 0,58 0,17 1,10 0,02 
50 MICAL3_14 0,61 0,12 0,98 0,03 
51 CYP2B6_5 0,60 0,24 0,66 0,07 
52 TMED3_3 0,63 0,21 0,99 0,09 
53 SULT1E1_5 0,62 0,22 0,82 0,02 
54 MEIS2_8 0,65 0,11 1,02 0,04 
55 PC_7 0,65 0,18 1,06 0,05 
56 PLEKHO1_4 0,67 0,44 1,00 0,08 
57 NAT8L_3 0,68 0,20 0,92 0,08 
58 THBS4_6 0,70 0,15 0,96 0,08 
59 ALPK2_11 0,71 0,15 0,97 0,05 
60 PLEKHO1_3 0,72 0,19 1,06 0,04 
61 SULT1E1_7 0,73 0,21 1,09 0,04 
62 CKLF_11 0,79 0,09 0,97 0,06 
63 MYOM1_10 0,79 0,22 0,79 0,08 
64 MICAL3_17 0,80 0,13 0,84 0,13 
65 HAS2_5 0,81 0,17 0,97 0,08 
66 TUBB2B_1 0,85 0,14 0,93 0,08 
67 FOXF2_5 0,89 0,32 0,85 0,09 
68 PPP1R15A_5 0,88 0,13 1,11 0,04 
69 C8orf4_7 0,88 0,17 1,00 0,05 
70 BCR_5 0,92 0,38 0,95 0,06 
71 FOXF2_4 0,86 0,33 0,91 0,03 
72 LOC400655_8 0,92 0,20 1,14 0,04 
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Figure A8 ↑ Expression controls of HF candidate genes stably expressed in Huh7-LP cells. (A) mRNA level of CRYM 
in Huh7-LP-CRYM-FLAG relative to -empty-FLAG cells as assessed via qPCR. (B) mRNA level of LBHD1 in Huh7-LP-
LBHD1-FLAG relative to -empty-FLAG cells as assessed via qPCR. (C) mRNA level of CRAMP1 in Huh7-LP-CRAMP1-
FLAG relative to -empty-FLAG cells as assessed via qPCR. (D), (E) Immunoblots for expression control of HF candidate 
genes expressed as C-terminally FLAG- (D) or N-terminally HA-tagged constructs (E). Asterisks indicate correct 
molecular weights of indicated constructs. Adapted from [278]. 
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Figure A9 ↑ ↑ ↑ HCV replication upon overexpression of THAP7-FLAG and expression controls. (A) Huh7-LP cells 
stably overexpressing THAP7-FLAG or an empty-FLAG control were electroporated with a subgenomic gt1b luciferase 
reporter replicon (sgCon1-ET) and luciferase activity was measured after 4, 24, 48, and 72 hours. (B) qPCR of Huh7-LP 
overexpressing THAP7-FLAG or empty-FLAG. Expression in (Huh7-LP-)THAP7-FLAG is normalized to GAPDH and 
relative to the control cell line (Huh7-LP-)empty-FLAG. (C–E) Overexpression control of Huh7-LP-HA-THAP7 cells via 
qPCR (C), immunoblot (D), or immunofluorescence (E) using a THAP7-specific antibody. (F–H) Overexpression control 
of Huh7-Lunet-HA-THAP7 cells via qPCR (F), immunoblot (G), or immunofluorescence (H) using a THAP7-specific 
antibody. **** p ≤ 0.0001. Adapted from [278]. 
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Figure A10 ↑ ↑ ↑ HCV replication upon overexpression of NR0B2-FLAG and expression controls. (A) Huh7-LP cells 
stably overexpressing NR0B2-FLAG or an empty-FLAG control were electroporated with a subgenomic gt1b luciferase 
reporter replicon (sgCon1-ET) and luciferase activity was measured after 4, 24, 48, and 72 hours. (B) qPCR of Huh7-LP 
overexpressing NR0B2-FLAG or empty-FLAG. Expression in (Huh7-LP-)NR0B2-FLAG is normalized to GAPDH and 
relative to the control cell line (Huh7-LP-)empty-FLAG. (C–E) Overexpression control of Huh7-LP-HA-NR0B2 cells via 
qPCR (C), immunoblot (D), or immunofluorescence (E) using a NR0B2-specific antibody. (F–H) Overexpression control 
of Huh7-Lunet-HA-NR0B2 cells via qPCR (F), immunoblot (G), or immunofluorescence (H) using an NR0B2-specific 
antibody. White arrows in (E) indicate cytoplasmic, punctate NR0B2 localization. **** p ≤ 0.0001. Adapted from 
[278]. 
 
 
Figure A11 ↑ Jc1 infection increases NR0B2 expression in Huh7-Lunet cells. Huh7-Lunet cells were infected with cell 
culture produced Jc1 (MOI 1) for 72 hours. RNA was extracted and mRNA levels were quantified by qPCR. Data shows 
mean +/- standard deviation from three independent biological experiments. **** p ≤ 0.0001. Adapted from [278]. 
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Figure A12 ↑ HA-NR0B2 overexpression reduces bile acid content in Huh7-Lunet cells. (A) Total bile acid content of 
Huh7-Lunet-HA-NR0B2 or -HA-eGFP cells was assessed using the Total Bile Acid Assay Kit (Cell Biolabs). Squares 
represent standard samples and the blocked dotted line is a linear regression. (B) Quantification of total bile acids in 
Huh7-Lunet-HA-NR0B2 or -HA-eGFP cells. Data shows mean +/- standard deviation from two independent 
experiments. * p ≤ 0.05. Adapted from [278]. 
 
